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ABSTRACT 
Heteregeneous ribonucleoproteins (hnRNPs) are a family of RNA-binding proteins (RBPs) 
implicated in several steps of RNA metabolism, including transcription, pre-mRNA 
splicing, mRNA transport and turnover. Therefore, alteration of their physiological levels 
may lead to many pathological disorders, such as neurodegeneration and cancer.  
In this thesis, we focused the attention on three hnRNP proteins, namely DAZAP1, hnRNP 
Q and hnRNP R, that we previously identified in Drosophila melanogaster as strong 
modulators of TAR DNA-binding Protein 43 kDa (TDP-43) activity, an RBP involved in 
Amyotrophyc Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).  
First of all, we evaluated the effects of their depletion on TDP-43-controlled mRNAs 
within human neuroblastoma SH-SY5Y cells and in a cellular model of TDP-43 loss-of- 
function. We found that DAZAP1 and, to a lesser extent, hnRNP Q were the most 
consistent modifiers of TDP-43 activity. Therefore, to examine the connection between 
DAZAP1 and TDP-43, we initially characterized the interaction between these two 
proteins by immunoprecipitation analysis, demonstrating that DAZAP1 does not bind 
TDP-43 but can bind TDP-43 controlled mRNAs. Next, we decided to identify all the 
potentially targets regulated by TDP-43 and DAZAP1, by looking at the transcriptome 
status of cells silenced for these two hnRNPs and we found differently expressed genes 
associated with neurodegeneration (ELAVL3 NOVA2, CELF5) and inflammation (TNF, 
TNFRSF9, ICAM1).  
Finaly, we extended our analysis to the characterization of hnRNP Q and hnRNPR, since 
the functional rescue of TDP-43 alterations was described only for hnRNP Q, but not for 
hnRNPR. We investigated the subcellular distribution and profiled differentially expressed 
genes analysis from RNA-seq after their knockdown. Interestingly, despite their high 
sequence similarity, these two proteins show different cellular distribution and affect 
	 24 
different cellular pathways, tipically associated with neurodegeneration (PENK, NGR3, 
RAB26, JAG1) and inflammatory response (TNF, ICAM1, TNFRSF9, ICAM5). In 
conclusion, our work provides insights on the involvement of the hnRNP family in 
controlling neuronal and inflammatory pathways, and suggests that the differential 
expression of these proteins could play an essential role in modulating the onset as well as 
the progression of neurodegenerative disorders, in particular when related to the TDP-43 
proteinopathies. 
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1. INTRODUCTION 
1.1 RNA-Binding Proteins and post-transcriptional gene 
regulation in brain 
1.1.1 A general overview of RNA-Binding Proteins  
Post-transcriptional gene regulation is an essential process involved in the cellular 
metabolism of coding and non-coding RNAs, that is regulated by the cooperative 
interaction of different ribonucleoprotein (RNP) complexes, consisting of RNA-binding 
proteins (RBPs) transiently or stably associated with RNAs (Dreyfuss et al., 1993).  
Although some RBPs were initially identified through the biochemical method, including 
members of the heterogeneous ribonucleoprotein (hnRNP) family (Pinol-roma et al., 1988; 
Dreyfuss et al., 1984), the growing amount of data generated by whole genome sequencing 
of all kingdoms of life have expanded the list of known RBP proteins. In an effort to 
validate RBPs across human genome, in 2014 Gerstberger and collaborators analysed 800 
domains from the protein family (Pfam) database known to bind RNA or to be found in 
RNA-related proteins, identifying 1542 RBPs (about 7.5% of all protein-coding genes in 
humans) (Gerstberger et al., 2014).  
In this census, RBPs were mainly divided into different groups based on literature reports 
(Figure 1A): 
- messenger RNA (mRNA)-binding; 
- pre-ribosomal RNA (pre-rRNA)-binding; 
- transfer RNA (tRNA)-binding; 
- small nuclear RNA (snRNA)-binding; 
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- small nucleolar RNA (snoRNA)-binding; 
- non-coding RNA (ncRNA)-binding; 
- ribosomal proteins; 
- diverse targets; 
- unknown targets. 
 
Moreover, phylogenetic analysis revealed the creation of gene families in which most of 
RBP paralogues share 20-70% sequence identity (Gerstberger et al., 2014), probably to 
increase protein synthesis or their regulation across different cell types (Figure 1B).  
 
 
Figure 1. Classification of RNA-binding proteins. RNA-binding proteins (RBPs) (A) and RBP families (B) 
are divided in groups based on RNA targets. The percentage of RBPs in each category is shown. (Source: 
Gerstberger et al., 2014) 
 
The importance of RBPs in the RNA metabolism became clear from their evolutionary 
conservation and abundance analysis. Bioinformatics analysis of yeast and Drosophila 
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genome have highlighted that 5-8% and 2-3% of genes are predicted to act as RBPs, 
respectively (Keene, 2001). Furthermore, a considerable number of orthologs of human 
RBPs have been found in lower organisms, such as archaea and bacteria (Anantharaman et 
al., 2002).  
Despite the fact that the majority of human RBPs are ubiquitously expressed, sometimes at 
higher levels than average cellular proteins (Vaquerizas et al. 2009; Kechavarzi & Janga 
2014), 82 specialized RBPs were found in brain, germ line, bone marrow, muscle, and 
liver. Overall, specialised RBPs represent 2% of all RBP families (Gerstberger et al., 
2014). Examples of tissue specific RBPs are proteins involved in the germ line 
development and maintenance, such as the Deleted in Azoospermia (DAZ) (Reynolds and 
Cooke, 2005), the Insulin-like Growth Factor-II mRNA-binding Proteins 1 (IGF2BP1) and 
3 (IGF2BP3) (Hammer et al., 2005) and P-element Induced Wimpy Testis (PIWI) (Siomi 
et al., 2011). Moreover, it is interesting to note that alterations in the cellular levels of 
RBPs are frequently recognized following their association with accessory binding partners 
(Han et al., 2010), during cellular senescence (Masuda et al., 2009) or in the presence of 
diseases (Pino et al., 2003). 
 
1.1.2 Structure of RNA-Binding Proteins 
As a structural point of view, RBPs have a modular architecture comprising multiple RNA 
binding domains that create a larger binding interface to recognize much longer stretches 
of nucleic acids (Figure 2) (Lunde et al., 2007). Specific regions called RNA-binding 
domains (RBDs) are responsible for the recognition of RNA sequences or RNA structural 
motifs belonging to different transcripts. In eukaryotes, the RNA-recognition motif (RRM) 
is by far the most common and characterized RBD. This highly conserved domain was first 
identified in the late 1980s by biochemical analysis which revealed the association between 
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heterogeneous nuclear RNAs (hnRNAs) with proteins (Dreyfuss et al., 1993). RRMs are 
composed of 80-90 amino acids disposed in a four-stranded anti-parallel β-sheet flanked on 
one side by two α-helices (α1 and α2) giving the β1α1β2β3α2β4 topology (Figure 2) 
(Oubridge et al., 1994). In this structure the RNA binding surface is represented by an 
arginine or lysine residue together with two conserved aromatic residues, located on the 
surface of the two central β-strands, β3 and β1, in the ribonucleoprotein (RNP) motif-1 
(RNP1) and ribonoucleoprotein (RNP) motif-2 (RNP2), respectively (Oubridge et al., 
1994). Analysis of conserved residues in the RRM-nucleic acid interface led to the 
definition of a common architecture of RRM-nucleic acid complex. In particular, the 
binding platform of RRM is based on a dinucleotide recognition by four conserved protein 
side chains in the centre of the β-sheet (Maris et al., 2005). Beyond these general features, 
the loop between secondary structure elements and the secondary structure elements 
themselves can be modified, in order to increase the RNA-binding affinity. For instance, 
the C-terminus of RRM2 and RRM3 in hnRNP I (also known as PTB) forms an extra β-
strand antiparallel to β 2 (Simpson et al. 2004), and the α-helix 1 in U2AF RRM is three 
fold longer than the canonical one (Kielkopf et al., 2004). Higher affinity can also be 
achieved by the combination of two or more RRM domains, as demonstrated for 
Polyadenylate Binding Protein (PABP) (Maris et al., 2005). Another particular feature of 
some RRM domains is the ability to mediate protein-protein interactions. This contact can 
occur between two RRMs, between an RRM associated to RNA and a non-RRM protein 
that acts as a cofactor, and between RRMs that do not bind RNAs and another protein. An 
example of the first type of protein-protein interaction is the case of hnRNP A1, in which 
the two RRMs contained in the N-terminal region make contacts by using their α-helix 2 
(Xu et al., 1997). Examples of the second and third types are the CBP20-CBP80-RNA 
complex and the Y14-Magoh complex, in which Y14 binds Magoh through the β-sheet of 
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the RRM domain, respectively (Maris et al., 2005).  
Despite the abundance of RRMs, other well-established domains can be involved in the 
RNA recognition, including the K-homology (KH) domain, the zinc-finger (ZnF) domain 
and the double-stranded RNA binding domain (dsRBD) (Lunde et al., 2007). The 
characteristics of these domains and other RBDs are summarized in Figure 2.  
 
Figure 2. Common RNA-binding domains. For each domain is reported a short description of the structure 
and properties. (Source: Lunde et al., 2007) 
 
Together with these latter, auxiliary modules, such as regions rich in serine and arginine 
(S/R), arginine and glycine (R/G) or lysine and arginine (K/R)-rich basic patches 
(Biamonti and Riva, 1994) help increase the functional diversity of RBPs and their ability 
to bind multiple targets. Amongst these different auxiliary domains, the glycine-rich type is 
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the most frequent. This is found in most basic heterogeneous riboproteins (hnRNPs), in 
Nucleolin, in Fibrillarin and in several yeast RBPs (Biamonti and Riva, 1994). Basically, it 
contains repeats of RGG and/or RG sequence, collectively referred as RGG/RG motifs or 
RGG boxes, that are able to mediate RNA-binding, protein-protein interaction and cellular 
localization in normal and stress conditions (Thandapani et al., 2013).  Moreover, the 
functional properties of the RGG/RG motifs can be affected by their interaction with 
proteins containing Tudor domains that are able to recognize arginine methylated RGG/RG 
motifs (Thandapani et al., 2013).  
Additional layers of complexity in the structure of RBPs are achieved by post-translational 
modifications, including phosphorylation, arginine methylation and small ubiquitin-like 
(SUMO) modification (Glisovic et al., 2008). For example, hnRNP A/B, hnRNP C and 
hnRNP U are phosphorylated in vivo, and hnRNP A1/A2 are also methylated on arginine 
residues in the RGG box domain (Dreyfuss et al., 1993). The functions of these 
modifications seem to modulate the interactions between these proteins and RNAs or other 
proteins. SUMO modifications were found in hnRNP C and hnRNP M where they could 
contribute to the subcellular localization of these two proteins and the nucleocytoplasmic 
transport of associated mRNA targets (Vassileva and Matunis, 2004).  
 
1.1.3 Different functions of RNA-binding proteins 
As mentioned before, RBPs are involved in all the aspects of RNA biology, from 
transcription, pre-mRNA splicing and polyadenylation to modification, transport, stability 
and degradation of all RNAs (Figure 3) (Glisovic et al., 2008). Most importantly, RBPs 
can assemble in distinct multimeric complexes in order to control RNA life cycles 
(Romano and Buratti, 2013). 
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Figure 3. Function of RBPs in RNA metabolism. In eukaryotes, pre-mRNAs are transcribed by RNA 
polymerase II in the nucleus and further processed in different steps including splicing, polyadenylation and 
RNA editing. Once these modifications are concluded mRNAs are transported in cytoplasm, where they are 
translated in proteins and successively degraded. Each of these complex phases are controlled and organized 
by a network of proteins able to establish RNA-protein and protein-protein interactions. (Source: Glisovic et 
al., 2008) 
 
In eukaryotes, the maturation of RNAs is a process that involves RNA cleavage and 
ligation reactions, in which nucleotide sequences called introns and exons are removed and 
joined together respectively. In protein-coding mRNAs (and long non-coding RNAs) this 
important step of RNA metabolism occurs in a large ribonucleoprotein (RNP) machinery, 
called the spliceosome (Lee and Rio, 2015). Pre-mRNA splicing takes place for > 95 to 
100% of human genes, and at least 74% of human genes transcribe multiple mRNAs 
through alternative splicing (Lee and Rio, 2015; Glisovic et al., 2008). Extrinsic 
nonspliceosomal RNA-binding proteins play a role in controlling alternative splicing, 
basically promoting or inhibiting the recognition of alternative regions by the spliceosome 
machinery. Among these splicing regulator proteins are Serine Arginine Rich Splicing 
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Factors (SR proteins), hnRNPs and tissue-specific RBPs (Baralle and Giudice, 2017). An 
example of the participation of RBPs in alternative splicing events is the regulation of β-
tropomyosin pre-mRNA, in which two SR proteins called SF2/ASF and SC35 act in an 
opposite way on the intronic enhancer-dependent splicing of exon 6A (Van Der Houven 
Van Oordt et al., 2000).  
Other two important steps in post-transcriptional gene regulation are the polyadenylation 
of the 3'-end of pre-mRNAs and the RNA editing. Polyadenylation involves an RBP, 
called Nuclear Poly(A) Binding Protein (PABPN1) that is responsible for the addition of 
the poly(A) tail on the extremity of each transcript after cleavage of 3'-end (Glisovic et al., 
2008). The Polyadenylation Specificity Factor (CPSF) complex stimulates the poly(A) 
polymerase activity of PABPN1. RNA editing prevalently involves the deamination of 
adenosine (A) to inosine (I). This conversion requires the presence of enzymes belonging 
to the ADAR family, which are RNA-binding proteins. Indeed, ADAR2 combines its 
dsRBD with an auxiliary deaminase domain that is responsible for this conversion (Valente 
and Nishikura, 2005). 
Once pre-mRNA processing is completed, the transcripts are exported from nucleus to the 
cytoplasm and this further level of RNA metabolism is promoted by a network of RBPs. 
These include the Zipcode-binding Protein (ZBP1), which is an RBP involved in the 
trafficking and translation of β-actin mRNA (Hüttelmaier et al., 2005).  
Finally, RBPs are also key factors of mRNA turnover and stability, as described by the 
regulation of neuronal specific transcripts by RNA-binding proteins belonging to the 
ELAV/Hu family (Keene, 1999). 
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1.1.4 Implication of RNA-Binding proteins in brain development, 
maintenance and disease 
RNA-binding proteins are key factors of neuronal development. Several studies have 
demonstrated that neurons have a unique system for regulating RNA metabolism, 
consisting of tissue-specific RBPs (De Conti et al., 2016).  
In mammals, the ELAV/Hu family is involved in the stability and trafficking of specific 
transcripts containing AU-rich elements (ARE) predominantly in neurons. These 
transcripts are particularly interesting because they encode functional subsets of Early-
Response Genes (ERG) or immediate gene products, including proto-oncoproteins and 
cytokines (Keene, 2001). The ELAV/Hu family is composed of four members: HuR, that is 
widely expressed and HuB, HuC and HuD which are specifics of neurons. HuR (also 
called HuA) has a high level of homology with a Drosophila nuclear protein namely 
Embryonic Lethal Abnormal Division (ELAV). Elav deletion is lethal due to abnormal 
development of neurons (Robinow and White, 1991). The importance of ELAV/Hu 
proteins is also relevant in pathology. Indeed, it is interesting to note that tumours outside 
the nervous system can express these proteins leading to Paraneoplastic Neurologic 
Syndrome (PNS) (Albert and Darnell, 2004). 
The crosstalk of different RPBs controls RNA splicing patterns essential for neuronal 
development and maintenance. In neuronal progenitors, Polypyrimidine Tract-binding 
Protein 1 (PTBP1) induces the exon skipping of Polypyrimidine Tract-binding Protein 2 
(PTBP2) exon 10 to form a transcript with a premature stop codon subject to non-sense 
mediated mRNA decay (NMD). Nevertheless, when the progenitors start to differentiate 
into neurons, the negative effect of PTB1 on PTBP2 exon 10 is lost by PTBP1 
downregulation and at the same time upregulation of the splicing enhancer Ser/Arg 
Repetitive Matrix Protein 4 (SRRM4) (Quesnel-Vallières et al. 2015; Makeyev et al. 
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2007).  
Another important RBP implicated in brain development and differentiation is the Neuro-
Oncological Ventral Antigen 2 (NOVA2). This protein inhibits Disabled Homologue 1 
(DAB1) exon 7bc splicing inclusion in late-generated cortical and Purkinje neurons. In 
turn, DAB1 regulates the Reelin signalling, an important pathway involved in neuronal 
development. Neuronal migration defects found in neurons with the DAB1 longer isoform, 
corresponding to the inclusion of exon 7b and 7c, are similar to those observed in Nova2-/- 
mice (Yano et al. 2010). Similarly to ELAV/Hu proteins, the abnormal expression of 
NOVA1/NOVA2 in breast cancer determines the enstablisment of a PND form called 
Opsoclonus Myoclonus Ataxia (POMA). In fact, the alteration of NOVA proteins leads to 
immune system activaction and consequent formation of autoantibodies responsible for 
neuronal cell death in the regions of the nervous system where NOVA proteins are 
expressed (Lukong et al., 2008). 
RNA regulation during neuronal differentiation can also involve alternative splicing of the 
RBP mRNAs themselves. During synaptic development, exon 19 of RNA-binding Protein 
FOX1 Homologue 1 (RBFOX1) is alternatively spliced by RBFOX proteins, giving rise to 
nuclear or cytoplasmic protein isoforms. Moreover, mutations in RBFOX proteins have 
been found in people suffering from autism and are related to alterations of transcripts, 
such as SH3 and Multiple Ankyrin Repeat Domains Protein 3 (SHANK3), Voltage-
dependent L-type Calcium Channel Subunit α1C (CACNA1C) and Tuberous Sclerosis 2 
Protein (TSC2) (Baralle and Giudice, 2017). 
Finally, the spatial and temporal organization of gene expression is a particular feature 
adopted by the nervous system to control the synaptic plasticity (Zukin, Richter and Bagni 
2009). In order to avoid the premature translation and degradation of specific mRNAs, 
silent mRNAs, RBPs and miRNAs are associated in macromolecular assemblies, including 
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synaptic mRNA-silencing foci, processing bodies (P-bodies) and stress granules (SGs). 
Silent mRNAs wait inside the granules to reach the exact localization in which translation 
can start (De Conti et al., 2016). Examples of RBPs that participate to the formation of SG 
granules are hnRNPA2, TATA-Box Binding Protein Associated Factor 15 (TAF15), fused 
in Sarcoma/Translocated in Liposarcoma (FUS/TLS) and TAR DNA-binding Protein 43 
(TDP-43). Stress conditions, mutations in RBPs, aging and other pathological disorders 
can alter the equilibrium between soluble, disperse and aggregated states leading to 
increased SG formation, and progressively the formation of stable and long-lived 
aggregates that resemble the characteristics of pathological inclusions. Indeed, several 
studies have identified the presence of SGs in Alzheimer’s diseases (AD), amyotrophic 
lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) (Wolozin & Apicco 
2015; De Conti et al. 2016). 
 
1.2 Transcriptome analysis using RNA sequencing and its 
applications in the characterization of RNA binding proteins 
1.2.1 From hypothesis-driven approaches to high-throughput screening 
(HTS) approaches 
The analysis of the complete set of all RNA molecules transcribed in a cell at a specific 
developmental stage or physiological condition, called its transcriptome, has given insights 
into how the genome is packaged and expressed, and has been useful to clarify important 
aspects related to genome evolution (Wang, 2001; Elliott, 2014).  
In the last decade, several efforts have been made to clarify the role of RBPs in 
transcriptome regulation, and their involvement in neurodegeneration. Initially, the 
characterization of novel regulatory factors in the field of RNA metabolism was based on 
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traditional hypothesis-driven approaches, in which the investigation of biological effects 
was initiated by a prediction (Buratti, Romano and Baralle, 2013). For example, 
preliminary studies correlating splicing inclusion of Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) exon 9, and the number of UG(m)/U(n) repeats close to 
the 3' splice site of exon 9 (Cuppens et al., 1998; Larriba et al., 1998), identified TDP-43 as 
the major hnRNP involved in this splicing recognition (Buratti et al., 2001). The 
advantages of using this approach are the capability to set up a precise series of 
experiments aimed at confirm or reject the original hypothesis. However, the process that 
is necessary to reach an in-depth characterization is laborious and could lead to the loss of 
some information important for the comprehension of the initial question (Buratti, Romano 
and Baralle, 2013). Thanks to the advancement of system-wide approaches and 
bioinformatics, the analysis of gene expression changes and the identification of 
RNA/protein targets at a global cellular level have became more popular and have allowed 
more open-ended approaches that are not strictly hypothesis-driven (Buratti et al., 2013).   
The term high-throughput screening (HTS) is referred to the way of rapidly assessing a 
large number of biological factors and chemical compounds in order to identify those 
which can modulate a specific cellular pathway (Buratti, Romano and Baralle, 2013). 
Examples of these new techniques aimed to analyse transcriptomes are microarrays 
(GeneChip), RNA sequencing (RNA-seq) and cross-linking immunoprecipitation 
sequencing (CLIP-seq) (Figure 4).  
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Figure 4. High-throughput screening (HTS) approaches. Flowchart of microarray (A), RNA-seq (B) and 
CLIP-seq (C) experiments. (Source: Buratti et al., 2013) 
 
Briefly, microarray screening consists of a pool of DNA sequences spotted on a solid 
surface that are hybridized with RNAs extracted from cells or tissues, labelled with 
fluorescent probes, washed and then finally analysed based on the fluorescence emitted 
(Dalma-Weiszhausz et al., 2006). These arrays can be designed in order to detect predicted 
splicing junctions, and therefore to analyse possible changes in splicing events.  
Despite microarrays being extensively used for the characterization of RNA binding 
factors, including TDP-43 (Colombrita et al., 2012; Narayanan et al., 2013), hnRNP K (Liu 
and Szaro, 2011), hnRNP L (Hung et al., 2008) and hnRNP A1 (Liu et al., 2017), this 
approach has some limitations, such as the necessity to design/synthesize the probes that 
have to be attached on the solid surface. Hence, knowledge of the sequence to make the 
probe set is mandatory, making it impossible to detect mRNAs absent from databases or 
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with incomplete/incorrect genome annotations (Hurd and Nelson, 2009). Furthermore, the 
phenomenon of cross-hybridization makes it problematic to analyse and obtain 
reproducible results for highly related sequences. This restricts microarray analysis to non-
repetitive genome sequences, therefore making arduous the analysis of splicing isoforms, 
allelic gene variants, and single-nucleotide polymorphisms (SNPs) (Shendure, 2008; Hurd 
and Nelson, 2009; Buratti, Romano and Baralle, 2013). Other limitations regard signal-to-
noise ratio and the problems related to detect low-abundance sequences, the necessity to 
obtain DNA from PCR amplification with the possibility to introduce bias into samples, 
and finally, the wide amount of preparative methodologies, microarray formats and 
analytical approaches currently available (Hurd and Nelson, 2009; Ioannidis et al., 2009).  
Some drawbacks have been solved by the sequencing of transcriptome. Therefore, in the 
next paragraphs, the attention will be focalised on the RNA-seq analysis and its 
applications in the characterization of RNA binding proteins. 
 
1.2.2 Next-generation sequencing (NGS): RNA sequencing  
The concept of sequencing was developed in the late 70s by the pioneering works of 
Sanger and Coulson (Sanger, Nicklen and Coulson, 1977) and Maxam and Gilbert (Maxam 
and Gilbert, 1977). However, the effective power of this approach applied in the research 
field, has been possible later with the support of industries and the development of 
instruments able to produce hundreds of gigabases of nucleotide sequence output in a 
single run (Metzker, 2010). Nowadays, we talk about next-generation sequencing (NGS) 
technology to describe seq-based methods, such as RNA-seq. NGS analysis has allowed us 
to overcome the limitations of other HTS approached not seq-based (e.g. microarray). 
Indeed, the gene expression analysis carried out using RNA-seq does not require the prior 
knowledge of genome sequences, making possible the detection of RNA editing events and 
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the quantification of splicing isoforms (Hurd and Nelson, 2009; Sánchez-Pla et al., 2012; 
Buratti, Romano and Baralle, 2013). Moreover, the fact that the sample of interest is 
directly sequenced results in the removal of experimental bias from the analysis, such as 
cross-hybridation issue and mapping of repetitive sequences, as well as problems in the 
quantification of signal, because it is based on counting sequence tags rather than the 
relative measurement between samples. Finally, nanograms of materials are necessary and 
sufficient for sequencing, reducing the reliance of extensive PCR amplification of the 
material (Hurd and Nelson, 2009). 
However, there are some shortcoming in the RNA-seq approach, including the necessity to 
analyse biological replicates to avoid problems related to the sample assignment to lanes or 
runs, and the normalization of the counts after the alignment to a reference genome. This 
normalization resolves issue related to the libray size, the gene length and the distribution 
of counts among samples  (Sánchez-Pla et al., 2012). 
Differential gene expression (DGE) analysis (Costa-Silva, Domingues and Lopes, 2017), 
characterization of alternative splicing events (Park et al., 2018) and detection of gene 
fusion events (Kumar et al., 2016), as well as specific RNA species (Andrés-León, Núñez-
Torres and Rojas, 2016) are examples of RNA-seq applications. The type of RNA-seq 
application affects the choice of the sequencing platform and the relative bioinformatics 
analysis.  
Nowadays, there are different available platforms, which were initially developed for 
DNA, but they can easily be applied to RNA sequencing after the conversion from RNA 
into more stable cDNA molecules by reverse transcriptase (Sánchez-Pla et al., 2012). 
Moreover, each platform uses different methodologies for template preparation, 
sequencing-imaging and gene alignment, determining a wide range of data output in terms 
of cost and quality (Metzker, 2010).  Examples of platforms are Illumina (Miseq, NextSeq 
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500, HiSeq 2500, HiSeq X Ten), Life Technologies Ion Torrent (PGN and Proton 
systems), Pacific Biosciences PacBio RSII and Oxford Nanopore Tecnologies MinION 
(Reuter et al., 2015). For instance, Illumina’s and Ion Torrent’s technologies provide the 
possibility to generate short read length (for HiSeq 2500 and Ion PGN: reads length up to 
125 bp and 200 or 400 bp, respectively) making them less suitable for particular studies, 
including gene isoform detection (Reuter et al., 2015). On the other hand, PacBio RII and 
MinION systems features to obtain long-read sequence data (> 14 kb and ~ 6-65 kb, 
respectively) suitabled for the identification of gene splicing events, althought they are 
limitated by the lower coverage comparing to Illumina and Ion Torrent platforms (Reuter 
et al., 2015). 
 
1.2.3. RNA sequencing applied to the characterization of RNA binding 
proteins 
An increasing number of works described the application of sequencing analysis to explore 
all the possible RNA targets of a specific RBP (Buratti, Romano and Baralle, 2013), as 
well as to profile the transcriptomes of brain tissue affected from neurodegenerative 
disorders (Twine et al., 2011). In this regard, RNA-seq has been used to analyse the effect 
of TDP-43 knockout in the central nervous system of Drosophila (Hazelett et al., 2012) 
and in mouse embryonic stem cells (Chiang et al., 2010).   
Nowadays, improvements in sequencing technology also provide the possibility to map the 
sites at which proteins are bound to the RNA, by coupling this technique with RNA 
immunoprecipitation (RIP) (Marchese et al., 2016) or cross-linking immunoprecipitation 
(CLIP) (Licatalosi et al., 2008). In RIP-seq analysis the RNA-complexes formed between 
the protein of interest and its interacting RNAs are co-immunoprecipitated and the bound 
RNAs are subsequently sequenced, while in the CLIP-seq analysis the target protein is 
Introduction 	
 41 
previously cross-linked in vitro with its RNA targets and successively these RNAs are 
immunoprecipitated and sequenced.  
For instance, in order to describe TDP-43 targets in TDP-43-containing protein complexes 
within rat cortical neurons, deep sequencing analysis was performed following RNA-
immunoprecipitation (Sephton et al., 2011). RIP-seq was also used to characterize mRNA 
targets of hnRNP L in prostate cancer LNCaP cells (Fei et al., 2017) and to identify 
spliceosome-associated genes in hnRNP H1 targets (Uren et al., 2016). Interestingly, most 
of the hnRNP H1 targets enriched in the analysis encoded other RBPs, including TDP-43, 
FUS, several hnRNPs and Serine and Arginine Rich Splicing Factors (SRSFs) (Uren et al., 
2016). One the other hand, CLIP-seq analysis has been used for mapping in vivo binding 
positions of other RNA-binding proteins, including NOVA (Licatalosi et al., 2008), 
CELF1 (Le Tonquèze et al., 2016) and Transformer-2 Protein Homolog β (Tra2β) 
(Grellscheid et al., 2011). 
 
1.3 The Heterogeneous Ribonucleoprotein (hnRNP) family 
1.3.1 General characteristics of the hnRNP family 
The most abundant RBPs belong to the heterogeneous ribonucleoprotein (hnRNP) family 
(Glisovic et al., 2008). hnRNPs were originally described as RBPs transiently bound to the 
heterogeneous nuclear RNA (hnRNA, also known as pre-mRNAs) produced by RNA 
polymerase II in the nucleus of eukaryotic cells (Dreyfuss et al., 1993). The 40S core 
particle was the first mRNA-protein complex, isolated by sucrose density gradients, and 
contained hnRNP A/B and C (Beyer et al., 1977). Later on, several other hnRNPs were 
characterized by immunoprecipitation with monoclonal antibodies and UV-cross-linking 
experiments leading to the identification of 20 major types of hnRNPs. These were 
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alphabetically named from hnRNP A1 to hnRNP U (Figure 5) (Geuens et al., 2016; Han et 
al., 2010). Although, the hnRNPs have many features in common with other RBPs, such as 
the SR proteins and ELAV-like proteins, they are generally described as a separated 
family. The basis for this classification arises from historical motivations, rather than 
phylogenetic, structural or functional evidence (Han et al., 2010). 
Besides these canonical hnRNPs, several studies have classified other proteins as hnRNP-
like RNA binding factors, such as CELF proteins, FOX proteins, NOVA, or TDP-43 
(Busch and Hertel, 2012). 
 
 
Figure 5. Structure of the canonical hnRNP family members. hnRNP proteins have different molecular 
weight ranging from 34 kDa to 120 kDa. Several structural features are shared among the hnRNP family, 
including RNA-binding domains (RRM, RNA-recognition motif; qRRM, quasi-RNA recognition motif and 
KH, K-homology domain), Arginine-glycine-glycine box (RGG-box) and auxiliary domains. (Source: 
Geuens et al., 2016) 
 
Structurally, hnRNP proteins share common features, including RBDs (with the exception 
of hnRNP U). The majority of hnRNPs also have RGG-boxes and auxiliary domains. In 
addition, hnRNPs can have different splicing variants and undergo post-translation 
Introduction 	
 43 
modifications and nucleocytoplsmic shuttling (Han et al., 2010). However, regarding the 
latter, there are difference between the mechanisms that different hnRNPs adopt to 
translocate from nucleus and cytoplasm and vice-versa. For instance, hnRNP A1 and 
hnRNP I do not contain canonical nuclear localization signals (NLSs) and their 
translocation is coupled with transcription (Gama-Carvalho and Carmo-Fonseca, 2001). 
Interestingly, it has also been demonstrated that stress-dependent phosphorylation of 
hnRNP A1 is responsible for its cytoplasmic accumulation within SGs (Guil et al., 2006). 
On the contrary hnRNP K contains NLS and its movement is uncoupled with transcription 
(Gama-Carvalho and Carmo-Fonseca, 2001). 
Although hnRNPs are prevalently abundant in the nucleus, it has been ascertained that 
hnRNP U and C are also found in cytoplasmic RNA granules (Kanai et al., 2004; Piñol-
Roma and Dreyfuss, 1992), one of the hnRNP M isoforms is a membrane-bound receptor 
(Bajenova et al., 2003) and hnRNP Q is predominantly cytoplasmic and it is localized in 
mRNA granules (A Mizutani et al., 2000). hnRNP P (FUS) is also localized in cytoplasm 
inside stress granules (Andersson et al., 2008). 
 
1.3.2 Multiple functions of hnRNPs 
Several of the biological functions of hnRNPs involve cooperative and dynamic 
interactions with different proteins. Indeed, across all the steps required for mRNA 
biogenesis, there is a continuous remodelling of the hnRNP complex, represented by the 
association of particular hnRNPs with pre-mRNAs, in which the loss or acquisition of 
hnRNP proteins as well as other RBPs create what has been classically defined as an 
‘‘mRNP code’’. This “mRNP code” is unique for each transcript and the protein 
composition of the complex reveals its cytoplasmic fate (Singh and Valcárcel, 2005).  
Many of the functions of RBPs previously described in this thesis take place thanks to 
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hnRNP proteins and their interplay. For example, a role in transcriptional regulation was 
first described in 1996, when hnRNP K was found to bind in vitro to pyrimidine-rich (CT) 
elements in single strand DNA (ssDNA) (Michelotti et al., 1996). Successively, it has been 
demonstrated that hnRNP K can act as a transcriptional repressor of the Osteocalcin gene 
by inhibiting the formation of a transcriptional complex on the CT element of the 
Osteocalcin promoter (Stains et al., 2005). The transcriptional repressor activity can also 
take place without direct contact with DNA, as it occurs during the inhibition of α1-Acid 
Glycoprotein (AGP) gene (Miau et al., 1998). 
Among all the process that influence transcriptome complexity, alternative splicing is the 
most important event in which hnRNPs are involved. Recently, it has been demonstrated 
that multiple hnRNPs, among which TDP-43, hnRNP L, PTB/nPTB and hnRNPA1/A2 are 
able to modulate with disparate strength the inclusion of Sortilin 1 (SORT1) exon 17b 
(Mohagheghi et al., 2016). 
Interestingly, there is also substantial evidence supporting the role of RBPs in the 
maintenance of genome integrity and in the regulation of telomeres (Nishida et al., 2017). 
Indeed, hnRNP L and hnRNP C have been identified in complexes that work as DNA 
double strand breaks (DSB) sensors (Nishida et al., 2017). FUS/TLS is another 
transcriptional regulatory sensor of DNA damage, and is recruited to the Cyclin D1 
promoter after ionizing radiation exposure where it functions as a transcriptional repressor 
(Lagier-Tourenne et al., 2010). 
Furthermore, FUS/TLS interacts through its RGG domains with a G-quadruplex consisting 
of telomere DNA and the functional non-coding RNAs called Telomeric Repeat- 
containing RNA (TERRA) to regulate histone modifications of telomeres (Takahama et al., 
2015). In addition, hnRNP A/B together with other hnRNPs and telomere-binding factors, 
regulates the structure of telomeres, protecting them from degradation (Han et al., 2010). 
Introduction 	
 45 
1.3.3 Role of hnRNPs in neurodegenerative disorders 
Albeit the equilibrium of hnRNP proteins is finely regulated and neurons are characterized 
by a very adaptive and dynamic architecture, perturbation of their neuronal homeostasis 
can lead to neurodegenerative disorders, such as ALS, FTLD, spinal muscular atrophy 
(SMA) and Alzheimer’s disease. In particular, these pathologies are characterized by the 
presence of protein aggregates, also including RBPs/hnRNP proteins (Neumann et al., 
2006). The formation of these aggregates is a result of several steps consisting of protein 
misfolding, oligomerization and eventually formation of protofribrils or amyloid fibrils 
(Stefani and Dobson, 2003). A clear example of the involvement of hnRNPs in 
neurodegeneration is the finding of TDP-43 and FUS/TLS in ALS and FTLD inclusions. 
These inclusions can act as a “sink” influencing the clearance of these proteins from 
nucleus and it can, in turn, explain the aberrant RNA processes (e.g. alternative splicing) 
observed in aggregation-bearing cells. Both TDP-43 and FUS contain a prion-like domain 
that confers them an intrinsic propensity to aggregate (Gitler and Shorter, 2011). Together 
with this consideration, variations in the protein sequence can trigger the establishment of 
diseases. In both TDP-43 and FUS coding genes the presence of ALS-linked mutations 
have been described, and in the case of TDP-43 it has been demonstrated that TDP-43 
ALS-linked mutations accelerate aggregation in vitro (Ugras and Shorter, 2012). More 
recently, the presence of ALS/FTLD-associated mutations have also been described in the 
prion-like domain of hnRNP A1, A2/B1 and putative mutations have also been 
hypothesized by a yeast functional screening in TAF15 encoding gene (Couthouis et al., 
2011). 
Most importantly, these hnRNPs seem to not act alone in mediating neurodegeneration. 
Indeed, it is thought that GGGGCC repeat expansion in the C9orf72 gene are the causative 
agents of associate ALS/FTLD pathologies, due to the fact that these repetitions can cause 
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the subtraction of a significant amount of RBPs from the protein milieu (De Conti et al., 
2016). 
A plethora of intracellular systems are designed to maintain this intracellular homeostasis, 
including the ubiquitin proteasome system (UPS) (Kriegenburg et al., 2012) and the 
autophagy system (Feng et al., 2014). In the UPS, proteins are primarily targeted for 
degradation through the covalent attachment of a small protein, called ubiquitin, and then 
directed to the proteasome complex for degradation (Glickman and Ciechanover, 2002). 
Disruption of proteasome activity is sufficient to induce cytoplasmic accumulation and 
aggregation of TDP-43 in primary hippocampal and cortical neurons, as well as in the 
immortalized motor neuron cell line NSC-34 (van Eersel et al., 2011).  
In the autophagy system, harmful substances contained in the cytoplasm are degraded 
within lysosomes/vacuoles, and the resulting macromolecular constituents are recycled 
(Feng et al., 2014). Recently, it has been demonstrated that the induction of autophagy 
system triggered the neuronal clearance of TDP-43 with consequent enhancement of 
survival in human Induced Pluripotent Stem Cell (iPSC)-derived neurons and astrocytes 
obtained from patients with familial ALS (Barmada et al., 2014). 
 
1.4 Trans-activating Response Region (TAR) DNA-Binding 
protein of 43 kDa (TDP-43) 
1.4.1 Brief introduction on TDP-43  
Trans-activating response region (TAR) DNA-binding protein of 43 kDa (TDP-43) is a 
ubiquitously expressed and highly conserved protein of 414 amino acid residues belonging 
to the heterogeneous nuclear ribonucleoprotein (hnRNP) family. Originally described as a 
transcription factor bound to the regulatory element in the Human Immunodeficiency 
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Virus Type 1 (HIV-1) long terminal repeat known as TAR (Ou et al., 1995), in 2001 TDP-
43 was rediscovered as a splicing factor involved in the regulation of CFTR exon 9 and 
successively linked to different aspects of RNA metabolism, such as mRNA stability 
(including its own), mRNA transport, translation, and non-coding RNAs (miRNA, 
lncRNAs, etc.) processing (Buratti and Baralle, 2012).  
Furthermore, although mostly nuclear, TDP-43 continuously shuttles from the nucleus to 
the cytoplasm where it forms high molecular mass complexes that include proteins and 
RNAs (Sephton et al., 2011; Ayala, Zago, et al., 2008). 
In 2006, TDP-43 was identified as a major component of the ubiquitin-positive, a-
Synuclein and Tau-negative cytoplasmic inclusions recognized in the brain and spinal cord 
tissues of Frontotemporal Dementia with Ubiquitin-positive Inclusions (FTLD-U) and 
ALS patients (Arai et al., 2006; Neumann et al., 2006). Successively TDP-43 inclusions 
were also reported at lower frequencies in other neurodegenerative diseases, including 
Alzheimer’s, and Parkinson’s (PD) disease and Lewy body (LB) disorders (Nakashima-
Yasuda et al., 2007). Following the growing amount of data regarding the involvement of 
TDP43 protein in neurodegeneration, several other studies have focused their attention on 
understanding the biochemistry mechanisms behind cellular functions of TDP-43 in 
physiology and pathology. Some of these findings are summarized in the paragraphs 
below. 
 
1.4.2 Characteristics of TDP-43 
TDP-43 is encoded by the TARDBP gene located on the short arm (p) of human 
chromosome 1 at position 36.22 (1p36.22) (Figure 6), and is highly conserved among 
Drosophila melanogaster, Caenorhabditis elegans, mouse and human (Wang et al., 2004). 
The TARDBP gene consists of 6 exons. Exons 2-6 encode the functional TDP-43 protein. 
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However, the genomic analysis of TARDBP gene performed by Wang and colleagues and 
successively by Alton et al., have also highlighted the presence of different splicing 
isoforms of TDP-43 (D’Alton et al., 2015; Wang et al., 2004). Furthermore, more than 38 
nonsynonymous TARDBP mutations have been identified in both familiar and sporadic 
ALS (Scotter et al., 2015). 
 
Figure 6. Localization of TARDBP gene on human chromosome 1. The Genomic locus encoding TDP-43 
is identified by a yellow arrow. (Source: Genetic home resource) 
 
TDP-43 expression is developmentally regulated. High levels of TDP-43 expression were 
found during early embryogenesis, but progressively and markedly decrease with age in 
post-natal brains (Sephton et al., 2010). In agreement with this finding, Huang and 
colleagues demonstrated the expression of TDP-43 in all post-natal tissues, such as 
cerebellum, forebrain, brainstem, spinal cord, skeleton muscle, heart, liver, lung, spleen 
and kidney, with a global decrease of TDP-43 levels with the advancement of age (Huang 
et al., 2010). Furthermore, TDP-43 knockout mice were also lethal during embryonic 
stages (Sephton et al., 2010). This observation has also been confirmed in Drosophila 
where the disruption of TDP-43 was lethal at the second larval stage (Fiesel et al., 2010), 
although in other Drosophila models, TDP-43 null flies were able to survive through 
adulthood (Feiguin, Vinay K. Godena, et al., 2009), suggesting the influence of modifier 
genes affecting TDP-43 in developmental regulation.  
From a structural point of view, TDP-43 architecture reassembles the general hnRNP 
structural organization (Figure 7).  
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Figure 7. Schematic representation of TDP-43 protein domains and their associated functions. TDP-43 
is composed of an N-terminal domain containing NLS, two RNA-recognition motifs (RMM1 and RRM2 in 
which NES is present) and a C-terminal domain containing a glycine-rich region (GRR). ALS-linked 
mutations are also reported in the figure. (Source: Janssens and Van Broeckhoven, 2013) 
 
TDP43 protein is composed of: 
- The N-terminal domain: contains the nuclear localization sequence (NLS) that is 
composed of NLS1 (K82RK84) and NLS2 (K95VKR98). Mutations in these two 
positions reduce the nuclear localization of TDP-43 (Buratti and Baralle, 2001). 
- Two RRMs: highly evolutionary conserved 60 residue-long motifs. D. 
melanogaster and C. elegans homologs can functionally substitute for the human 
protein and vice-versa (Feiguin, Vinay K. Godena, et al., 2009; Ayala et al., 2005). 
1. RRM1: is responsible for binding to single-stranded RNA containing UG-
repeated motifs (Ayala, Zago, et al., 2008; Buratti and Baralle, 2001). These 
repeats are found more often in long introns and 3¢ untranslated regions (3¢-
UTRs) rather than exons inside the human genome. Through RRM1, TDP-
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43 also binds single-stranded DNA with TG repeats, as demonstrated by the 
electromobility shift assay (EMSA) technique (Buratti and Baralle, 2001), 
and double-stranded TG repeats DNA as described in the nitrocellulose 
filter-binding assay (Kuo et al., 2009). In particular, these interactions are 
mediated by two residues (Phe 147 and Phe 149) and their substitution was 
found to be sufficient to abolish RNA-binding properties and splicing 
regulatory activities of TDP-43 (Buratti & Baralle 2001; D'Ambrogio et al. 
2009). 
2. RRM2: Together with the N-terminal sequence from residues 3 to 183, 
RRM2 is supposed to be involved in the TDP-43 self-interaction (ability to 
form homo-dimers and -multimers) (Shiina et al., 2010; Kuo et al., 2009).  
A role in chromatin organization has also been suggested, since it may co-
crystallize with TG-rich single stranded DNA in order to form highly 
thermal-stable dimeric assemblies (Ayala, Zago, et al., 2008). Furthermore, 
this region of TDP43 protein is predicted to contain a strong nuclear export 
signal (NES) (Strong et al., 2007).  
- The C-terminal domain: represents almost half of the protein, spanning residues 
261- 414. It contains a glycine-rich region, corresponding to residues 345 to 366, 
that is essential for the interaction with other proteins, including hnRNP A2/B1 and 
hnRNP A1 (Buratti et al. 2005; D’Ambrogio et al. 2009). Furthermore, the region 
comprising amino acids 216–315 together with the RNA-recognition motif 1 
domain are implicated in the assembly of TDP-43 into SGs (Colombrita et al., 
2009). This region is also the “hot-spot” position in which the majority of 
TARDBP mutations have been identified in ALS and FTLD patients (Lagier-
Tourenne et al., 2010). Moreover, the C-terminal domain includes a 
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Glutamine/Asparagine (Q/N) spanning residues 321-369 (D’Ambrogio et al. 2009; 
Fuentealba et al. 2010) that is considered the putative “prion-like domain” of TDP-
43, since it has a strong tendency to aggregate (Budini et al. 2012). Deletions and 
mutations in the TDP-43 C-terminal domain significantly reduce the solubility of 
the protein and results in formation of large nuclear and cytoplasmic aggregates, 
thought to be a result of the lack of interaction between TDP-43 and other protein 
factors that promote TDP-43 solubility (Ayala, Zago, et al., 2008). Finally, the 
integrity of this region is extremely important for many of TDP-43’s functional 
properties. Indeed, TDP-43 protein lacking the C-terminal domain is no longer able 
to regulate the skipping of exon 9 in the CFTR gene (Wang et al., 2004).  
- TDPBR (extended binding region for TDP-43): is present in the 3’¢-UTR of TDP-
43 mRNA and contains several non-UG sequences that are essential for the auto-
regulation of TDP-43 mRNA (Igaz et al., 2011; Polymenidou, Lagier-tourenne, et 
al., 2011). 
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1.4.3 Functions of TDP-43 
As previously mentioned, TDP-43 has many functional properties that are summarised in 
Figure 8. 
 
 
Figure 8. Schematic representation of TDP-43 functions. TDP-43 covers many functions in cells 
including starting from transcription to translation and degradation. TDP-43 is also involved in miRNA 
processing and auto-regulation. (Source: Buratti & Baralle, 2012)  
 
TDP-43 functions include: 
- Transcriptional regulation: TDP-43 was initially discovered as having a role in 
HIV-1 transcriptional repression, from which its name derives (Ou et al., 1995). 
However, the involvement of TDP-43 in HIV-1 regulation has not been confirmed 
by other studies, suggesting a restrictive role during HIV-1 replication in immune 
cells (Nehls et al., 2014). TDP-43 was also implicated in the regulation of 
spermatogenesis, because of its binding to the promoter of the mouse Spermatid-
specific SP-10 (ACRV1) gene and promoting its transcriptional repression (Lagier-
Tourenne et al., 2010). Moreover, consisting with is involvement in transcription, 
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TDP-43 was found in the human brain and in cell cultures to be associated with 
euchromatin (containing actively transcribed genes) through its RMM2 (Lagier-
Tourenne et al., 2010). 
- Pre-mRNA splicing: is the best-characterized function of TDP-43. An example of 
an alternative splicing event regulated by TDP-43 is the skipping of exon 9 of 
CFTR gene, which is promoted by the TDP-43 recognition of an UG-tract near the 
3¢	splice-site of this exon (Buratti and Baralle, 2001; Buratti et al., 2001). As in the 
case of CFTR gene, TDP-43 is considered to be a splicing silencer of other genes, 
like Apolipoprotein AII (ApoII) exon 3 (Mercado et al., 2005), Eukaryotic 
Translation Termination Factor 1 (ETF1) and Retinoid X receptor gamma (RXRG) 
exon 7 (Passoni et al., 2012). However, TDP43 can also promote exon splicing, as 
in the case of breast cancer 1 (BRCA1) -mutated substrate exon 12 (Passoni et al., 
2012) and polymerase delta interacting protein/S6 kinase 1 Aly/REF-like target 
(POLDIP3/SKAR) exon 3 (Fiesel et al., 2012). 
- micro-RNA (miRNA) biogenesis: mass spectrometry analysis has shown an 
interaction between TDP-43 and the Nuclear RNase III-type Protein (Drosha) that 
is involved in the first step of miRNA maturation (Gregory et al., 2004). A further 
confirmation of the involvement of TDP-43 in the miRNA biogenesis has arisen 
from the demonstration of TDP-43’s association with Argonaute 2 (AGO2) and 
DDX17 (Freibaum et al., 2010). Indeed, DDX17 directly interacts with Drosha 
(Shen and Hung, 2015) and AGO2 is a catalytic component of the RNA-induced 
Silencing Complex (RISC) (Sen and Blau, 2005). 
- RNA subcellular localization and translation: although TDP-43 is predominantly 
nuclear, it has been visualized in cytoplasmic puncta strongly stained for PABPC1, 
a marker for cytoplasmic RNA SGs (Freibaum et al., 2010). It is thought that 
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cytoplasmic RNA granules may represent physiological accumulations of mRNAs 
and ribonucleoproteins that regulate gene expression by affecting translation, 
trafficking and stability (Anderson and Kedersha, 2009). This function is 
particularly important for neuroplasticity in which the mRNA translation is 
dependent on its subcellular localization. In the motoneuron-like cell line NSC-34, 
TDP-43 moved into SGs as a response to oxidative stress and to environmental 
insults (Colombrita et al., 2009). Although the link between TDP-43 and its 
presence into SGs is still not completely clear, it is thought that it can mediate the 
stabilization and localization of Low Molecular Weight Neurofilament (NEFL) 
mRNA during axonal repair (Lagier-Tourenne et al., 2010) by binding its 3'UTR 
region from 135 to 185 residues after the stop codon (Buratti and Baralle, 2008). 
Furthermore, in 2008 Wang and colleagues have observed the presence of TDP-43 
in dendritic processing body and demonstrated that it could act as a translational 
repressor in vitro (Wang et al., 2008). 
- mRNA turnover: TDP-43 is associated with the mRNA turnover from different 
genes, including Cyclin-Dependent Kinase 6 (CDK6) (Ayala, Misteli, et al., 2008) 
and Histone Deacetylase 6 (HDAC6) (Fiesel et al., 2010) through the binding to 
their 3'UTR within the mRNA sequences. Furthermore, TDP-43 can physically 
interact with the mRNA of the Drosophila melanogaster homologue of 
Microtubule-associated Protein 1B, called Futsc, preventing synaptic defects 
related to Futsc downregulation (Godena et al., 2011) and that the depletion of 
TDP-43 could destabilized the mRNA of Autophagy Related 7 (ATG7) with the 
consequent impairment of autophagy and accumulation of polyubiquitinated 
proteins (Bose, Huang and Shen, 2011). 
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- Auto-regulation: TDP-43 is able to regulate own expression by promoting RNA 
instability through the binding to different polyadeylation (polyA) sites localized in 
the TDPBR at its 3'UTR (Ayala et al., 2011). Under normal conditions, two main 
splicing isoforms and one isoform expressed at low levels arise from the usage of 
either the proximal polyA1 site or the distal polyA4 and polyA2 sites, respectively, 
with the efficient production of TDP-43 (Ayala et al., 2011; Eréndira Avendaño-
Vázquez et al., 2012). When the nuclear levels of TDP-43 are abundant there is an 
increase in the binding of TDP-43 to its TDPBR. This event promotes a dual effect: 
the activation of a normally silent intron (intron 7) which in turn eliminates 
utilisation of polyA1, resulting in the preferentially usage of polyA2. At the same 
time, this determines the direct competition of TDP-43 with the cleavage polyA 
factor Cstf-64 over polyA1 with the consequence usage of polyA4 (Eréndira 
Avendaño-Vázquez et al., 2012). Both polyA2 and polyA4 are significantly 
retained in the nucleus and rapidly degraded thus reducing TDP-43 levels (Eréndira 
Avendaño-Vázquez et al., 2012). On the contrary, low levels of TDP-43 causes the 
preferentially usage of polyA1 site instead of the other possible choices (polyA2 
and polyA4), resulting in an efficient TDP-43 production (Eréndira Avendaño-
Vázquez et al., 2012). 
 
1.4.4 TDP-43 interacting proteins 
Given the importance to understand the RNA-processing functions, nuclear–cytoplasmic 
shuttling and aggregation properties of TDP-43, many recent studies have focused their 
attention on identifying TDP-43 interacting proteins. Nowadays, the most important 
binding partners of TDP-43 are members of the hnRNP family, such as hnRNP A2/B1, 
hnRNP A1, and hnRNP C1/C2 (Buratti et al., 2005). These protein interactions are 
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probably essential for the modulation of the functional properties of TDP-43. For example, 
in the case of hnRNPA1 the alteration of mRNA processing following the loss of this 
RNA–binding protein correlates well with the formation of TDP-43-positive inclusions in 
sporadic ALS motor neurons (Honda et al., 2015). Further evidence that hnRNP proteins 
can play a modulatory role on TDP-43 function has been provided using cell and animal 
models. In particular, functional experiments of the fruit fly orthologs of the human 
hnRNP A1/A2 (Hrp38) overexpression in HEK293 cells have demonstrated that TDP-43 is 
required for the spicing inhibitor activity of this protein (Romano et al., 2014). 
Additionally, experiments show that the interaction between TDP-43 and fly hnRNP 
A2/B1 homologues Hrb87F and Hrb98DE is important to suppress CGG repeat-induced 
neurotoxicity in a Drosophila model of Fragile X-associated Tremor/Ataxia Syndrome 
(FXTAS) (He et al., 2014). 
Notwithstanding all this evidence, the relationship between pathological mislocalization of 
TDP-43 and general levels of hnRNP proteins, with regards to altered RNA processing 
events occurring in neurodegenerative diseases, still remains unclear. In an effort to answer 
this question, Molecular Pathology Laboratory has been recently demonstrated that the 
interaction of TDP-43 with hnRNP L, PTB/nPTB and hnRNP A1/A2 affects the inclusion 
of the exon 17b in the neurotrophic receptor SORT1 mRNA, a pathologically-relevant 
splicing event known to be regulated by TDP-43 (Mohagheghi et al., 2016). Interestingly 
in this work, Mohagheghi and colleagues also looked at the expression levels of these 
hnRNPs in the temporal cortex of FTLD-TDP patients, in which a significant increase in 
exon 17b inclusion was previously observed. A significant increase in the splicing 
repressors hnRNP A1/A2 and PTB in FTLD-TDP-43 was observed in patients relative to 
controls. This may suggest that different hnRNP expression levels, which may depend on 
individual or age-related differences, on top of similar TDP-43 pathologies could 
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potentially account for different disease courses, with regards to both onset and 
progression. 
Given these results, our group decided to further characterize the linkage between TDP-43 
and hnRNP proteins, with the aim of finding other potential TDP-43 modulators belonging 
to this family. Taking advantage of Drosophila melanogaster and its available models of 
TDP-43 proteinopathies (see paragraph below), it was then possible to identify three 
promising hnRNPs, namely DAZAP1, hnRNP Q and hnRNP R (Appocher et al., 2017) 
that have subsequently become the object of my PhD thesis. Therefore, what is currently 
known about these factors will be reviewed in the next paragraphs. 
 
1.4.5 TDP-43 proteinopathies 
Abnormal cellular distribution and post-translational modifications of TDP-43 are present 
in many neurodegenerative disorders, which are now generally referred to as TDP-43 
proteinopathies (Scotter et al., 2015). In pathology, TDP-43 was described as the major 
component of the ubiquitin-positive, α-Synuclein and Tau-negative cytoplasmatic 
inclusions recognized in the brain and spinal cord tissues of FTLD-U and ALS patients 
(Arai et al., 2006; Neumann et al., 2006). These intracellular aggregates are characterized 
by ubiquitination, S409/410 phosphorylation, and proteolytic cleavage forming C-terminal 
fragments (CTFs) of 20-25 kDa (Neumann et al., 2006). TDP-43 inclusions have also been 
reported to occur in other neurodegenerative disorders, including 30% of Alzheimer 
patients and various forms of Parkinson’s disease, although TDP-43 inclusions exist side-
by-side but only partially co-localize with tau or α-Synuclein aggregates (Lagier-Tourenne 
et al., 2010). Two hypotheses have been suggested to explain the pathogenic role of TDP-
43 inclusions: gain-of-function (GOF) and loss-of-function (LOF). It is important to note 
that neither hypothesis excludes the other one, and they can act at the same time to 
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determine the onset and progression of the disease (Lee et al., 2011). Briefly, the “gain-of-
function” mechanism is based on the cytotoxicity induced by the formation of aggregates 
or toxic C-terminal fragments localized in the cytoplasm (Lee et al., 2011). According to 
this model, stress conditions can lead to redistribution of TDP-43 into the cytoplasm 
resulting in aggregation. Due to the fact that the auto-regulation of TDP-43 mRNA is a 
cytoplasmic event, it is possible that TDP-43 aggregates can still bind RNA and therefore 
auto-regulate themselves. This consequently may result in the decrease of newly 
synthesized TDP-43 proteins in affected cells and hence, nuclear clearance. The loss of 
normal nuclear TDP-43 may further increases cellular stress, again resulting in a vicious 
circle leading to cell death (Figure 9). 
 
 
Figure 9. Schematic representation of the TDP-43 gain-of-function model. Stress conditions lead to the 
formation of cellular aggregates (1). These aggregates promote TDP-43 auto-regulation (2), determining a 
decrease of TDP-43 synthesis (3) and loss of TDP-43 nuclear functions (4), with consequent cell death (5). 
(Source: Lee et al., 2011) 
 
On the other hand, the “loss-of-function” model is based on the hypothesis that cellular 
stress may lead to the formation of pathological stress granules or mislocalization of RNA 
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transport granules that are usually localized within peripheral neuritis, determining the 
formation of cytoplasmic inclusions that act as a “TDP-43 sink” with the clearance of this 
protein from the nucleus and the consequent dysregulation of many TDP-43-controlled 
events in RNA processing (Figure 10) (Igaz et al., 2011). 
 
 
Figure 10. Schematic representation of TDP-43 loss-of-function model. Stress conditions lead to 
cytoplasmic mislocalization and formation of cellular aggregates (1). These aggregates promote loss of TDP-
43 from nucleus (2), determining an increase of TDP-43 synthesis (3) and aggregation (4), with consequent 
cell death (5). (Source: Lee et al., 2011) 
 
1.4.6 Drosophila as a model for understanding TDP-43 proteinopathies 
The interest in Drosophila melanogaster as a powerful organism for studying cell biology 
became evident in the early twentieth century. Initially, Drosophila was introduced as an 
experimental model for investigating the Mendelian theory of heredity (Muqit and Feany, 
2002), but successively it has been widely used in the neurodegeneration field. Indeed, 
Drosophila presents many advantages, including a short life cycle (from 40 to 120 days), a 
compact genome, the possibility to screen substances/drugs very quickly and a high 
Introduction 	
 60 
neuronal complexity due to receptors, ion channels and neurotransmitters also found in 
humans (Romano et al., 2012). 
There are different species of Drosophila with differences in morphology, genetic 
background and habitat. Interestingly, Drosophila melanogaster has approximately 75% of 
genes whose the equivalent human homologue is associated with disease (Romano et al., 
2012).  
Regarding neurodegenerative disorders, various fly models have been used to understand 
the pathological mechanisms behind Parkinson’s, Alzheimer’s and Huntington’s disease, 
well as spinocerebellar ataxia, tauopathies and TDP-43 proteinopathies (Muqit and Feany, 
2002).  
Here, I am going to present some of the characteristics of the main homologue of human 
TDP-43 in Drosophila, called TBPH, and some of the findings obtained using this 
organism as an experimental model. 
Briefly, TDP-43 and TBPH have a strong homology at the level of the region containing 
RRM1 and RRM2 (Figure 11A) (Wang et al., 2004). Another characteristic in common 
with TDP-43 is the presence of different splicing isoforms (Figure 11B) (Wang et al., 
2004), as well as, the preferential binding to UG-rich sequences (Ayala et al. 2005).  
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Figure 11. Comparison of human TDP-43 and Drosophila TBPH proteins. Schematic representation of 
the protein structure in both (A) and alignment of the human (TDP-43) and fly (TBPH) proteins (B) are 
reported. (Source: Modified from Romano et al., 2012) 
 
Functionally, TBPH shows same splicing inhibitory effects both in vitro and in vivo (Ayala 
et al., 2005), and although the C-terminal tail of TBPH represents the region with less 
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homology with TDP-43 it can still bind to the same nuclear protein interactors as TDP-43 
(D’Ambrogio et al. 2009).  
Most importantly, it is possible to achieve different fly phenotypes, including null allele 
flies (loss-of-function model), transgenic flies overexpressing wild-type TDP-43 or ALS-
related mutations (gain-of-function model), and transgenic flies silenced for this factor 
(RNA interference transgenic flies)  
These approaches are described as follows: 
- Loss-of-function model (null allele flies): were created by the disruption of TBPH 
gene to test if an ALS-like phenotype could be generated. Different approaches 
were used to achieve this aim, including: knockout of TBPH through the partial 
removal of its coding and regulatory sequence (Feiguin et al., 2009); point mutation 
(G>A) in order to create a stop codon (Lu et al., 2009); deletion of 932 bp at the 5¢ 
end of TBPH (Lin et al., 2011); and the generation of null allele in which the entire 
coding sequence was deleted (Fiesel et al., 2010). Interestingly, in this latter 
approach, Fiesel and collaborators observed lethality at the second larval stage. 
This is in contrast to the TBPH knockout approach of Feiguin and collaborators that 
has reported viability of some larvae after embryogenesis, with most of them able 
to reach the pupal stage and undergo metamorphosis but do not eclose, remaining 
trapped inside their pupal cages. However, the knockout flies able to get rid the 
external cuticle presented uncoordinated movements, reduction of axonal branches 
and synaptic boutons present inside muscles (Feiguin et al., 2009). Nevertheless, 
the overexpression of human TDP-43 (hTDP-43) was able to rescue the aberrant 
phenotype (Feiguin et al., 2009; Lu et al., 2009). 
- Transgenic flies: were achieved by the creation of transgenic flies using the Gal4-
UAS system (Figure 12) (Brand and Perrimon, 1993). This system permits the 
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ectopic expression of a human transgene (gain-of-function model), as well as the 
knockdown of an endogenous gene (RNA interference transgenic flies) in a specific 
tissue or cell type. For instance, it has been widely demonstrated that the 
overexpression of hTDP-43 or TBPH is able to cause eye degeneration associated 
with cell death (Hanson et al., 2010; Estes et al., 2011). In a similar way, the 
overexpression of wild-type TDP-43 in mushroom bodies and in motor neurons 
caused neuronal death and axonal loss, whereas the overexpression of TDP-43 in 
motor neurons lead to cytoplasmic and axonal aggregation (Li et al., 2010). Loss of 
motor neurons and reduction in life span were also identified after the 
overexpression of ALS/FTLD-linked and synthetic mutations (Voigt et al., 2010). 
Furthermore, it has been demonstrated that the ectopic expression of wild-type 
TDP-43 or its variants was associated with age- and dose-dependent toxicity 
(Hanson et al., 2010). TDP-43 toxicity was also found to correlate with its 
subcellular localization (Ritson et al., 2010; Miguel et al., 2011). Indeed, 
cytoplasmic and nuclear inclusions of TDP-43 were found toxic in different tissues, 
such as eyes, muscles and glia (Miguel et al., 2011). However, the formation of 
inclusions was not a prerequisite for TDP-43 toxicity, since increased levels of both 
nuclear and cytoplasmic TDP-43 were found toxic even in absence of inclusions 
(Miguel et al., 2011). In contrast, the generation of transgenic flies silenced for 
TBPH exclusively in neuronal tissue was found to induce similar locomotive 
defects observed in the null allele flies (Feiguin, et al., 2009) . Moreover, Li and 
collegues showed that the depletion of TBPH in the central nervous system and the 
mushroom bodies of Drosophila caused axonal loss and neuronal death (Li, et al., 
2010). 
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Transgenic flies were not used only to assay the TDP-43 misregulation in the 
context of ALS-linked mutations, but also to clarify the role of TDP-43 in other 
degenerative disorders, as in the case of the Inclusion Body Myopathy associated 
with Paget’s Disease of Bone and Frontotemporal Dementia (IBMPFD) (Ritson et 
al., 2010). 
 
 
Figure 12. Gal4-UAS system. This system is based crossing two transgenic fly lines. The first fly line 
(UAS–human-transgene fly) harbours the transgene of interest that is placed downstream of a UAS activation 
domain consisting of GAL4-binding sites. The second fly line (enhancer-trap GAL4 fly) harbours a yeast 
transcriptional activator called GAL4 located downstream of a cell- or tissue- specific promoter. These latter 
flies are known as “drivers”. In this system, the ectopic expression of the transgene of interest is obtained by 
crossing the two fly lines.  There is a wide array of promoters available for the ectopic expression of a 
transgene, such as the pan-neural promoter elav (embryonic lethal, abnormal vision) or the eye-specific 
promoter GMR (Glass Multimer Reporter). (Source: Muqit & Feany, 2002) 
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1.5 DAZ Associated Protein 1 (DAZAP1) 
1.5.1 Characteristics of DAZAP1 
DAZ associated protein 1 (DAZAP1) was originally identified as an RBP associated with 
the DAZ proteins, DAZ and DAZ-Like (DAZL), using a yeast two-hybrid system (Tsui et 
al., 2000). DAZAP1 is encoded by the DAZAP1 gene located on the short arm (p) of 
human chromosome 19 at position 13.3 (19p13.3) (Figure 13). DAZAP1 consists of 12 
exons spanning about 28 kb (Dai et al., 2001; Tsui et al., 2000). 
 
 
Figure 13. Localization of DAZAP1 gene on human chromosome 19. The Genomic locus encoding 
DAZAP1 is identified by a yellow arrow. (Source: Modified from Genetic home resource) 
 
Two major DAZAP1 transcript variants of 1.75 and 2.4 kb are generated through 
alternative polyadenylation (Yang and Yen, 2013; Tsui et al., 2000). These transcripts are 
highly abundant in human testis (Dai et al., 2001; Tsui et al., 2000) and ovaries (Pan et al., 
2005), with a low expression level in non reproductive organs including liver, brain, 
placenta, heart, skeletal muscle, kidney and pancreas (Dai et al., 2001; Tsui et al., 2000).  
Furthermore, DAZAP1 is extremely conserved among the evolution. Human and mouse 
DAZAP1 share 89% similarity in the coding sequence, although they diverge in protein 
sequence for 9 amino acid residues: 7 substitutions and 2 deletions/insertions. Furthermore, 
both of the mammalian proteins share 89% similarity and 81% identity with the Proline-
rich RNA Binding Protein (Prrp) of Xenopus (Dai et al., 2001). 
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From a structural point of view, the full-length protein represents the major splicing 
isoform that is composed of 407 amino acid residues (≈ 45 kDa), with two RRMs in the N-
terminal portion, and a proline-rich (Pro-rich) C-terminal region (Figure 14) (Dai et al., 
2001; Tsui et al., 2000). The high level of similarity of these RRMs with those present in 
many other hnRNPs (e.g. Drosophila hnRNP 27C) makes DAZAP1 a member of the 
hnRNP protein family (Dai et al., 2001; Tsui et al., 2000). 
 
 
 
Figure 14. Schematic representation of DAZAP1 domains. The full-length DAZAP1 (407 amino acid 
residues) is composed of an N-terminal domain containing two RNA-recognition motifs (RMM1 and RRM2) 
and a C-terminal domain containing a proline-rich region (Pro-rich).  
 
Furthermore, DAZAP1 was found to shuttle between nucleus and cytoplasm during 
different stage of mouse spermatid maturation, as well as in non germinal cells in response 
to external stimuli (Vera et al., 2002; Lin and Yen, 2006). In 2006, a study carried out in 
somatic cells demonstrated DAZAP1’s association with nuclear structures as a component 
of hnRNP particles, and mapped the region comprising the last 25 amino acids at the C-
terminus (C25) as important residues for the nuclear localization (Lin and Yen, 2006). This 
C25 region does not share sequence similarity to other NLS or shuttling signals, and it also 
contains the nuclear export signal for cytoplasmic localization. Therefore, it was called the 
nucleocytoplasmic shuttling signal (ZNC) (Lin and Yen, 2006).  
The sublocalization of DAZAP1 was also found to be associated with the transcription 
state of its mRNA targets (Lin et al., 2012) and the acetylation of the Lysine 150 residue 
within its second RRM (Sasaki et al., 2012). In particular, the signal necessary and 
407 aa RRM1	 RRM2	 Pro-rich	N- -C 
       10                          190       222                          385 
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sufficient for the transcription-dependent nuclear localization of DAZAP1 was represented 
by a sequence of 42 amino acid residues located at the N-terminal (N42) of DAZAP1 (Lin 
et al., 2012), and the mutation of Lysine 150 was correlated with its cytoplasmic retention 
and association with mitochondria (Sasaki et al., 2012). 
 
1.5.2 Functions of DAZAP1 
Nowadays, little information is available in literature regarding the natural RNA substrates 
and cellular functions of DAZAP1, albeit, as a member of hnRNP family, its cellular 
activity can be related to the regulation of RNA metabolism. 
The first evidence supporting this hypothesis came out when DAZAP1 was found to be 
associated with RNA homopolymers, preferentially polyU and polyG tracts, in vitro (Dai 
et al., 2001; Tsui et al., 2000); and later when it was identified as an AU-rich element 
(ARE) binding protein bound to the ARE of the Tumor Necrosis Factor-alpha (TNF-α)  
(Rousseau et al., 2002) and the Cellular Oncogene Fos (c-Fos)  (Morton et al., 2006) 
mRNAs. Two consensus sequences (AAAUAG and GU1-3AG) and two secondary 
structures (loops L1 and L2) were further characterized in the RNA ligands of the mouse 
DAZAP1 orthologous and in the 3'UTR of the all known target mRNAs of Xenopus Prrp 
(Hori et al., 2005). Interestingly, the AUG sequence contained in both the DAZAP1 
consensus sequences was also reported in the mRNA targets of other RBPs, including 
hnRNP A1 (Burd and Dreyfuss, 1994), hnRNP D (Kajita et al., 1995) and Musashi1 
(Msi1) (Imai et al., 2001). In this context, it has been proposed the role of DAZAP1 in the 
transport/localization (Lin et al., 2012; Lin and Yen, 2006; Zhao et al., 2001) and 
translation of different mRNAs is through the binding to their 3'UTRs (Smith et al., 2011; 
Yang et al., 2009; Morton et al., 2006). In particular, DAZAP1 was found to be 
accumulated in the cytoplasm when transcription was inhibited, suggesting that this protein 
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could translocate from nucleus to cytoplasm with exported mRNAs (Lin and Yen, 2006) as 
described for hnRNP A1 (Piñol-Roma and Dreyfuss, 1992). Moreover, DAZAP1 was able 
to stimulate translational initiation of mRNAs in a manner that was sensitive to the 
adenylation status of those mRNAs (Smith et al., 2011). 
Other interesting findings demonstrate that the nuclear fraction of DAZAP1 is able to 
affect the splicing of different transcripts. It was identified, together with hnRNP A1, as a 
splicing-inhibitor factor of the mutant T6 of BRCA1 exon 18 (Goina et al., 2008). 
DAZAP1 was also implicated in the mRNA splicing of the Ataxia Teleangectasia Mutated 
(ATM) gene through the interaction with Alu-derived Intronic Splicing Enhancer (ISE) and 
the consequent inclusion of a cryptic exon (Pastor and Pagani, 2011). DAZAP1 was also 
found to regulate the intron inclusion of different mRNA targets in a minigene system 
(Chen et al., 2013), and was described as binding to an intronic splicing enhancer or 
silencer in human cells (Wang et al., 2012, 2013). Moreover, a recent publication has 
highlighted the role of DAZAP1 in cell proliferation and migration. Indeed, mRNA-seq 
analysis of HEK293 cell line identified several genes, most of them related to the 
maintenance of cell proliferation, regulated by the splicing activity of DAZAP1. This 
activity was also found to be affected by the Extracellular Signal-regulated Protein Kinase 
(MEK/Erk) signalling pathway through the phosphorylation of the DAZAP1 proline-rich 
domain (Choudhury et al., 2014). 
 
1.5.3 DAZAP1 interacting proteins 
Few DAZAP1 binding partners are described in the literature. The first well-characterized 
interactors are certainly DAZ and DAZL (Dai et al., 2001; Tsui et al., 2000), but other 
putative interacting proteins were established later. In most of the cases, the DAZAP1-
protein contacts occurred between the RRMs of DAZAP1 and the C-terminus of its 
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partners, as described for hnRNP U like 1, hnRNP A/B, hnRNP A1, hnRNP D and DEAD-
Box Helicase 20 (DDX20) (Yang et al., 2009). However, more recently it has been 
reported that the transcription-dependent nuclear localization of DAZAP1 could be 
involved in the association of DAZAP1 to its partners, as described for the binding to the 
Steroid Receptor RNA Activator Stem-loop Interacting RNA Binding Protein (SLIRP) 
(Lin et al., 2012). 
Moreover, the phosphorylation state of DAZAP1 was demonstrated to disrupt the 
interaction with binding partners, affecting its cellular functions. Indeed, the 
phosphorylation of Thr269 and Thr315 in its Proline-rich C-terminus by the Extracellular 
Signal Regulated Kinase 2 (ERK2) could promote the dissociation of DAZAP1 from DAZ, 
allowing the interaction of DAZ with other proteins involved in mRNA translation such as 
PABP (Morton et al., 2006). 
 
1.5.4 DAZAP1 and pathologies 
A link between alteration of DAZAP1 homeostasis and the development of disorders is 
still not clear. However, two studies have described how the t(1;19)(q23;p13.3) 
translocation present in TS-2 Acute Lymphoblastic Leukemia (ALL) cells could lead to the 
expression of two in-frame fusion proteins between DAZAP1 gene and Myocyte Enhancer 
Factor 2D (MEF2D) gene with oncogenic properties: DAZAP1/MEF2D and 
MEF2D/DAZAP1. Indeed, DAZAP1/MEF2D and MEF2D/DAZAP1 efficiently activated 
the transcription of genes important for lymphocyte growth and retained RNA-binding 
properties, respectively, indicating for the first time DAZAP1 as a putative factor 
implicated in cancer (Prima and Hunger, 2007; Prima et al., 2005). 
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1.6 Heterogeneous Nuclear Ribonucleoprotein Q (hnRNP Q) 
and Heterogeneous Nuclear Ribonucleoprotein R (hnRNP R): 
two closely related hnRNP proteins 
1.6.1 Characteristics of hnRNP Q and hnRNP R 
The RNA binding protein hnRNP Q, also known as SYNCRIP, was first described in 1997 
as a nucleocytoplasmic protein interacting with the synaptotagmin isoform II (Syt-II) 
C2AB domain in mouse brain lysate (Mizutani et al., 1997). hnRNP Q was subsequently 
found in association with human Survival of Motor Neurons (SMN) (Mourelatos et al., 
2001).  The hnRNP Q protein is encoded by the SYNCRIP gene located on the long arm (q) 
of human chromosome 6 at position 14.3 (6q14.3) (Figure 15). SYNCRIP consists of 12 
exons that are subjected to alternative splicing resulting in different isoforms, three of 
which are the most representative: hnRNP Q3, hnRNP Q2 and hnRNP Q1 (Figure 16A-C) 
(Mourelatos et al., 2001). 
 
 
Figure 15. Localization of SYNCRIP gene on human chromosome 6. The Genomic locus encoding 
hnRNP Q is identified by a yellow arrow. (Source: Modified from Genetic home resource) 
 
Regarding these isoforms, the nucleic acid sequence of hnRNP Q3 (also known as GRY-
RBP) (Neubauer et al., 1998) encodes the longest variant with the closest protein sequence 
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identity (83% homology) to hnRNP R (Mourelatos et al., 2001). hnRNP Q3 is composed 
of 623 amino acid residues (≈ 70 kDa) containing an acidic domain (AcD), three RRMs, 
two NLS and a RGG-box (Figure 16B). The Q2 variant (≈ 65 kDa) lacks of 36 amino acids 
(302-336) between RRM2 and RRM3 comparing to the longest variant hnRNP Q3 (Figure 
16A), while hnRNP Q1 (≈ 62 kDa) lacks of the second NLS and RGG-box region (549-
623) with respect to hnRNP Q3 and contains a unique C-terminal domain 
(VKGVEAGPDLLQ) (Figure 16C) (Mourelatos et al., 2001). Furthermore, hnRNP Q is 
expressed in different tissues, such as spinal cord, muscle, brain, heart, kidney, liver and 
spleen (Rossoll et al., 2002). 
 
Figure 16. Schematic representation of protein domains and major isoforms of hnRNP Q. The 
SYNCRIP gene encodes three main splicing isoforms: hnRNP Q2 (A), hnRNP Q3 (B) and hnRNP Q1 (C). In 
this figure AcD (acidic domain), RRMs (RNA-recognition motifs), NLS (nuclear localization signal), RGG 
(Arg-Gly-Gly)-box and Glutamine/Asparagine (Q/N)-rich domain are highlighted in coloured boxes; relative 
sequence position and amino acid length of each isoform is also reported. (Source: Modified from Cappelli et 
al., 2018) 
 
On the other hand, a 2.5 kb cDNA clone corresponding to hnRNP R was first described in 
1998 in the serum of patients with autoimmunity symptoms (Hassfeld et al., 1998) and 
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subsequently identified, like hnRNP Q, as a factor bound to the SMN protein (Rossoll et 
al., 2002).  The protein hnRNP R is encoded by the HNRNPR gene located on the p arm of 
human chromosome 1 at position 36.12 (p36.12) (Figure 17) and consists of 11 exons. 
Different isoforms are generated from alternative splicing events.   
 
Figure 17. Localization of HNRNPR gene on human chromosome 1. The Genomic locus encoding 
hnRNP R is identified by a yellow arrow. (Source: Modified from Genetic home resource) 
 
The isoform 1 of hnRNP R (hnRNP R1) is the most highly expressed and it is composed of 
633 amino acid residues (≈ 82 kDa) containing an AcD domain, three RRMs, two NLS, a 
RGG-box and a Q/N-rich domain at C-teminus (Figure 18A) (Hassfeld et al., 1998). 
Moreover, this variant is ubiquitously expressed in all tissues (Huang et al., 2005; Rossoll 
et al., 2002). Recently a low level expressed and neuronal-specific isoform (hnRNP R2, ≈ 
75 kDa) has been characterized. This isoform differs from the R1 because of the exclusion 
of exon 5 (114 bp) from the cDNA sequence, resulting in the absence of 41 amino acids 
(129-166) between the AcD domain and the first RRM (Figure 18B) (Huang et al., 2005).  
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Figure 18.  Schematic representation of protein domains and major isoforms of hnRNP R. The 
HNRNPR gene encodes two main splicing isoforms: hnRNP R1  (A) and  hnRNP R2 (B). In this figure AcD 
(acidic domain), RRMs (RNA-recognition motifs), NLS (nuclear localization signal), RGG (Arg-Gly-Gly)-
box and Glutammine/Asparagine (Q/N)-rich domain are highlighted in colored boxes; relative sequence 
position and amino acid length of each isoform is also reported. (Source: Modified from Cappelli, Romano 
and Buratti, 2018) 
 
Interestingly, hnRNP Q and hnRNP R are extremely conserved through evolution, 
although in lower organisms (e.g. D. melanogaster and C. elegans) they are represented by 
just one well-conserved orthologue (Cappelli et al., 2018; McDermott et al., 2012; Kabat et 
al., 2009). This suggests the occurrence of a progressive functional divergence into two 
distinct paralogues in higher organisms, such as mammals. In particular, the Drosophila 
homologue CG17838 (Syp) shares 46-47% sequence identity and ca. 57-60% of similarity 
to mammalian hnRNP Q and hnRNP R (Cappelli et al., 2018; McDermott et al., 2012). 
The human counterparts share almost 50% amino acid identity in their three RNA-binding 
domains with HRP-2, the nematode homologue of the mammalian hnRNP Q and R 
proteins (Kabat et al., 2009). 
Regarding the subcellular localization of hnRNP Q and hnRNP R, the presence of a NLS    
motif in the protein sequence indicates the prevalent retention of these RBPs in the 
nucleus, even if translocation in the cytoplasm was observed in the case of hnRNP Q 
(McDermott et al., 2014; Quaresma et al., 2009; Akihiro Mizutani et al., 2000). Indeed, the 
transport of hnRNP Q within the dendrites of cultured rat hippocampal neurons has been 
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described as a component of mRNA granules (Bannai et al., 2004). hnRNP Q was also 
found re-localized to cytoplasmic granules after stress condition (Quaresma et al., 2009). 
Moreover, in a study performed in 2006, the methylation status of the RGG box of hnRNP 
Q was reported to be associated with its shuttling (Passos et al., 2006).  
Contrary to hnRNP Q, Mizutani and collaborators proposed the existence of a second 
putative bipartite-type NLS motif (KRKADGYNPDSKRR), similar to that observed for 
nucleoplasmin (Robbins et al., 1991), located at the C-terminal region of hnRNP R (572–
586 amino acids) to explain the prevalently nuclear localization of hnRNP R (Mizutani et 
al., 2000). However, the expression of hnRNP R was not only detected in the nucleus, but 
was also found in cytoplasm and neurites of cultured embryonic motor neurons (Dombert 
et al., 2014; Rossoll et al., 2002) and in the cytoplasm, dendrites and axon terminals of rat 
bipolar cells (Peng et al., 2009). 
 
1.6.2 Functions of hnRNP Q and hnRNP R 
Functionally, hnRNP Q and hnRNP R are known to regulate different aspects of RNA 
maturation. For example, the C. elegans orthologue of hnRNP Q and hnRNP R was found 
to be involved in the alternative splicing of genes containing cassette exons flanked by an 
intronic UCUAUC motif (Kabat et al., 2009). 
More specifically to the mammal hnRNP Q counterpart, the Q3 isoform was identified as a 
component of the spliceosome in 1998 (Mourelatos et al., 2001; Neubauer et al., 1998). 
Subsequently the capability of all the other variants to bind in vitro pre-mRNA and intron-
containing RNA intermediates has been discovered (Mourelatos et al., 2001). Recently, 
hnRNP Q1 was found to promote inclusion of SMN2 exon7, whereas the other two variants 
(hnRNP Q2/Q3) were found to antagonize the activity of hnRNP Q1 by inducing exon 7 
exclusion (Chen et al., 2008).  
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Controlling RNA editing was described as another hnRNP Q function, since the Q3 
isoform was discovered to inhibit C-to-U RNA editing of the Apolipoprotein B (apoB) 
mRNA (Blanc et al., 2001). In addition, hnRNP Q3 can also affect mRNA transport, as 
demonstrated by its colocalization with ribosomal proteins and other RBPs in neuronal 
mRNA granules (Bannai et al., 2004; Kanai et al., 2004), and translation by competing 
with poly(A) binding proteins (Svitkin et al., 2013) or as in the case of mouse Cytochrome 
1 (Cry) gene by binding its 5'UTR (Lim et al., 2016). 
On the other hand, hnRNP R was identified as a splicing factor involved in the assembly of 
the pre-catalytic spliceosome during stress conditions (Tonevitsky et al., 2009). Depletion 
of hnRNP R impairs translocation of β-actin mRNA to the axonal growth cone in isolated 
embryonic mouse motor neurons (Glinka et al., 2010). Moreover, hnRNP R is involved in 
the transcription and degradation process of c-Fos mRNA in retinal cells (Huang et al. 
2008) and in the expression of immunity factors (Meininger et al., 2016; Reches et al., 
2016). 
Finally, hnRNP Q and hnRNP R regulate the morphology and the development of neural 
structures (McDermott et al., 2012, 2014; Chen et al., 2012). For instance, Drosophila Syp 
is required to regulate the postsynaptic morphology of neuromuscular junction (NMJ) 
through the maintenance of protein levels of important transcripts associated with 
neuron/cell projection morphogenesis or development (McDermott et al., 2014). 
Drosophila Syp also coordinates the translation in post-synapses with retrograde signalling 
to pre-synapses (Halstead et al., 2014). Moreover, hnRNP Q1 is also able to modulate 
neuronal morphogenesis and neurite branching in a mouse neuroblastoma cell line by 
interacting with different mRNAs related to Cdc42 signalling (Chen et al., 2012). 
Depletion of hnRNP R can reduce axonal 7SK, a nuclear RNA that modulates 
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transcription, and in turn led to defective axon growth in NSC-34 cells (Briese et al., 
2018). 
 
1.6.3 hnRNP Q and hnRNP R interacting proteins  
The interest in hnRNP Q and hnRNP R characterization was initially promoted by the 
identification of SMN protein as a potential binding partner (Rossoll et al., 2002; 
Mourelatos et al., 2001). The RGG motif in the C-terminus of both hnRNP Q and hnRNP 
R was proposed to mediate this association (Rossoll et al., 2002). 
At the present, however, few studies have described additional interacting proteins. Among 
them, hnRNP Q and hnRNP R were identified as putative TDP-43-associated proteins 
(Ling et al., 2010), as well as it has been demonstrated their interaction with Rev protein of 
HIV (Hadian et al., 2009). Moreover, hnRNP Q was found to bind specifically to galectin-
3, a protein that stimulates proliferation in various cell types (Yoo et al., 2009) and the Q1 
isoform was found to be associated through its Gly-rich C-terminus with the 
multifunctional nuclear phosphoprotein NS1 required for viral replication of the minute 
virus of mice (Harris et al., 1999).  
 
1.6.4 Implication of hnRNP Q and hnRNP R in pathology 
Nowadays, information about the development and progression of diseases associated with 
aberrant levels of hnRNP Q and hnRNP R is still incomplete. One study has investigated 
the role of hnRNP Q1 in tumorigenesis of colorectal cancer (Lai et al., 2017). Both hnRNP 
Q1 protein and mRNA levels were found to be upregulated in human tumor tissues 
compared with adjacent normal ones. Moreover, hnRNP Q1 was identify to bind to the 
5'UTR of Aurora-A mRNA regulating its translation and in turn increasing cell 
proliferation and tumor progression (Lai et al., 2017).  
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Replication of the minute virus of mice (Harris et al., 1999) and HIV (Hadian et al., 2009) 
were also affected by hnRNP Q. In the first case, hnRNP Q1 was proposed as a cofactor in 
the double-stranded DNA-binding activity of NS1, whereas in the second study, the 
overexpression of hnRNP Q in concert with other hnRNP proteins, including hnRNP R, 
influenced the HIV-1 production by persistently infected astrocytes.
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2. AIM OF THE PROJECT 
As mentioned in the previous Chapters, several evidences have suggested an interesting 
correlation between TDP-43 pathology and hnRNP misregulation. In order to clarify the 
tangled scenario underlying TDP-43 metabolism and identify physiological partners of 
TDP-43 among the hnRNP family, the Molecular Pathology laboratory at ICGEB has 
recently taken advantage of Drosophila melanogaster as a TDP-43 proteinopathy model. 
First of all, we evaluated how many human hnRNP proteins have homologs in Drosophila. 
In total, we found 11 human hnRNPs having a counterpart conserved in Drosophila. Then, 
in order to determine which of these genes were able to modulate TDP-43 activity in vivo, 
we performed a systematic gene suppression screening crossing flies silenced for these 
hnRNPs either with TBPH/TDP-43 hypomorphic flies (loss-of-function model) or 
transgenic flies overexpressing TBPH/TDP-43 in the eye compartment (gain-of-function 
model). We found that three hnRNPs, namely Hrb27c (DAZAP1) and Syncrip/Syp 
(hnRNP Q and R) had an extremely negative effect when knocked out in combination with 
TBPH. However, at the same time, they seemed to be protective in the TBPH gain-of-
function expression model. Taken together, these results suggested that alteration of the 
expression levels of hnRNP proteins could represent a response against TDP-43 gain and 
loss-of-function events and could enable an in vitro characterization by using cell cultures.  
Therefore, the main purpose of my PhD project was to clarify the bases of the opposite 
results observed in both the Drosophila models of TDP-43 proteinopathies after DAZAP1, 
hnRNP Q and hnRNP R depletion. This was achieved through the investigation of their 
functional relationship with TDP-43 within human neuronal-like cells, in order to highligh 
differences and similarities in regulation of RNA metabolism. 
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Initially, I studied the influence of each hnRNP protein on well-known TDP-43 regulated 
events and subsequently analysed the overall transcriptome status of RNA samples 
collected from human neuroblastoma (SH-SY5Y) cells treated with siRNA against TDP-43 
and each hnRNP, in order to identify commonly regulated RNA targets involved in neuron 
development and neurodegeneration disease.  
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3. MATERIALS AND METHODS 
3.1 Cell cultures, gene knockdown and cell differentiation 
3.1.1 Cell cultures 
Human neuroblastoma SH-SY-5Y cells (ATCC), HeLa cells (ATCC) and Flp-In HEK293 
cells (Invitrogen, ThermoFisher, Waltham, MA, USA) expressing inducible Flag-tagged 
TDP-43 12XQ/N aggregates were cultured in DMEM–Glutamax-I (Gibco-BRL, Life 
Technologies Inc., Frederick, MD, USA) supplemented with 10% fetal bovine serum 
(Gibco-BRL, Life Technologies Inc., Frederick, MD, USA) and 1% Antibiotic-
Antimycotic-stabilized suspension (SigmaAldrich, St. Louis, MO, USA) at 37°C in an 
incubator with humidified atmosphere of 5% CO2.  
The mouse motor neuron-like NSC-34 cell line (a kind gift of Antonia Ratti, University of 
Milan, Milan, Italy) was cultured in Dulbecco’s modified Eagle’s medium (DMEM)–
Glutamax-I (Gibco- BRL, Life Technologies Inc., Frederick, MD, USA) supplemented 
with 5% fetal bovine serum (FBS) (SigmaAldrich, St Louis, MO, USA) and 1% 
Antibiotic-Antimycotic-stabilized suspension (Sigma-Aldrich, St Louis, MO, USA) at 
37°C in an incubator with humidified atmosphere of 5% CO2.  
All the cell cultures were used up to 20 passages. 
 
3.1.2 Gene knockdown of SH-SY5Y neuroblastoma cell line 
To achieve optimal knockdown efficiency, three rounds of silencing were performed on 
day 1, 3 and 5 using HiPerFect Transfection Reagent (Qiagen Inc, Gaithersburg, MD, 
USA), according to the manufacturer’s instructions. Briefly, 50X104 cells were seeded in 
6-well plates and silenced with a mix composed of 100 µl Opti-MEM (Life-Technologies, 
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CA, USA), 3 µl of 40 µM siRNA and 6 µl hyperfectamine (day 1). At the third day (day 3) 
cells were trypsinised, plated in a p60 plate and silenced for the second time using a double 
volume of mix. The same procedure was repeated at the third time (day 5) plating cells in a 
p100 plate and using a double volume of mix with respect to the second round of silencing. 
The final siRNA concentration for each time of silencing was 80 nM. After 48 hours cells 
were analysed by western blot (WB), pre-mRNA splicing, gene expression or used for 
immunofluorescence (IF) analysis.  
For experiments with double knockdown (siTDP-43/siDAZAP1, siTDP-43/sihnRNP Q 
and siTDP-43/sihnRNP R) the amount of siRNA used for depletion of each gene was the 
half of the single knockdown. 
The siRNA sense sequences used in this study are described in Table 1. 
 
Table 1. siRNA sequence from 5¢-prime to 3¢-prime are listed.  
Target gene siRNA sense sequence 
Fire-fly luciferase (siLUC-control) 5’-uaaggcuaugaagagauac-3’ 
TDP-43 (siTDP-43) 5’-gcaaagccaagaugagccu-3’ 
DAZAP1 (siDAZAP1) 5’-gagacucugcgcagcuacu-3’ 
hnRNP Q (sihnRNP Q) 5’-agacagugaucucucucau-3’ 
hnRNP R (sihnRNP R) 5’-cauuugggaucuacgucuu-3’ 
 
 
3.1.3 Gene knockdown of Flp-In HEK293 cell line expressing TDP-43 
aggregates  
Flp-In HEK293 cells with inducible siRNA resistant FLAG-tagged TDP-43-12XQ/N 
aggregates (75X104) were seeded in 6-well plates in 1.5 ml of culture medium containing 
serum and antibiotics. A total of 4 µl of 40 µM siRNA against DAZAP1, hnRNP Q and 
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hnRNP R was diluted in 90 µl of Opti-MEM (Life-Technologies, CA, USA) and 6 µl of 
HiPerFect Transfection Reagent (Qiagen Inc, Gaithersburg, MD, USA) (day 1). Second 
and third siRNA treatment were performed at day 2 and day 3, respectively. For each 
round of silencing, cells were tripsinised, plate in a new 6-well and silenced with the same 
amount of siRNA mixture as described for day 1. Importantly, for all the conditions, the 
silencing was performed in duplicates because of one plate was used for WB analysis and 
the second one for IF analysis. For this latter, the third round of siRNA treatment was 
performed in 6-well plates containing microscope slides treated with 0.1 mg/ml Poly-L-
Lysine (Sigma-Aldrich, St Louis, MO, USA). 
The list of siRNA used for silencing Flip-In HEK293 is the same described in section 3.1.2 
and reported in Table 1. 
At day 4, culture medium was changed and the TDP-43 12XQ/N aggregation was induced 
by addition of 1 µg/ml tetracycline solution (Sigma-Aldrich, St Louis, MO, USA). After 48 
hours, cells were prepared for WB or IF analysis. 
 
3.1.4 NSC-34 differentiation 
NSC-34 cells were seeded to reach 70% confluence the day after and the proliferation 
medium was exchanged 24 hours later to fresh differentiation medium containing 1:1 
DMEM/F-12 Ham (Sigma-Aldrich, St Louis, MO, USA), 1% FBS (Sigma-Aldrich, St 
Louis, MO, USA), 1% modified Eagle’s medium nonessential amino acids (NEAA) 
(Sigma-Aldrich, St Louis, MO, USA), 1% Antibiotic-Antimycotic-stabilized suspension 
(Sigma-Aldrich, St Louis, MO, USA) and 1 μM all-trans retinoic acid (RA) (Sigma-
Aldrich, St Louis, MO, USA). Differentiation medium was changed every two days and 
cells were allowed to differentiate for up to 5 days. NSC-34 cells, maintained on 
proliferation medium (DMEM, 5% FBS, 1% Antibiotic-Antimycotic suspension) 
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represented the undifferentiated control group. Images of undifferentiated (control, 
CNTRL) and differentiated NSC-34 cells were acquired by light microscopy using a Leica 
DMIL LED mycroscope equipped with a 20X objective, a Leica DFC450 C camera (Leica 
Microsystems, Cambridge, UK) and LAS v.4.4.0 Software (Leica application suit). The 
average length of neurites in the differentiation media was compared to that in the 
proliferation media and quantified using Fiji NeuronJ (Meijering et al., 2004). Neurite 
length was analyzed by imaging a minimum of 5 cells per field. The mean of neurite length 
± standard error is reported. Statistical significance was calculated using t-test (indicated as 
*** for P ≤ 0.001). 
 
3.2 DNA plasmids for protein overexpression 
3.2.1 Generation of competent DH5a Escherichia coli cells 
To prepare competent DH5a E. coli cells, the protocol of Chung and collaborators (Chung 
et al., 1989) was followed introducing few modifications. DH5a stored in glycerol (1:1) at 
-80 °C were defrosted in ice and then plate in Petri dishes containing Luria-Bertani broth 
(LB) without antibiotics. The day after, one colony was picked up and grown overnight at 
37 °C with 10 ml of LB (pre-inoculum). The third day 1-2 ml of pre-inoculum was diluted 
into 50 ml of LB and grown at 37 °C until its optical density reached an OD590 value of 
0.3-0.4. Once the OD desired was obtained, bacteria were collected by centrifugation at 
1000 xg for 10 minutes at 4 °C, resuspended into 5 ml of ice-colled diluted TSS 1X pH 6.5 
(Table 2) and aliquoted in 1.5 ml sterile tubes and instantly frozen in liquid NO2 for 
storage at -80 °C. To evaluate the competence of cells, 0.1 ng/µl of pUC18 plasmid was 
used to transform 100 µl of DH5a cells (see section below). Competence was calculated as 
following: 
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𝐶𝑜𝑚𝑝𝑒𝑡𝑒𝑛𝑐𝑒	(10-) 	= 𝐶𝑜𝑙𝑜𝑛𝑦	𝐹𝑜𝑟𝑚𝑖𝑛𝑔	𝑈𝑛𝑖𝑡𝑠𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝑜𝑓	𝑝𝑈𝐶18	 
 
Table 2. Composition of TSS 1X. 
Reagent Amount for 50 ml  
Polyethylene glycol (PEG 400) (SERVA 
Electrophoresis GmbH, Heidelberg,Germany) 
5 g 
MgCl2 35 mM 
DMSO 5% 
Up to 50 ml with LB 35 ml ca. 
 
 
3.2.2 Trasformation of competent DH5a cells 
The amplification of desired plasmid DNA was obtained through bacteria trasformation. 
Competent bacteria (30 µl) were transformed with 0.1 ng/µl plasmid DNA as follows: 
- Incubation 30 minutes on ice 
- Heat-shock 2 minutes at 42 °C 
- Incubation 1 minute on ice 
- Incubation 30 minutes at 37 °C (shaking) in the presence of 60- 100 µl of LB 
without antibiotic 
- Plate in Petri dish supplemented with antibiotic and incubate over-night at 37 °C 
The next day, one colony was picked up and grown overnight at 37 °C in the presence of 
50 ml (inoculum for Midiprep) or 6 ml (inoculum for Miniprep) of LB with antibiotic. 
After that, cells were collected through centrifugation for 30 minutes at 1937 xg and the 
resulting pellets were stored at -20 °C.  
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3.2.3 Small scale preparation of plasmid DNA (Miniprep) 
Small scale preparation of plasmid DNA was performed using Wizard Plus SV Minipreps 
DNA purification system (Promega,  Fitchburg, WI, USA) following the manufacturer’s 
instructions. Basically, bacteria pellets were resuspended with 250 µl of cell resuspension 
solution by vortexing. Successively, 250 µl of Cell Lysis Solution and 10 µl of Alkaline 
Protease Solution was added to sample, mixed by inversion 4 times and incubated for 5 
minutes at room temperature. To block the reaction, the Neutralization Solution (350 µl) 
was added into the bacteria lysate, mixed by inversion 4 times and centrifuged at 
maximum speed for 10 minutes at room temperature. After that, the cleared lysate was 
decanted into a spin column and centrifuged at maximum speed for 1 minute at room 
temperature. The flow-through was discarded and the spin column was washed two times 
with 750 µl and 250 µl of Wash Solution, respectively. Each step of washing was spaced 
out by centrifugation at maximum speed for 1 and 2 minutes at room temperature. Finally, 
the plasmid DNA was eluted by adding 100 µl of Nuclease-Free water into the spin 
column and centrifuging at maximum speed for 1 minute at room temperature. The 
obtained DNA was stored at -20 °C.  
 
3.2.4 Middle scale preparation of plasmidic DNA (Midiprep) 
Middle scale preparation of plasmid DNA was performed using JETSTAR Plasmid 
Purification kit (Genomed, Brussels, Belgium) following manufacture’s instructions. 
Before starting with the solution within the kit, 50 µl of RNAse A was added to the cell 
pellet. Successively, 4 ml of Cell Resuspension Buffer E1 (supplemented with RNAse A) 
was used for resuspending the pellet until its homogenization. After that, 4 ml of Lysis 
Buffer E2 was added into the cell resuspension, mixed by inverting the capped tube and 
incubated at room temperature for 15-20 minutes to facilitate the lysis of bacteria. To 
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precipitate the nucleic acids, 4 ml of Precipitation Buffer (E3) was added to the lysate, 
mixed by inverting the tube and centrifugated at 1937 xg for 30 minutes at 4 °C.  The 
supernatant was then loaded onto a pre-equilibrated column with 10 ml of Equilibration 
Buffer (E4) and the solution was allowed to drain by gravity flow. The column was then 
washed twice with 10 ml Wash Buffer (E5) and the flow-through was discarded. To elute 
plasmid DNA, 5 ml of Elution Buffer (E6) was added to the column previously placed in a 
new sterile 50 ml centrifuge tube. 3.5 ml of isopropanol was then added to the eluate, 
mixed well and centrifuged at 1937 xg for 30 minutes at 4°C. Finally, after air-drying the 
pellet for 10 minutes, the DNA pellet was resuspended in 200-300 µl of Nuclease-Free 
water and stored at -20 °C. 
 
3.2.5 Overexpression of Flag-tagged siRNA resistant TDP-43 and Flag-
tagged DAZAP1 in HeLa cells 
In this thesis, I used two plasmid DNA vectors (pFLAG-CMV4 and pFLAG-CMV2) 
containing a cloned sequence for the overexpression of Flag-tagged siRNA resistant TDP-
43 and Flag-tagged DAZAP1, respectively (Figure 19A-B). 
The expression of each cloned DNA was performed by transfection of HeLa cells with 
Effectene Transfection Reagent (Qiagen Inc, Gaithersburg, MD, USA) following the 
manufacturer’s instructions. Briefly, cells were plated in a p100 tissue culture dish and 
grown under their normal conditions (see section 3.1.1) to reach 70% confluence on the 
day of transfection. The day of transfection, 3 µg of plasmid was diluted with 300 µl of 
DNA-condensation buffer (Buffer EC). After that, 16 µl of Enhancer was added into the 
solution, mixed by vortexing, spun down and incubated 5 minutes at room temperature to 
allow the condensation of DNA. Effectene reagent (20 µl) was then added to the 
condensed DNA, mixed by vortexing 10 seconds, spun down and incubated 10 minutes at 
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room temperature to produce condensed Effectene-DNA complexes. Cells were washed 
with 1X PBS and the culture medium was exchanged with new one. After 10 minutes of 
incubation, the Effectene-DNA complexes were mixed with medium and directly added to 
the cells. 
 
Figure 19. plasmid DNA for overexpression. (A) Map of pFLAG-CM4-TDP-43 (siRNA resistant). (B) 
Map of pFLAG-CMV2-DAZAP1. 
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3.3 Protein detection analysis 
3.3.1 Western blot analysis for checking gene knockdown  
Total protein extracts were obtained by sonicating cells two times for 5 minutes, high 
power with a BioRuptor UCD-200 (Diagenode, Belgium) in a mild lysis buffer composed 
of 1X Phosphate Saline Buffer (PBS) and 1X Complete Protease Inhibitor Cocktail (Roche 
Diagnostics, Mannheim, Germany). Disrupted cells were centrifuged 5 minutes at 16100 
xg and the supernatant (protein extract) was collected in a new tube. Protein extract (20 
µg) from each sample was resuspended in 1X sample buffer (Table 3), boiled at 95 °C for 
5 minutes and loaded on a 10% Sodium Dodecyl sulfate (SDS)–polyacrylamide denaturing 
gel (Table 4). The gel was then electroblotted onto a PVDF blotting membrane 
(Immobilion-P, Millipore, Billerica, USA) pre-activated with 100% methanol by using a 
semi-dry protein blotter (Lighting Blotter, PerkinElmer, Massachusetts, USA) for 30 
minutes keeping the voltage constant at 27 V. After blotting, the membrane was blocked 
with 4 % skimmed milk (Non-fat dry milk) or 4 % Bovine Serum Albumin (BSA) (Sigma-
Aldrich, St Louis, MO, USA) in 1x PBS and 0.1% Tween-20 as described in the Table 5. 
Proteins were probed with incubation of primary (AbI) and subsequently HRP-conjugated 
secondary (AbII) antibodies in order to confirm the gene knockdown efficacy. The list of 
primary (AbI) and secondary (AbII) antibodies used for western blot are shown in Table 5. 
The chemiluminescence of the target proteins were detected with ECL Luminata Classico 
Western HRP substrate (Merck Millipore, Burlington, MA, USA) and the images were 
acquired using Alliance 9.7 Western Blot Imaging System (UVItec Limited, Cambridge, 
UK) or using X-ray film. Tubulin, available in-house, was used as total protein loading 
control. In order to quantify the percentage of remaining protein after siRNA knockdown, 
densitometric analysis of the Western Blot bands was performed using ImageJ software. 
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Table 3. Composition of stock 4X sample buffer. 
Reagent Final concentration  
Tris-HCL pH 6.8 240 mM 
Glycerol  40% 
SDS 8% 
Bromophenol blue 0.04% 
2-mercaptoethanol 5% 
 
Table 4. Composition of 10% SDS-acrylamide gel. 
Running gel 10% Stacking gel 
Reagent Volume Reagent Volume 
Tris-HCL 1.5 M pH 8.8 5 ml Tris-HCL 0.5 M pH 6.8 2.50 ml 
Protogel 30% (w/v) Acrylamide: 0.8 % 
(w/v) bis-acrylamide Stock Solution 
6.66 ml Protogel 30% (w/v) Acrylamide: 0.8 % 
(w/v) bis-acrylamide Stock Solution 
560 µl  
10% SDS 200 µl 10% SDS 50 µl 
Ammonium persulfate (APS) 200 µl Ammonium persulfate (APS) 50 µl 
Tetramethylethylenediamine (TEMED) 20 µl Tetramethylethylenediamine (TEMED) 10 µl 
H2O 8.34 ml H2O 2 ml 
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Table 5. Specifics of AbI and AbII used for checking gene knockdown. 
Blocking 
solution 
AbI Compa
ny 
Dilution AbII Company Dilution 
Milk Polyclonal rabbit a-
TDP-43 
Proteint
ech 
1:2000 Polyclonal goat a-
rabbit 
Dako Denmark A/S 1:2000 
Milk Polyclonal rabbit a-
DAZAP1 
Homem
ade 
1:500 Polyclonal goat a-
rabbit 
Dako Denmark A/S 1:2000 
BSA Polyclonal rabbit a-
hnRNP Q 
Sigma-
Aldrich 
1:500 Polyclonal goat a-
rabbit 
Dako Denmark A/S 1:2000 
BSA Polyclonal rabbit a-
hnRNP R 
Abcam 1:500 Polyclonal goat a-
rabbit 
Dako Denmark A/S 1:2000 
Milk Polyclonal mouse a-
Tubulin 
Homem
ade 
1:10000 Polyclonal goat a-
mouse 
Dako Denmark A/S 1:2000 
 
 
3.3.2 TDP-43 and DAZAP1 co-immunoprecipitations (CO-IP) analysis 
HeLa cells (1.2X106) were grown overnight in a p100 tissue culture dish to achieve 70% of 
confluence for transfection with 3 μg of pFLAG-TDP-43 wild-type using the Effectene 
reagent as described in section 3.2.5. After 24 hours, cell culture medium was removed and 
cells were washed with cold 1X PBS and harvested. Cells were lysed in 500 μL of IP 
buffer (Table 6) by sonication (3 min., mid power) in an ice-cooled sonicating bath 
(BioRuptor UCD-200, Diagenode, Belgium). The cell lysate was pre-cleared by incubation 
with 30 μl Protein A/G PLUS agarose beads (Santa Cruz Biotechnology Inc., Dallas, 
Texas, USA) in IP buffer for 1.5 hours at 4 °C. The pellet was discarded, and the 
supernatant was used for immunoprecipitation: the cell lysate was incubated with 2 μg of 
mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, St Louis, MO, USA) on a 
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rotating device for 1 hour at 4 °C. Then, 30 μl of Protein A/G PLUS agarose beads were 
added to each sample and incubated overnight at 4°C. The pellet was then washed three 
times in ice-cold IP buffer. The supernatant was discarded, and the pellet was re-suspended 
in 30 μl of 4X loading buffer. The samples were fractionated by SDS-PAGE (10%) and 
analysed by immunoblotting as described in section 3.3.1 using the antibodies reported in 
Table 7.  
 
Table 6. Composition of IP buffer. 
Reagent Final concentration  
Tris-HCL pH 7.5 20 mM 
NaCl 110 mM 
Triton-X 0.5% 
Complete Protease Inhibitor Cocktail 1X 
 
Table 7. List of AbI and AbII used for CO-IP experiment. 
Blocking 
solution 
AbI Company Dilution AbII Company Dilution 
Milk Polyclonal rabbit 
a-TDP-43 
Proteintech 1:2000 Polyclonal goat a-
rabbit 
Dako Denmark A/S 1:2000 
Milk Polyclonal rabbit 
a-DAZAP1 
Homemade 1:500 Polyclonal goat a-
rabbit 
Dako Denmark A/S 1:2000 
Milk Polyclonal rabbit 
a-hnRNP H 
Homemade 1:500 Polyclonal goat a-
rabbit 
Dako Denmark A/S 1:2000 
 
 
3.3.3 Nuclear and cytoplasmic extraction using NER-PER kit 
SH-SY5Y cells were seeded in p100 dishes to reach 90% confluence the day of nuclear 
and cytoplasm extraction. Cells from two dishes were pooled together and the resulting 
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pellet was treated using NER-PER Nuclear and Cytoplasmic Extraction Reagents 
(ThermoFischer, Waltham, MA, USA) as described in the manufacturer’s instructions.  
Briefly, 24 hours after seeding cell culture medium was removed and cells were washed 
with 1X PBS and harvested. The cell pellet was resuspended with ice-cold CER I buffer 
according to the packed cell volumes (Table 8) and vortexed on the highest setting for 15 
seconds to fully suspend the cell pellet. The lysate was incubated on ice for 10 minutes and 
successively ice-cold CER II buffer according to Table 8 was added to tube. After that, the 
lysate was vortexed twice for 5 seconds on the highest setting with 1 minute incubation on 
ice between each round and then centrifuged for 5 minutes at maximum speed. The 
obtained supernatant (cytoplasmic fraction) was transferred to a pre-chilled tube and stored 
at -80°C until WB analysis. The insoluble pellet, containing nuclei, was suspended with 
ice-cold NE buffer according to Table 8, vortexed in the highest setting for 15 seconds 
every 10 minutes for a total of 40 minutes. After that, the nuclear fraction was centrifuged 
at maximum speed for 10 minutes and moved in a pre-chilled tube stored at -80 °C until 
the WB analysis. 
For each sample fractionated with NER-PER kit, 15 µg of cytoplasmic and nuclear extracts 
were analyzed by WB as described in section 3.3.1 using the antibodies reported in Table 
9. 
 
Table 8. Reagent volumes for different packed cell volumes. 
Packed cell volume (µl) CER I (µl) CER II (µl) NER (µl) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
100 1000 55 500 
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Table 9. List of AbI and AbII antibodies used for nuclear and cytoplasmic fractionation. 
Blocking 
solution 
AbI Company Dilution AbII Company Dilution 
BSA Polyclonal rabbit a-
hnRNP Q 
Sigma-
Aldrich 
1:500 Polyclonal 
goat a-rabbit 
Dako Denmark 
A/S 
1:2000 
BSA Polyclonal rabbit a-
hnRNP R 
Abcam 1:500 Polyclonal 
goat a-rabbit 
Dako Denmark 
A/S 
1:2000 
Milk Polyclonal mouse 
a-Tubulin 
Homemad
e 
1:1000 Polyclonal 
goat a-
mouse 
Dako Denmark 
A/S 
1:2000 
Milk Monoclonal mouse 
a-p84 
Abcam 1:1000 Polyclonal 
goat a-
mouse 
Dako Denmark 
A/S 
1:2000 
 
 
3.4 pre-mRNA splicing, gene expression and RNA-seq analysis 
3.4.1 RNA extraction 
RNA was obtained using EuroGold Trifast (Euroclone, Milan, Italy), following the 
manufacturer’s instructions. Briefly, cell culture medium was removed and cells were 
washed with cold 1X PBS and harvested. According to the volumes reported in Table 10, 
cell pellet was resuspended with EuroGold Trifast by pipetting and incubated for 5 minutes 
at room temperature.  Chloroform (Table 10- chloroform I) was then added to each sample 
and the mixture was strongly shacked and incubated 10 minutes at room temperature. 
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Subsequently, samples were centrifuged at maximum speed for 20 minutes at 4 °C and the 
supernatant fraction (transparent upper phase) was transferred in a new sterile tube and 
mixed with an equal volume of chloroform for a second cleaning step (chloroform II). 
Samples were then centrifuged at maximum speed for 10 minutes at 4 °C and the 
supernatant was transferred in a new sterile tube. The RNA was precipitated adding 
isopropanol to this latter (Table 10), incubated for 10 minutes on ice, and then centrifuged 
at maximum speed for 20 minutes at 4 °C. At the end of the process, the resulting pellet 
(RNA) was washed with 70% ethanol, centrifuged at maximum speed for 5-10 minutes at 
4 °C, resuspended in 30-60 µl of RNase-free water and quantified with Nanodrop 1000 
(ThermoFisher, Waltham, MA, USA). 
 
Table 10. Volume of reagent using for RNA extraction according to cell dish. 
6-well/ p35 dish p100 dish 
Reagent Volume Reagent Volume 
EuroGold Trifast 500 ml EuroGold Trifast 1 ml 
Chloroform I 100 µl Chloroform I 200 µl 
Isopropanol 250 µl Isopropanol 500 µl 
70 % Ethanol 400 µl 70 % Ethanol 800 µl 
RNase-free water 30 µl RNase-free water 60 µl 
  
 
3.4.2 Reverse transcription reaction 
Complementary DNA (cDNA) was retrotranscribed by using 1 μg of total RNA in the 
presence of random primers (Sigma-Aldrich, St Louis, MO, USA) and Moloney murine 
leukemia virus (M-MLV) Reverse Transcriptase (Invitrogen, ThermoFisher, Waltham, 
MA, USA). RNA samples prepared as described in Table 11 were denaturated at 85 °C for 
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5 minutes and chilled 1 minutes on-ice to avoid renaturation of RNA. After that, 20 µl of 
mixture containing M-MLV enzyme (Table 12) were added to RNA sample mixture (20 
µl) and incubated 1-2 hours at 37 °C for reverse transcription reaction. cDNA samples 
were then stored at -20 °C or placed on-ice for pre-mRNA splicing analysis or gene 
expression analysis. 
 
Table 11. Preparation of RNA sample mixture. 
Reagent Final concentration (20 µl of reaction) 
RNA sample 50 ng/µl 
Random primers 1 ng/µl 
 
Table 12. Mixture for reverse transcription reaction.  
Reagent  Final concentration (20 µl of reaction) 
5X First strand buffer  2X 
Dithiothreitol (DTT) 0.1 M 0.02 M 
Deoxynucleotide (dNTP) Solution Mix 5mM 1 mM 
M-MLV 200 U/µl 5 U/µl 
 
 
3.4.3 pre-mRNA splicing analysis 
To evaluate the pre-mRNA splicing, polymerase chain reaction (PCR) was performed from 
cDNA obtained as described in section 3.4.2, and derived from SH-SY5Y cells depleted 
for TDP-43, DAZAP1, hnRNP Q and hnRNP R, or co-silenced for TDP-43/DAZAP1, 
TDP-43/hnRNP Q and TDP-43/hnRNP R. For each sample, 3 µl of cDNA was mixed with 
47 µl of PCR mix solution prepared as described in Table 13. Taq DNA polymerase (New 
England Biolabs, Ipswich, MA, USA) was used for reaction. Forward and reverse primer 
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sequences for each gene tested and the relative PCR conditions are reported in Table 14 
and figure 20A-B, respectively. For each target gene, PCR amplification was performed 
for 35 cycles and products (10 µl of total volume of reaction) were routinely fractionated in 
1.5% (w/v) agarose gels. The percentage of exon inclusion for each tested gene was 
evaluated by densitometric analysis using ImageJ software. For MADD gene was 
calculated the percentage of pseudoexon inclusion. The statistical significance was 
calculated using an unpaired t-test. P<0.05 was considered significant (n = 3) (* P < 0.05, 
** P < 0.01, and *** P<0.001). 
 
Table 13. PCR reaction mixture. 
Reagent Final concentration (50 µl of reaction) 
10X ThermoPol reaction Buffer  1X 
Deoxynucleotide (dNTP) Solution Mix 5mM 0.2 mM 
Primer Forward 10 ng/µl 0.3 ng/µl 
Primer Reverse 10 ng/µl 0.3 ng/µl 
Taq Biolabs 5 U/µl 0.02 U/µl 
 
Table 14. List of genes and relative primers (forward and reverse sequences) used for pre-mRNA splicing 
analysis. 
Target gene Forward sequence (5'-3') Reverse sequence (5'-3') 
POLDIP3 5′-gcttaatgccagaccgggagttg-3′ 5′-tcatcttcatccaggtcatataaatt-3′ 
TNIK 5′-caaaggcgagagaaggagctg-3′ 5′-ctgatgctgaagggaaactaag-3′ 
STAG2 5′-gtatgtttacttggaaaagttcatg-3′ 5′-tgattcatccataattgaagctgga-3′ 
MADD 5′-gacctgaattgggtggcgagttccct-3′ 5′-cattggtgtcttgtacttgtggctc-3′ 
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Figure 20. PCR conditions used in the pre-mRNA splicing assay. (A) Protocols for PCR amplification of 
POLDIP3 and TNIK gene. (B) Protocols for PCR amplification of STAG2 and MADD gene. 
 
3.4.4 RNA immunoprecipitation (RNA-IP) analysis 
HeLa cells (1.2X106) were grown overnight in a p100 tissue culture dish to achieve 70% of 
confluence for transfection with 3 μg flag-DAZAP1 plasmid using Effectene reagent as 
described in section 3.2.5. After 24 hours, the cell culture medium was removed and cells 
were washed with cold 1X PBS and harvested. Cells were lysated with HEGN buffer 
(Table 15) and sonicated (5 minutes, high power) in an ice-cooled sonicating bath 
(BioRuptor UCD-200, Diagenode, Belgium). HeLa lysate (40 μg) was incubated for 1 hour 
at 4 °C in HEGN buffer supplemented with 7.5 μg/μl heparin (Sigma-Aldrich, St Louis, 
MO, USA) and Protein A/G Agarose beads (Santa Cruz Biotechnology Inc., Dallas, Texas, 
USA), pre-coated for 1 hour, 4 °C in rotation with 5 μg of anti-Flag antibody (IP-Flag) 
(Sigma-Aldrich) or with uncoated beads as controls (IP-Beads). After washes with HEGN 
+ DOC 0.2% + Urea 0.5 M (four-times separated with centrifugation of 5 minutes at 15000 
xg), mRNA was extracted from immunoprecipitated RNPs using EuroGold Trifast (see 
section 3.4.1; volumes for p35 dish). The abundance of possible DAZAP1 target genes was 
measured by quantitative Real-Time PCR on three independent experiments as described 
below.  
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Table 15. Composition of HEGN buffer. 
Reagent  Final concentration 
Hepes pH 7.5 20 mM 
NaCl 150 mM 
EDTA 0.5 mM 
Glycerol 10% 
Triton-X 0.1% 
DTT 1 mM 
Complete protease inhibitor cocktail  1X 
 
 
3.4.5 Gene expression analysis 
Total RNA was extracted from SH-SY5Y cells transfected with siRNA against TDP-43, 
DAZAP1, hnRNP Q and hnRNP R or co-transfected with siRNA against TDP-43 in the 
presence of siRNA against each of the three tested hnRNPs as describe in section 3.1.2. 
RNA obtained from SH-SY5Y cells treated with siRNA against luciferase (siLUC) was 
used as a negative control. For each RNA sample, reverse transcription was performed in 
order to synthetize cDNA as described in section 3.4.2. The quantification of gene 
expression levels was carried out by quantitative Real-time PCR using iQ SYBR green 
supermix (Bio-Rad, Hercules, CA, USA).  For each sample, 4 µl of cDNA (diluted 1:10-
1:5 in sterile water) was mixed with 6 µl of iQ mix solution prepared as described in Table 
16. Quantitative Real-time PCRs were performed on a MiniOpticon real-time PCR and on 
a CFX96 Real-time systems (Bio-Rad, Hercules, CA, USA). The expression levels were 
determined using the 2-DDCT method (Schmittgen and Livak, 2008). For primer designer 
two online tools were used: PrimerBank (https://pga.mgh.harvard.edu/primerbank/) and 
qPrimerDepot (http://primerdepot.nci.nih.gov/). The list of primers (forward and reverse 
Materials and Methods 	
 99 
sequence) and the qPCR conditions are reported in Table 17 and Figure 21A-C, 
respectively. To normalize the results, the housekeeping gene Glyceraldehyde-3-phosphate 
Dehydrogenase (GAPDH), Ribosomal Protein L13a (RPL13A), Hypoxanthine 
Posphoribosyltransferase 1 (HPRT1) and RNA Polymerase II Subunit A (POLR2A) were 
also used (Table 18). In particular, GAPDH and RPL13A were used to normalize 
simultaneously the expression of MADD, BRD8, TNIK, ELAVL3, NOVA2, RELN, STX3, 
CELF5, YPEL4, ACHE, TNF, TNFRSF9 and ICAM1 gene in SH-SY5Y cells. Whereas, 
HPRT1 and POLR2A were used to normalize simultaneously the expression of PENK, 
KLF4, KLHL4, NRG3, RAB26, ARHGAP36, CT55, CARTPT, FOSB, JAG1, ICAM5, 
DUOXA1, HMOX1, KCNAB1, ACP5, SDCBP2, EFEMP1, SYNCRIP (hnRNP Q) and 
HNRNPR gene in SH-SY5Y cells. Moreover, Succinate Dehydrogenase Complex 
Flavoprotein Subunit A (SDHA) was used as a negative control for RNA-
immunoprecipitation analysis performed in HeLa cells. 
The mean of relative expression levels ± standard deviation/ standard error of three 
independent experiments are reported. Statistical significance was calculated using an 
unpaired t-test. P<0.05 was considered significant (n = 3) (* P < 0.05, ** P < 0.01, and *** 
P<0.001).  
 
Table 16. Composition of iQ mix solution. 
Reagent Final concentration 
iQ SYBR green supermix Dilution 1:2 
20 µM Primer forward  0.05 µM 
20 µM Primer forward 0.05 µM 
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Table 17. List of target genes and relative primers (forward and reverse sequences) used for gene expression 
analysis. 
Target gene Forward sequence (5'-3') Reverse sequence (5'-3') 
MADD 5'-ttgagaccaactctgccaca-3' 5'-agactcgctggctcacatct-3' 
BRD8 5'-gcagcctgttacagatgac-3' 5'-aatagttgacaaatccataggc-3' 
TNIK 5'-tggaacatacgggcaagttt-3' 5'-tcctcttcatcccctgtgac-3' 
POLDIP3 5'-tctcagcccattggaaggc-3' 5'-tgatggcatcgtcctttttcac-3' 
STAG2 5'-aaaatcaaaaccatctacagg-3' 5'-tactactactttcttcagtgag-3' 
ELAVL3 5'-cctcaaattacagacgaagacca-3' 5'-gctgacgtacaggttagcatc-3' 
NOVA2 5'-aaggcgaatacttcctgaaggt-3' 5'-gctgacgtacaggttagcatc-3' 
RELN 5'-ttggaggttccagtgctttc-3' 5'-tcctcatcggttgtctttttgc-3' 
STX3 5'- tcggcagaccttcggattc-3' 5'-tcctcatcggttgtctttttgc-3' 
CELF5 5'-aaactcttcgtgggccagat-3' 5'-ggcacagtaggtg aggaagg-3' 
YPEL4 5'-cggagatctctggagcagac-3' 5'-gtgtttcagggca ggagaag-3' 
ACHE 5'-agaaagcgtcttccggttct-3' 5'-tacgagccctcatccttcac-3' 
TNF 5'-cctctctct aatcagccctctg-3' 5'-gaggacctgggagtagatgag-3' 
TNFRSF9 5'-ttggatggaaagtctgtgcttg-3' 5'-aggagatgatctgcggagagt-3' 
ICAM1 5'- ggccggccagcttatacac-3' 5'-tagacacttgagctcgggca-3' 
PENK 5'-gtgcagctaccgcctagtg-3' 5'-tgcaggtttcccaaattttc-3' 
KLF4 5'-gcggcaaaacctacacaaag-3' 5'-ccccgtgtgtttacggtagt-3' 
KLHL4 5'-ttggagatgatggctgatga-3' 5'-aagagtttgctctgcgtggt-3' 
NRG3 5'-tattcaaaggtggaaaggcatcc-3' 5'-tgaaggcattcctatggagca-3' 
RAB26 5'-tcatctccaccgtaggcatt-3' 5'-ccggtagtaggcatgggtaa-3' 
ARHGAP36 5'-ttgaactgacagccacgatg-3' 5'-gccagactatccacagacac-3' 
CT55 5'-atgttgtgactggcaacgtg-3' 5'-gccagactatccacagacac-3' 
CARTPT 5'-ccgagccctggacatctact-3' 5'-atgggaacacgtttactcttgag-3' 
FOSB 5'-accctctgccgagtctcaat-3' 5'-gaaggaaccgggcatttc-3' 
JAG1 5'-atcgtgctgcctttcagttt-3' 5'-gatcatgcccgagtgagaa-3' 
ICAM5 5'-ggctcttcggcctctcag-3' 5'-gcagttggtgctgcaattc-3' 
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DUOXA1 5'-ccaagccaaccttcccgat-3' 5'-cccgatgaataagctggtcac-3' 
HMOX1 5'-gccagcaacaaagtgcaag-3' 5'-gagtgtaaggacccatcgga-3' 
KCNAB1 5'-gcaaatcgaccggacagtaac-3' 5'-gccatgccttggtttatcacat-3' 
ACP5 5'-ctacccactgcctggtcaag-3' 5'-cacgccattctcatcttgc-3' 
SDCBP2 5'-ccactacgtgtgtgaggtgg-3' 5'-tgctcgtagatcacactggg-3' 
EFEMP1 5'-cgagcaaagtgaacacaacg-3' 5'-gatatccaggagggcactga-3' 
SYNCRIP (hnRNP Q) 5'-actgttgaatgggctgatcc-3' 5'-cctccaagtctttgccattc-3' 
HNRNPR 5'-gcaaggtgcaagagtccaca-3' 5'-cacgccagagtacacactgtc-3' 
 
 
Table 18. List of housekeeping genes and relative primers (forward and reverse sequences) used for 
normalization of gene expression analysis. 
Housekeeping gene Forward sequence (5'-3') Reverse sequence (5'-3') 
GAPDH 5'-cgctctctgctcctcctgtt-3' 5'-ccatggtgtctgagcgatgt-3' 
RPL13A 5'-cctggaggagaagaggaaagaga-3' 5'-ttgaggacctctgtgtatttgtcaa-3' 
SDHA 5'-tgggaacaagagggcatctg-3' 5'-ccaccactgcatcaaattcatg-3' 
HPRT1 5'-tgacactggcaaaacaatgca-3' 5'-ggtccttttcaccagcaagct-3' 
POLR2A 5'-gcccacgtccaatgacat-3' 5'-gtgcggctgcttccataa-3' 
 
Materials and Methods 	
 102 
 
Figure 21. Real-Time PCR conditions for gene expression analysis. (A) Standard protocol for 
amplification of target genes. (B) Specific Real-Time PCR protocol for amplification of MADD, BRD8 and 
TNIK gene. (C) Specific Real-Time PCR protocol for amplification of YPEL4, CELF5, KLF4, KLHL4 gene. 
 
3.4.6 RNA-seq and analysis of differentially expressed genes (DEGs)  
Total RNA was extracted from luciferase (control), TDP-43, DAZAP1, hnRNP Q and 
hnRNP R depleted SH-SY5Y cells, as described previously. RNA sequencing was 
performed by Eurofins (www.eurofins.com) using an Illumina HiSeq 2500 instrument on 
three independent experiments obtained for each tested hnRNPs. Data processing was 
carried out with the following software: HiSeq Control Software v2.0.12.0, RTA 
v1.17.21.3 and bcl2fastq-1.8.4. Alignment to human reference sequence was performed by 
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BWA-MEM (version 0.7.12-r1039,http://bio-bwa.sourceforge.net/) and the raw read 
counts were created using featureCounts (http://bioinf.wehi.edu.au/featureCounts/). Only 
reads with unique mapping positions and a mapping quality score at least 10 were 
considered for read counting. Raw read counts were converted to Counts per million 
(CPM) values by Trimmed mean of M-values (TMM) normalization (edgeR package 
http://bioconductor.org/packages/release/bioc/html/edgeR.html, (Robinson and Oshlack, 
2010). Features had to have a counts-per-million value of more than one in at least three 
samples or were removed, resulting in the removal of 47622 of the 64769 features. 
Differential expression analysis was performed on the remaining 17417 genes using edgeR 
package.  
Regarding the interpretation of the differential expression genes data and pathway mapping 
related to TDP-43 and DAZAP1, PANTHER (Protein ANalysis THrough Evolutionary 
Relationships) Classification System and the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) v6.7 tools were used. Venn diagrams were generated using 
the VENN diagram generator at http://bioinfogp.cnb.csic.es/tools/venny/. GOseq package 
from R (Young et al., 2010) was also used for Gene ontology (GO) and KEGG pathway 
analysis of RNA-seq data. Categories significantly enriched (P< 0.05) were considered. 
 
3.4.7 Statistical analysis of data 
Statistical analysis of gene expression and splicing analysis were carried out by an 
unpaired two-sample t test on three independent experiments. P<0.05 was considered 
significant (* P < 0.05, ** P < 0.01, and *** P<0.001). Regarding the RNA-seq analysis, 
DEGs were identified using the fold change cut-off of 30% with respect to a control 
sample treated with siRNA against fire-fly luciferase (siLUC) (upregulation cut-off: >1.3; 
downregulation cut-off: <0.7-FC) and the cut-off P< 0.05 for statistical significance. 
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3.5 Immunofluorescence (IF) analysis 
3.5.1 Immunofluorescence analysis of Flp-In HEK293 cell line expressing 
TDP-43 aggregates 
Flp-In HEK293 cells expressing inducible TDP-43 aggregates were plated and treated as 
described in section 3.1.3. For immunofluorescence analysis the cells were washed 3 times 
with PBS, fixed in 3.2% paraformaldehyde in PBS for 1 hour at room temperature and 
permeabilized by using 0.3% Triton in PBS for 5 minutes on ice. Cells were then blocked 
with 2% BSA/PBS for 20 minutes at room temperature and incubated overnight at 4 °C in 
a humidified chamber with 60 µl of primary antibody against TDP-43 and the FLAG-tag 
prepared as described in Table 19. The day after, cells were washed 3 times with PBS, 
incubated with secondary antibodies conjugated with probes (Table 19) for 1 hour at room 
temperature and coverslipped with Vectashield-DAPI mounting medium (Vector 
Laboratories, Burlingame, CA, USA). Each slide was analyzed using Nikon Ti-E confocal 
microscope with a 60X oil objective. 
 
Table 19. List of AbI and AbII for IF analysis of Flp-In HEK293 expressing TDP-43 12XQ/N. 
AbI Company Dilution AbII Company Dilution 
Polyclonal rabbit 
a-TDP-43 
Proteintech 1:200 AlexaFluor 488 donkey 
a-rabbit  
Invitrogen 1:500 
Monoclonal 
mouse a-FLAG 
Sigma-
Aldrich 
1:200 AlexaFluor 594 donkey 
a-mouse  
Invitrogen 1:500 
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3.5.2 Immunofluorescence analysis of SH-SY5Y cells and differentiated 
NSC-34 cells 
SH-SY5Y cells (40×104), SH-SY5Y treated with siRNA against DAZAP1, hnRNP Q and 
hnRNP R (40×104) and differentiated NSC-34 cells (35×104) were plated in 6-well plates 
containing coverslips. For SH-SY5Y depleted cells and differentiated NSC-34 cells 
coverslips were coated with poly-L-lysine solution at a final concentration of 0.01% (w/v) 
in H20 (SigmaAldrich, St Louis, MO, USA). After 24 hours, cells were washed three times 
with PBS, fixed in 3.2% paraformaldehyde in PBS for 1 hour at room temperature and 
permeabilized by using 0.3% Triton in PBS for 5 minutes on ice. Cells were then blocked 
with 2% BSA/PBS for 20 minutes at room temperature and incubated overnight at 4 °C in 
a humidified chamber with 60 µl of primary antibodies prepared as described in Table 20. 
The day after, cells were washed 3 times with PBS, incubated with secondary antibodies 
conjugated with a fluorescent dye (Table 20) for 1 hour at room temperature and 
coverslipped with Vectashield-DAPI mounting medium (Vector Laboratories, Burlingame, 
CA, USA). Each slide was analysed using Nikon Ti-E confocal microscope with a 60X oil 
objective available in ICGEB institute or at the microscopy facility of University of 
Trieste, using a Nikon Eclipse C1si confocal microscope system mounted on a Nikon TE-
2000U inverted microscope with a 60X objective. 
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Table 20. List of AbI and AbII for IF analysis of SH-SY5Y cells and differentiated NSC-34 cells. 
AbI Company Dilution AbII Company Dilution 
Polyclonal rabbit 
a-TDP-43 
Proteintech 1:200 AlexaFluor 594 donkey 
a-rabbit  
Invitrogen 1:500 
Polyclonal rabbit 
a-hnRNP Q 
Sigma-
Aldrich 
1:200 AlexaFluor 488 donkey 
a-rabbit 
Invitrogen 1:500 
Polyclonal rabbit 
a-hnRNP R 
Abcam 1:200 AlexaFluor 488 donkey 
a-rabbit 
Invitrogen 1:500 
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4. RESULTS 
4.1 Effects of DAZAP1, hnRNP Q and hnRNP R suppression on 
TDP-43 activity in SH-SY5Y cell line  
4.1.1 DAZAP1, hnRNPQ and hnRNPR can regulate and rescue TDP-43 
controlled splicing events without altering the expression of TDP-43 
Thanks to the results obtained from the Drosophila melanogaster model of TDP-43 loss- 
or gain-of-function, in collaboration with the Neurobiology group in ICGEB, we decided 
to investigate the effects of DAZAP1, hnRNP Q and hnRNP R within human 
neuroblastoma (SH-SY5Y) cells. First of all, we measured the efficiency of siRNA 
treatment against each hnRNP and subsequently, we evaluated if the silencing of 
DAZAP1, hnRNP Q and hnRNP R was capable to affect the expression of TDP-43 at the 
protein level, by using Western Blot analysis. As shown in Figure 22A-B the efficiency of 
siRNA treatment against TDP-43, DAZAP1, hnRNP Q and hnRNP R was sufficient to 
knockdown ~ 80-70% of each protein in SH-SY5Y cells. Moreover, the depletion of these 
hnRNP proteins was not able to modify TDP-43 expression (Figure 22B), as well as the 
protein expression of DAZAP1, hnRNP Q and hnRNP R did not change after siRNA 
depletion of TDP-43 (Figure 22C-E). 
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Figure 22. Western Blot analysis of siRNA treatments in SH-SY5Y cells. (A) Protein expression level of 
DAZAP1, hnRNP Q and hnRNP R after siRNA treatment comparing to cells treated with siRNA against fire-
fly luciferase (siLUC) used as a control. The percentage of residual protein is also reported. (B) TDP-43 
expression level following siRNA silencing of DAZAP1, hnRNP Q, and hnRNP R comparing to siLUC 
treated cells. Silencing of TDP-43 is also reported (the percentage of residual protein is 27%). (C-E) Protein 
expression level of DAZAP1 (C), hnRNP Q (D) and hnRNP R (E) were measured in SH-SY5Y cells treated 
with siRNA against TDP-43 comparing to siLUC treated cells. These experiments were performed in 
collaboration with Dr. Fatemeh Mohagheghi. 
 
Successively, we analysed the ability of these hnRNP proteins to modulate pre-mRNA 
splicing events known to be controlled by TDP-43. Indeed, recent studies have 
demonstrated that the knockdown of TDP-43 causes exon 3 skipping of the 
POLDIP3/SKAR gene (Fiesel et al., 2012), as well as an increase in TNIK exon 15 
(Colombrita et al., 2015) and STAG2 exon 30b inclusion (De Conti et al., 2015) and the 
exclusion of exon 31, in addition to the inclusion of a pseudoexon, in the MADD gene 
(De Conti et al., 2015) 
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We silenced each tested hnRNP protein (including TDP-43) in SH-SY5Y cells by using 
siRNA, and then we evaluated the different splicing pattern of SKAR/POLDIP3 exon3, 
TNIK exon 15, STAG2 exon 30b and MADD exon 31. According to previous studies, the 
silencing of TDP-43 was able to reproduce the splicing profile observed for each tested 
gene (Figure 23). As expected, the silencing of TDP-43 was associated with an increased 
exclusion of POLDIP3 exon 3 (Figure 23A), with an increased inclusion of TNIK exon 15 
(Figure 23B), and of STAG2 exon 30b (Figure 23C), as well as with a decrease of exon 31 
inclusion and symultaneous activation of a pseudoexon in the MADD gene (Figure 23D). 
On the other hand, knocking down expression of DAZAP1 boosted POLDIP3 exon 3 
inclusion (Figure 23A), and reduced both TNIK exon 15 (Figure 23B) and of STAG2 exon 
30b inclusion below normal levels  (Figure 23C). Likewise, removal of hnRNP Q was 
associated with a drop in the inclusion of both POLDIP3 exon 3 (Figure 23A) and TNIK 
exon 15 (Figure 23B). Finally, knocking down expression of hnRNP R was able to alter 
only the splicing of the TNIK gene, by causing an enhancement of exon 15 inclusion 
(Figure 23B). Notably, the splicing profile of MADD gene was modified only by TDP-43 
silencing (Figure 23D). 
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Figure 23. Effects of different siRNA treatment on TDP-43-regulated events. SH-SY5Y cells were 
treated with different siRNA against TDP-43, DAZAP1, hnRNP Q and hnRNP R and RT-PCR was used to 
evaluate the effects of this depletion on POLDIP3 exon 3 (A), TNIK exon 15 (B), STAG2 exon 30b (C) and 
MADD exon 31 (D). The agarose gel was loaded with the following samples: control siRNA Luciferase 
transfected cells (lane 1, siLUC), depleted of TDP-43 (lane 2, siTDP-43), depleted of DAZAP1 (lane 3, 
siDAZAP1), depleted of hnRNP Q (lane 4, sihnRNPQ) and depleted of hnRNP R (lane 5, sihnRNPR). The 
identity of the various transcripts is reported on the right. For the MADD gene, the appearance of a 
pseudoexon is also reported (Ps.Ex.). *P < 0.05, **P < 0.01, ***P < 0.001 (n = 3), calculated by an unpaired 
t-test. These experiments were performed in collaboration with Dr. Fatemeh Mohagheghi. 
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As a result of these changes, we were also interested in investigating if the co-silencing of 
TDP-43 and DAZAP1, hnRNP Q or hnRNP R could rescue the splicing alteration induced 
by TDP-43 depletion. Therefore, we silenced SH-SY5Y cells with both siRNA against 
TDP-43 and each hnRNP, and we analysed the resulting splicing profile of POLDIP3, 
TNIK, STAG2 and MADD gene.  Co-silencing of DAZAP1 and TDP-43, on one hand, 
restored the splicing patterns of the TNIK  (Figure 24B) and the MADD gene  (Figure 24D) 
as observed in the control transfections. On the other hand, it was able to counteract 
partially the POLDIP3 exon3 skipping (Figure 24A), and completely STAG2 exon30b 
inclusion (Figure 24C), caused by TDP-43 silencing alone. 
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Figure 24. Rescue of TDP-43 controlled events. SH-SY5Y cells were co-silenced with siRNA against 
TDP-43 in the presence of siRNA against DAZAP1, hnRNP Q and hnRNP R. RT-PCR was used to evaluate 
the effects of this depletion on POLDIP3 exon 3 (A), TNIK exon 15 (B), STAG2 exon 30b (C) and MADD 
exon 31 (D). The agarose gel was loaded with the following samples: control siRNA Luciferase transfected 
cells (lane 1, siLuc), depleted of TDP-43 (lane 2, siTDP-43), depleted of TDP-43 and DAZAP1 (lane 3, 
siTDP-43/siDAZAP1), depleted of TDP-43 and hnRNP Q (lane 4, siTDP-43/sihnRNP Q) and depleted of 
TDP-43 and hnRNP R (lane 5, siTDP-43/sihnRNP R). The identity of the various transcripts is reported on 
the right. For the MADD gene, the appearance of a pseudoexon is also reported (Ps.Ex.). *P < 0.05, **P < 
0.01, ***P < 0.001 (n = 3), calculated by an unpaired t-test. These experiments were performed in 
collaboration with Dr. Fatemeh Mohagheghi. 
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Figure 25 summarizes these results: 
 
 
Figure 25.  Schematic diagram of TDP-43, DAZAP1, hnRNPQ and hnRNPR activity on RNA splicing 
of POPLDIP3, STAG2, TNIK and MADD gene. Exon inclusion and exon exclusion are highlighted in green 
and red, respectively. The colours also indicate the relative effects (enhancer or silencer activity) of each 
hnRNP on the target genes. Moreover, the figure reports the rescue of TDP-43 depletion together with 
silencing of each hnRNP. 
 
The second important event that we decided to test was the effect of these hnRNPs on gene 
expression levels of the TDP-43-controlled genes, previously published in our laboratory. 
Once again, we treated SH-SY5Y cells with siRNA against TDP-43 and each hnRNP of 
interest and then we analysed the expression of MADD and BRD8 genes, since their 
expression was found to be altered in HEK293 cells depleted for TDP-43 (De Conti et al., 
2015). We also included the evaluation of TNIK gene expression levels as a control. As 
shown in Figure 26A-C, a significant reduction of MADD gene expression levels was 
associated with siRNA depletion of TDP-43, and a slight but significant reduction of TNIK 
gene expression levels was observed after siRNA depletion of hnRNPQ, suggesting that 
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the other hnRNPs were not able to modify the expression of these TDP-43 targets. 
Afterwards, the co-silencing effects of TDP-43 and DAZAP1, hnRNP Q or hnRNP R on 
the gene expression were tested. Apparently, only the simultaneous depletion of TDP-43 
and DAZAP1 was able to rescue the reduction of MADD gene expression levels and 
induce a significant increment of BRD8 gene expression levels (Figure 26D). No 
statistically significant effect was detected for TNIK gene expression levels (Figure 26F). 
 
 
Figure 26. Effects of DAZAP1 and hnRNP Q/R depletion in the absence (A-C) or in the presence (D-F) 
of TDP-43 co-silencing on gene expression events controlled by TDP-43. Real-time PCR quantification 
analysis of MADD (A, D), BRD8 (B, E) and TNIK (C, F) endogenous transcript levels following siRNA 
transfection in SH-SY-5Y cells from three independent experiments. Each bar reports the mean ± standard 
deviation of three independent experiments. *P < 0.05, **P < 0.01 (n = 3), calculated by an unpaired t-test.  
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4.1.2 DAZAP1, hnRNP Q and hnRNP R do not alter TDP-43 nuclear 
localization 
Since modifications of mRNA splicing/expression were observed in TDP-43 controlled 
genes after hnRNP depletion, we were also interesting in studying the localization of 
endogenous TDP-43, as its nucleo-cytoplasmic shuttling usually occurs after protein 
homeostasis alterations within the cells. For this reason, we performed 
immunofluorescence assays on SH-SY5Y cells treated with siRNA against each hnRNP 
protein of interest. As shown in Figure 27A-D, none of these treatments caused appreciable 
changes in TDP-43 localization, that remained mostly nuclear. 
  
 
Figure 23. Localization of endogenous TDP-43 in SH-SY5Y cells. Cells were transfected with siRNA 
against fire-fly Luciferase (control) (A), DAZAP1 (B), hnRNP Q (C) and hnRNP R (D). Cell nuclei were 
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visualized using DAPI staining. Scale bars: 32 µm. For each image, b/w inserts (scale bars: 10 µm) of a 
selected area (white dashed square) indicating DAPI (on the left) and a-TDP-43 (on the right) staining are 
also provided. 
 
4.2 Cellular model of TDP-43 pathology 
4.2.1 Analysis of siRNA-mediated depletion of DAZAP1, hnRNP Q and 
hnRNP R using a cellular model of TDP-43 loss-of-function 
To examine in depth the effects of siRNA-mediated depletion of DAZAP1, hnRNP Q and 
hnRNP R in a context more close to the scenario of TDP-43 pathology, we have taken 
advantage of a cellular model of TDP-43 loss-of-function. This model is already available 
in our laboratory and enstablished in Flp-In HEK293 cell line. Recently, it has been 
described a TDP-43 aggregation system, consisting of 12 tandem repeats carrying the 331–
369-residue Gln/Asn region of TDP-43 fused to FLAG-tag or green fluorescentprotein 
(EGFP), reproduces many features of the TDP-43 inclusions observed in patients suffering 
from ALS and FTLD (Budini et al., 2012, 2014) (Figure 28A). Therefore, in order to 
evaluate the localization of the endogenous TDP-43 in this cellular model, we used Flp-In 
HEK293 cells producing FLAG-TDP43-12XQ/N aggregates (upon tetracycline induction) 
to perform immunofluorescence assays, after DAZAP1, hnRNP Q and hnRNP R 
knockdown. Despite it is difficult to quantify the amount of TDP-43 aggregation, the 
results obtained in this experiment show that the endogenous TDP-43 seems to co-localize 
with the inducible aggregates, and remains mostly nuclear either in the presence or absence 
of siRNA treatment (Figure 28). Therefore, the depletion of DAZAP1, hnRNP Q and 
hnRNP R appears not able to affect the aggregation propency of TDP-43, suggesting why, 
at the present, there is no evidence of the presence of these hnRNPs in the TDP-43 
inclusions of ALS and FTLD patients. 
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Nonetheless, the silencing of both DAZAP1 and hnRNP Q seems to restore POLDIP3 
exon 3 inclusion (Figure 28C, left panel) and STAG2 exon 30b skipping  (Figure 28C, right 
panel) induced by the formation of the aggregates, as previously observed in the RNA 
splicing experiments performed in the SH-SY5Y cells. 
 
Figure 24. Effects of hnRNP silencing in Flp-In HEK293 cells expressing FLAG-TDP43-12XQ/N 
aggregates. (A) Schematic representation of TDP-43 12XQ/N. (B) Immunofluorescence analysis showing 
the localization of endogenous (green) and aggregated (red) TDP-43 in the absence of hnRNP silencing 
(TDP-12XQ/N) and in the presence of siRNA against fire-fly Luciferase (siLUC, control), DAZAP1, hnRNP 
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Q and hnRNP R. Co-localization of endogenous TDP-43 with 12XQ/N aggregates is observed as yellow 
dots. Scale bars: 16 μm. Western Blot for checking hnRNP silencing is also reported. (C) RT-PCR of 
POLDIP3 and STAG2 genes in the presence of TDP-12XQ/N aggregates (lane 1, Tet) and silencing of siLUC 
(lane 2, control), siDAZAP1 (lane 3), sihnRNP Q (lane 4) and sinhRNP R (lane 5). Splicing analysis of 
POLDIP3 and STAG2 genes were performed in collaboration with Dr. Fatemeh Mohagheghi. 
 
4.3 Characterization of TDP-43 and DAZAP1 interaction 
4.3.1 DAZAP1 does not bind to TDP-43 but can bind in vivo to TDP-43 
controlled mRNAs 
Another possible connection between TDP-43 and hnRNP proteins able to explain the 
results obtained until now could be represented by their ability to bind TDP-43 and directly 
affect its functional properties. To this regard, proteomic studies on TDP-43 have 
confirmed the presence of hnRNP Q and hnRNP R in complexes that contain TDP-43 
(Blokhuis et al., 2016; S. Ling et al., 2010), but no previous studies have uncovered a 
possible interaction between TDP-43 and DAZAP1. Therefore, we examined this 
interesting aspect by transfecting HeLa cells with flagged-TDP-43 and testing the presence 
of DAZAP1 by a co-immunoprecipitation (Co-IP) assay. This experiment shows that TDP-
43 and DAZAP1 do not seem to co-IP together (Figure 29A).  
Considering that data, we tested if DAZAP1 could be capable of binding to TDP-43 
mRNA targets analysed in Figure 23, 24 and 26. To do this, we performed an RNA-
immunoprecipitation (RNA-IP) assay by transfecting HeLa cells with flagged-DAZAP1, 
immunoprecipitating the RNA bound to DAZAP1 and testing by RT-qPCR the binding of 
DAZAP1 to BRD8, TNIK, STAG2, POLDIP3 and MADD transcripts. As shown in Figure 
29B, all these transcripts were enriched after RNA-IP analysis, although BRD8 and TNIK 
in smaller amount. This could be dependent on their lower abundance in HeLa cells and/or 
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it could be associated with their weaker/ unstabler interaction with TDP-43 than the other 
tested transcripts. GAPDH and SDHA were also tested as controls. 
Importantly, in both the experiments of immunoprecipitation we decided to take advantage 
of HeLa cells instead of using SH-SY5Y cells in order to maximize the transfection 
efficiency with plasmid DNA. 
 
 
Figure 25. Probing the DAZAP1 - TDP-43 interaction. (A) Co-immunoprecipitation experiment was 
performed by overexpressing FLAG-TDP-43 in HeLa cells and the immunoprecipitation was checked by 
Western Blot against DAZAP1 (upper panel). The presence of hnRNP H1 in the immunoprecipitated sample 
was used as a positive control (middle panel). The lower panel shows the levels of flagged and endogenous 
TDP-43 in the Input and immunoprecipitated sample. (B) RNA immunoprecipitation experiments (n=3) to 
monitor for DAZAP1 binding to BRD8, TNIK, STAG2, POLDIP3, MADD transcripts and also two 
housekeeping genes, GAPDH and SDHA (used as controls). RNA immunoprecipitation was performed in 
collaboration with Dr. Fatemeh Mohagheghi. 
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4.3.2 TDP-43 and DAZAP1 can alter the expression of neuronal related 
mRNAs in SH-SY5Y cells 
Based on the results obtained from mRNA analysis of TDP-43 targets, in order to 
determine the wide effects of the hnRNPs of interest, we decided to obtain the whole 
transcriptome status of SH-SY5Y cells depleted by TDP-43, DAZAP1, hnRNP Q or 
hnRNP R. 
In this regard, because DAZAP1 seems to be the best modifier of the TDP-43 controlled 
events, we initially focused the attention on the RNA-seq data achieved following 
silencing of DAZAP1 and TDP-43. Three independent experiments were performed. 
Notably, prior to the differential expression analysis, weak expression features with 
counts-per-million value (CPM) of less than one were excluded from the analysis, resulting 
in the removal of 47622 of the 64769 features initially generated by RNA-seq analysis. 
Therefore, a total of 17147 final features underwent to differential expression analysis. The 
putative differentially expressed genes (DEGs) were identified using a fold change (FC) 
cut-off of 30% with respect to a control sample treated with siRNA against fire-fly 
luciferase (siLUC) (upregulation cut-off: >1.3; downregulation cut-off: <0.7-FC).  
Among the total 17147 genes analysed, 3533 genes were differentially expressed in siTDP-
43 treated cells, in comparison to siLUC treated cells. Of these 3533 genes, 1173 (33%) 
genes were downregulated and 2360 (67%) genes were upregulated.  
In the same way, we analysed the results obtained from cells silenced for DAZAP1 and we 
found that among the total 17147 genes analysed, 7571 genes resulted to be differentially 
expressed in siDAZAP1 treated cells in comparison to siLUC treated cells. Of these 7571 
genes, 3244 (43%) genes were downregulated and 4327 (57%) genes were upregulated. 
Interestingly, enough 1924 genes of the differentially expressed genes in siTDP-43 and 
siDAZAP1 treated cells were commonly regulated (Figure 30A).  
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To validate the RNA-seq data, we selected 10 genes belonging to the top 100 differentially 
expressed genes by siTDP-43 and siDAZAP1 treatment, based on their involvement in 
neuron development and brain inflammation (Figure 30B). The fold changes obtained from 
RT-qPCR were compared with RNA-seq expression analysis results (Figure 30C). CUGBP 
Elav-like Family Member 5 (CELF5), Syntaxin 3 (STX3), Acetylcholinesterase (ACHE), 
Tumor Necrosis Factor (TNF), Tumor Necrosis Factor Receptor Superfamily, Member 9 
(TNFRSF9), Intercellular Adhesion Molecule 1 (ICAM1) and Yippee-like 4 (YPEL4), were 
prominently found to be upregulated both by siDAZAP1 treatment and by siTDP-43 
treatment. ELAV like Neuron-Specific RNA binding protein 3 (ELAVL3) and Neuron-
Oncological Ventral Antigen 2 (NOVA2) were found to be downregulated in both siTDP-
43 and siDAZAP1 treatment, whereas Reelin (RELN) was found to be downregulated only 
in siDAZAP1 treated cells and was chosen as a neutral gene (for TDP-43 treated cells) and 
it was also confirmed by qPCR validation. RNA-seq analysis for both TDP-43 and 
DAZAP1 was also represented by volcano plot and MAPlot (Figure 31 and 32, 
respectively), in which P <0.05 was used as a statistical hypothesis test. In both graphs, 
differentially expressed genes (DEGs) are highlighted in red (downregulated) and in green 
(upregulated) based on the Pvalue and the cut-off of 30% variation with respect to the 
control treated cells (siLUC). For both siTDP-43 and siDAZAP1 treated cells in the 
volcano plot is reported the position of the DEGs validated by using qPCR, whereas the 
position of TARDBP and DAZAP1 genes is reported in TDP-43-related MAPlot and 
DAZAP1-related MAPlot, respectively. 
Furthermore, we performed a pathway analysis using PANTHER Pathway and DAVID 
annotations to investigate functional associations of gene expression changes and pathways 
in which differentially expressed genes were involved and enriched. As shown in Figure 
30D 51% of 433 pathways identified in siTDP-43 treated cells and 57% of 889 pathways 
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identified in siDAZAP1 treated cells were related to brain function and neurodegeneration. 
Interestingly, the greater amount of common differentially regulated genes is related to 
inflammation (Figure 33B), suggesting an important role of this pathway in the presence of 
hnRNP dis-regulation. 
Finally, we also looked at the Gene ontology (GO) functional enrichment analysis using 
the UniProt-KB Retrieve/ID mapping tool (Figure 33A). This analysis showed that siTDP-
43 and siDAZAP1-treated cells share a similar amount of differentially expressed genes in 
the subgroups of “Biological process” and “Molecular function” categories. For both TDP-
43 and DAZAP1, the "molecular function" category of GO terms associated with regulated 
transcripts includes a large percentage of “transcription factor activity, transcription factor 
binding, nucleic acid binding transcription factor activity, signal transducer activity, 
transporter activity, molecular function regulator and receptor activity”. On the other hand, 
in the “biological process” category, a similar percentage in genes involved in “cellular 
process, biological regulation, single-organism process and metabolic processes” groups 
were notably represented for both siTDP-43 and siDAZAP1. 
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Figure 26. Validation of the TDP-43 or DAZAP1 silencing and comparison between RNA-seq and 
qRT-PCR results. (A) Summary of downregulated (<0.7× versus siLUC) and upregulated (>1.3× versus 
siLUC) genes after siTDP-43 or siDAZAP1 treatments. The number of common (between siTDP- 43 and 
siDAZAP1) downregulated and upregulated genes is also shown. (B) List of genes associated with brain 
functions (ELAV3, NOVA2, RELN, STX3, ACHE, YPEL4, CELF5) or inflammation (TNF, TNFRSF9, 
ICAM1) selected for validation of the RNA-seq analysis. The expression levels of genes following siTDP-43 
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or siDAZAP1 treatments versus the control condition (siLUC) is indicated. (C) Validation of RNA-seq by 
real time PCR of the ten selected transcripts. The results are represented as relative expression compared with 
the control (siLUC). Each bar reports the mean ± standard deviation of three independent experiments. The 
single asterisks indicate significant differences (P< 0.05) between the indicated measurements. (D) Pathways 
analysis of differentially expressed genes following TDP-43 and DAZAP1 depletion as determined by 
PANTHER, DAVID and UniProt analyses.  
 
 
Figure 27. Graphic representation of RNA-seq analysis performed on SH-SY5Y cells depleted for 
TDP-43. (A) Volcano plot reports in x-axis the magnitude (Log2FoldChange) and in y-axis the significance 
(–log10(Pvalue)) of siLUC versus siTDP-43 treated cells. Upregulated and downregulated genes are 
highlighted in green and red, respectively, and validated genes are signalled by arrows. The horizontal blue 
line signals statistical significance threshold (P= 0.05). (B) MAPlot reports in x-axis the normalized library 
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size (Log2CPM, counts per million) and in y-axis the magnitude (Log2FoldChange) of siLUC versus siTDP-
43 treated cells. Upregulated and downregulated genes are highlighted in green and red, respectively. The 
position of TARDBP gene (encoding TDP-43 protein) is highlighted by an arrow.  
 
 
Figure 28. Graphic representation of RNA-seq analysis performed on SH-SY5Y cells depleted for 
DAZAP1. (A) Volcano plot reports in x-axis the magnitude (Log2FoldChange) and in y-axis the significance 
(–log10(Pvalue)) of siLUC versus siDAZAP1 treated cells. Upregulated and downregulated genes are 
highlighted in green and red, respectively, and validated genes are signalled by arrows. The horizontal blue 
line signals statistical significance threshold (P= 0.05). (B) MAPlot reports in x-axis the normalized library 
size (Log2CPM, counts per million) and in y-axis the magnitude (Log2FoldChange) of siLUC versus 
siDAZAP1 treated cells. Upregulated and downregulated genes are highlighted in green and red, 
respectively. The position of DAZAP1 gene (encoding DAZAP1 protein) is highlighted by an arrow.  
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Figure 29. GO functional enrichment analysis of the genes significantly co-regulated by TDP-43 and 
DAZAP1. (A) For TDP-43, 2269 out of 3535 (1173 downregulated <0.7 and 2360 upregulated >1.3 vs. 
siLUC) Ensembl identifiers were successfully mapped to 8481 UniProtKB IDs. For DAZAP1, 5137 out of 
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7571 (3244 downregulated <0.7 and 4327 upregulated>1.3 vs. siLUC) Ensembl identifiers were successfully 
mapped to 19541 UniProtKB IDs. The clustered columns charts show the percentage of the successfully 
mapped Ensembl IDs. (B) Pathway analysis of the differentially expressed genes common between siTDP-43 
and siDAZAP1 depletions, as determined by PANTHER analysis. 
 
4.4 Characterization of hnRNP Q and hnRNP R 
4.4.1 Analysis of protein sequence identity and similarity  
To further refine the characterization of the hnRNPs in this study, we decided to extend our 
investigation to hnRNP Q and hnRNP R, in particular because they share similar protein 
sequence (Zissimos Mourelatos et al., 2001) and because in lower organisms, such as 
Drosophila melanogaster (McDermott et al., 2012) and Caenorhabditis elegans (Kabat et 
al., 2009), they were found in one well conserved ortholog, suggesting the occurrence of a 
progressive functional divergence during the evolution. 
Concerning this aspect, we decided to compare the protein sequence of the major splicing 
isoforms of each human counterpart with their D. melanogaster ortholog (Table 21). To 
this aim, we used EMBOSS needle (https://www.ebi.ac.uk/Tools/psa/emboss_needle/) and 
we calculated the percentage of identity and similarity of human hnRNP Q1, hnRNP Q2, 
hnRNP Q3, hnRNP R1 and hnRNP R2 with respect to the Drosophila variant CG17838 
(isoform F)/Syp (Figure 34), that we previously used in our TBPH loss- and gain-of-
function model and it has been well-described in larvae, pupae, and in all adult tissues 
(McDermott et al., 2012). The obtained results confirmed the high level of homology of 
each human splicing variant compared to the Drosophila one. 
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Figure 30. Structure of Drosophila melanogaster CG17838 (isoform F)/Syp variant. This variant contains 
a conserved AcD, three RRMs (RRM1, RRM2 and RRM3) and two NLS. Each domain is highlighted in 
colored boxes and the relative sequence position and amino acids length is also reported.  
 
Table 21. Percentage of identity and similarity of human hnRNP Q and hnRNP R with respect to Drosophila 
CG17838 (isoform F)/Syp variant. 
Isoform % identity % similarity 
hnRNP Q1 47.1 59.6 
hnRNP Q2 42.9 53.1 
hnRNP Q3 45.9 57.1 
hnRNP R1 46.0 58.2 
hnRNP R2 43.0 53.8 
 
 
4.4.2 Subcellular localization of hnRNP Q and hnRNP R in SH-SY5Y 
cells  
In order to investigate the reasons underlying a possible functional divergence between 
hnRNP Q and hnRNP R, we initially decided to look at their subcellular distribution in SH-
SY5Y cells through an immunofluorescence analysis. As shown in Figure 35, hnRNP Q 
was spread amongst cytoplasm and nucleus, while hnRNP R seemed to be mostly nuclear.  
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Figure 31. Cellular localization of endogenous hnRNP Q and hnRNP R in SH-SY5Y cells. 
Immunofluorescence analysis of the endogenous hnRNP Q and hnRNP R (shown in green) in SH-SY5Y 
cells. Nuclei were visualized using DAPI staining. Scale bars: 17 µm. 
 
These results were also confirmed by nuclear cytoplasmic fractionation, as reported in 
Figure 36. Regarding hnRNP Q, three major splicing isoforms have been so far previously 
reported (Mourelatos et al. 2001). These isoforms are characterized by the presence of two 
NLS in the hnRNP Q3 and hnRNP Q2 variants (with a molecular weight of 70 kDa and 65 
kDa, respectively) and one NLS in the hnRNP Q1 (with a molecular weight of 62 kDa). 
Our experiments detected three immunoreactive bands (∼ 58 kDa, ∼66 kDa and ∼ 75 kDa), 
differentially distributed between nucleus and cytosol (Figure 36A). The molecular weight 
of ∼ 75 kDa was consistent with that of hnRNP Q2/hnRNP Q3 isoforms and the molecular 
weight of ∼ 66k Da with that of hnRNP Q1 isoform. The lower band (~58 kDa) cannot be 
associated to any known hnRNP Q isoform and could correspond to a further variant that 
still remains to be characterized, or non-specific cross-reaction. This observation could be 
explained by the fact that the latter variant gives a weak signal and is therefore not always 
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detectable. For this, it was not detected in our previous Western Blot analysis (Figure 22, 
28A). 
The same analysis was repeated for hnRNP R, confirming its presence predominantly in 
the nuclear fraction (Figure 36B). The antibody used for staining the membrane (ab30930) 
detected three bands: ~71 kDa, ~75 kDa and ~80 kDa. In the first set of Western Blot 
experiments performed using hnRNP R antibody (Figure 22, 28A), we only reported the 
band corresponding to the predicted molecular size described in the datasheet provided by 
the company. Due to the fact that the literature regarding different hnRNP R isoforms (and 
consequently variable size of this protein) is still incomplete, in the second part of the 
current project, we decided to additionaly consider the other two hnRNP isoforms 
recognized by the same antibody. These two isoforms were not taken into account in the 
first part of the experiments, since they were not in agreement with the predicted size 
reported by the antibody producer.  
Therefore, according to the literature, we assigned the higher molecular weight band (~ 80 
KDa) to the major hnRNPR isoform, also known as R1 (NP_005817.1. NM_005826.4. 
[O43390-1]); and the second higher band (~75 kDa) to the more neuronal variant, namely 
R2 (NP_001284549.1, NM_001297620.1 [O43390-3]). On the other hand, we supposed 
that the lower band of ~71 kDa was associated with another splicing variant of hnRNP R 
that still needs to be characterized.  
Overall, the different localization of hnRNP Q and hnRNP R suggested that their nuclear-
cytoplasmic distribution is differentially regulated and this could result in a differential 
control of the regulated cellular pathways. 
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Figure 32. Nuclear and cytoplasmic fractions of endogenous human hnRNP Q and human hnRNP R. 
(A) Western blot analysis of hnRNP Q franctions. The asterisk (*) indicates possible splicing variant of 
hnRNP Q.  (B) Western blot analysis of hnRNP R franctions. Double asterisk (**) indicates possible 
alternative splicing variant of hnRNP R. In both of analysis a-p84 and a-tubulin were used as controls for 
nuclear and cytoplasmic fractions, respectively. 
 
4.4.3 Subcellular localization of hnRNP Q and hnRNP R is not altered by 
their reciprocal silencing 
Because of the close relationship between these two factors, we decided to investigate if 
the silencing of hnRNP Q was able to affect the gene expression and cellular localization 
of hnRNP R and vice-versa (Figure 37). We observed no significant differences in the 
mRNA levels, as well as in the endogenous localization of hnRNP Q after siRNA 
treatment against hnRNP R and of hnRNP R after siRNA treatment against hnRNP Q. 
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Figure 33. mRNA levels and cellular localization of endogenous hnRNP Q and hnRNP R after siRNA 
treatment in SH-SY5Y cells. (A) Relative expression of hnRNP Q after siRNA against hnRNP R (sihnRNP 
R) and vice-versa. All the samples were compared to siLUC treated cells. Each bar reports mean ± standard 
error (n=3). Statistical differences were evaluated using Student’s t-test (*** P<0.001). (B) 
Immunofluorescence analysis of the endogenous human hnRNP Q and hnRNP R (shown in green) in SH-
SY5Y cells after sihnRNP R and sihnRNP Q, respectively. Nuclei were visualized using DAPI staining. 
Scale bars: 17 µm. 
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4.4.4 Subcellular localization of hnRNP Q and hnRNP R is not altered by 
retinoic acid (RA)-induced neuronal differentiation in NSC-34 cells 
It is well-known that the activation of specific signaling pathways leading to cellular 
differentiation can be differently regulated depending on the subcellular localization of 
specific controlling factors (Robinow and White, 1991). It is also known that both hnRNP 
Q and hnRNP R can regulate neuronal pathways during development (Chen et al., 2012; 
McDermott et al., 2012, 2014). 
Therefore, we tested if hnRNP Q or hnRNP R might change their cellular localization 
under neuronal differentiation. To this aim, immunofluorescence experiments were carried 
out after inducing differentiation up to 5 days with RA at 1 µM (Figure 38A) of the murine 
motor neuron-like NSC-34 cell line. Considering the high conservation of hnRNP Q and 
hnRNP R in mouse (more than 99% identity and similarity), we decided to use this cell 
line due to its ability to differentiate in neuron-like cells better and faster than the SH-
SY5Y neuroblastoma cells. 
The results indicated that the differentiation did not affect the subcellular distribution of 
both hnRNP Q and hnRNP R (Figure 38B). 
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Figure 34. Endogenous localization of hnRNP Q and hnRNP R is not affected by differentiation with 1 
µM of RA in NSC-34 cells. (A) Light microscopy images of undifferentiated (CNTRL) and differentiated 
cells treated up to 5 days with medium containing 1 µM RA. Scale bars: 58 µm, 20X magnification. Neurite 
length comparison (grey bars) of CNTRL and RA is also reported as mean ± standard error (n=5). Statistical 
differences were evaluated using Student’s t-test (* P<0.001). (B) Immunofluorescence analysis of the 
endogenous mouse hnRNP Q and hnRNP R (shown in green) in NSC-34 cells with or without 1 µM RA 
treatment. Nuclei were visualized using DAPI staining. Scale bars: 17 µm. 
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4.4.5 Depletion of hnRNP Q and hnRNP R alters neuronal-related genes 
To define functional characteristics of human hnRNP Q and hnRNP R within cells, we 
decided to perform gene expression profiling of SH-SY5Y silenced for these hnRNPs. 
First of all, we demonstrated the reduction of mRNA levels of hnRNP Q and hnRNP R 
using qPCR after their knockdown (Figure 39A-40A).  
Then, we performed an RNA-seq analysis by comparing data obtained from sihnRNP Q or 
sihnRNP R treated cells, relative to siLUC control samples. Three independent 
experiments were performed.  
As described for RNA-seq analysis of DAZAP1 and TDP-43, prior to the differential 
expression analysis, weak expression features with counts-per-million value (CPM) of less 
than one were excluded from the analysis, resulting in the removal of 47622 of the 64769 
features initially generated by RNA-seq analysis. Therefore, a total of 17147 final features 
underwent to differential expression analysis. Up- and downregulated genes were 
identified applying a FC cut-off of 30% with respect to control siLUC samples 
(upregulation cut-off: >1.3; downregulation cut-off: <0.7-FC) and the P value < 0.05. 
Regarding sihnRNP Q, the total numer of DEGs was 2819 (out of the 17147 analyzed 
genes), among which 1380 (49%) genes were upregulated and 1439 (51%) genes were 
downregulated (Figure 39A). On the other hand, after treatment with siRNA against 
hnRNP R, the total number of DEGs was 1517 genes (out of the 17147 analyzed genes) 
among which 957 (63%) genes were upregulated and 560 (37%) genes were 
downregulated (Figure 40A).  
Validation of RNA-seq data was carried out by qPCR expression analysis of 10 genes 
selected among the top 100 DEGs for their potential involvement in brain functions and 
neuroinflammation (Figures 39B-40B). 
Regarding cells silenced for hnRNP Q, Tumor Necrosis Factor (TNF), Intercellular 
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Adhesion Molecule 1 (ICAM1), Proenkephalin (PENK), Tumor Necrosis Factor Receptor 
Superfamily, Member 9 (TNFRSF9), Kruppel-like Factor 4 (gut) (KLF4), Kelch-like 
Family Member 4 (KLHL4) and Neurogulin 3 (NRG3) were found to be upregulated, while 
RAB26, Member RAS Oncogene Family (RAB26), Rho GTPase Activating Protein 36 
(ARHGAP36) and Cancer/testis Antigen 55 (CT55) were found downregulated (Figure 
39C). On the other hand, concerning cells silenced for hnRNP R, CART prepropeptide 
(CARTPT), FBJ Murine Osteosarcoma Viral Oncogene Homolog B (FOSB), Jagged 1 
(JAG1), Intercellular Adhesion Molecule 5, Telencephalin (ICAM5), Dual Oxidase 
Maturation Factor 1 (DUOXA1) and Heme Oxygenase (decycling 1) (HMOX1) were found 
to be upregulated, while Potassium Voltage-gated Channel, Shaker-related Subfamily Beta 
(KCNAB1), Acid Phosphatase 5, Tartrate Resistant (ACP5), Syndecan Binding Protein 
(Syntenin) 2 (SDCBP2) and EGF containing Fibulin-like Extracellular Matrix Protein 1 
(EFEMP1) were found to be downregulated (Figure 40C). In conclusion, the results of our 
qPCR validation are consistent with those obtained with the RNA-seq analysis. 
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Figure 35. Validation of hnRNP Q silencing and comparison between RNA-seq and RT-qPCR results. 
(A) Summary of differentially expressed genes (DEGs) with number of downregulated (<0.7x versus siLUC) 
and upregulated (>1.3x versus siLUC) genes after sihnRNP Q treatment. Number of DEGs with P <0.05 is 
also reported. (B) List of DEGs validated by RT-qPCR and associated with brain 
functions/neurodegeneration (PENK KLF4, KLHL4, NRG3, RAB26 and ARHGAP36), inflammation (TNF, 
ICAM1, TNFRSF9) and other functions (CT55). (C) RT-qPCR validation of ten selected transcripts. Each bar 
reports mean ± standard error of three independent experiments. Statistical differences were evaluated using 
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Student’s t-test (* P<0.05, ** P<0.01, *** P<0.001). (D) Pathway analysis of differentially expressed genes 
following hnRNP Q depletion as determined by PANTHER, DAVID and UniProt analyses.  
 
 
Figure 36. Validation of hnRNP R silencing and comparison between RNA-seq and RT-qPCR results. 
(A) Summary of DEGs with number of downregulated (<0.7x versus siLUC) and upregulated (>1.3x versus 
siLUC) genes after sihnRNP R treatment. Number of DEGs with P<0.05 is also reported. (B) List of DEGs 
validated by RT-qPCR and associated with brain functions/neurodegeneration (CARTPT, FOSB, JAG1, 
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DUOXA1, HMOX1, KCNAB1, SDCBP2, EFEMP1), inflammation (ICAM5, ACP5). (C) RT-qPCR validation 
of ten selected transcripts. Each bar reports mean ± standard error of three independent experiments. 
Statistical differences were evaluated using Student’s t-test (*P<0.05, ** P<0.01, ***P<0.001). (D) Pathway 
analysis of differentially expressed genes following hnRNP R depletion as determined by PANTHER, 
DAVID and UniProt analyses.  
 
An overview of these RNA-seq data was also provided by volcano plots (Figure 41) and 
MAPlots (Figure 42). Upregulated and downregulated genes were highlighted in green and 
red, respectively. Moreover, in the volcano plot, we reported the position of the DEGs 
validated in Figure 39C and 40C using qPCR. On the other hand, in the MAPlot, we 
highlighted the position of SYNCRIP (hnRNP Q, Figure 42A) and HNRNPR (Figure 42B) 
gene, respectivelly. 
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Figure 37. Volcano plot of hnRNP Q and hnRNP R. Schematic representation of RNA-seq data of 
sihnRNP Q (A) and sihnRNP R (B) treated cells. Up- and downregulated genes are reported as green and red 
dots, respectively. Not DEGs are represented as grey dots. Black arrows show qPCR validated genes. The 
horizontal blue line signals statistical significance threshold (P= 0.05). 
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Figure 38. Graphic representation of RNA-seq analysis performed on SH-SY5Y cells depleted for 
hnRNP Q and hnRNP R. (A) MAPlot reports on the x-axis the normalized library size (Log2CPM, counts 
per million) and on the y-axis the magnitude (Log2FoldChange) of siLUC versus sihnRNP Q treated cells. 
Upregulated and downregulated genes are highlighted in green and red, respectively. The position of 
SYNCRIP gene (encoding hnRNP Q protein) is highlighted by an arrow. (B) MAPlot reports on the x-axis the 
normalized library size (Log2CPM, counts per million) and on the y-axis the magnitude (Log2FoldChange) 
of siLUC versus sihnRNP R treated cells.  Upregulated and downregulated genes are highlighted in green 
and red, respectively. The position of HNRNPR gene (encoding hnRNP R protein) is highlighted by an 
arrow.  
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4.4.6 hnRNP Q and hnRNP R show different and common features after 
GO enrichment and KEGG pathway analysis  
GO enrichment was performed to show up functional similarities and differences in DEGs 
regulated by hnRNP Q and hnRNP R. To this aim, we took advantage of the GOseq R 
Bioconductor package (Young et al., 2010) and considered for the final analysis only GO 
term of the “biological process” (BP), “molecular function” (MF), and “cellular 
component” (CC) categories reaching the P value threshold < 0.05 for significance. In 
particular, top 15 GO terms of each category were selected to find categories specific for 
hnRNP Q or hnRNP R and categories commonly present in both two proteins (Figure 43).  
In hnRNP Q data set, we found 1152 significantly enriched terms out of 2819 DEGs used 
as input for GO analysis. The top enriched GO categories were “membrane” (Pvalue = 
3.17E-08), “bounding membrane to organelle” Pvalue = 7.29E-07), “cell morphogenesis 
involved in differentiation” (Pvalue = 1.10E-06), “cell development” (Pvalue = 1.42E-06) 
and “cell adhesion” (Pvalue = 3.17E-06). On the other hand, in hnRNP R data set, we 
found 955 significantly enriched terms out of 1517 DEGs used as input for GO analysis. 
The top enriched GO categories were “system development” (Pvalue = 2.34E-08), “tissue 
development” (Pvalue = 4.21E-08), “multicellular organism development” (Pvalue = 
3.39E-07), “cell differentiation” (Pvalue = 4.28E-07) and “signal transduction” (Pvalue 
=1.13E-06). Notably, when we looked at GO terms differentially enriched in hnRNP Q and 
hnRNP R DEGs, we found that “intrinsic component of membrane”, “plasma membrane”, 
“cell periphery”, “integral component of membrane” and “membrane part” were 
particularly enriched in hnRNP Q depleted cells, while “signal receptor activity”, 
“transmembrane receptor activity”, “transmembrane signalling receptor activity”, “receptor 
activity” and “molecular transducer activity” were more enriched in hnRNP R depleted 
treated cells.  
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Regarding KEGG analysis, we found 29 and 16 terms with significant gene enrichment (P 
< 0.05) for hnRNP Q and hnRNP R, respectively (Figure 44) and the majority of them 
were inflammation-related pathways. Indeed, “toll-like receptor signalling pathway” 
(Pvalue = 0.002), “ECM-receptor interaction” (Pvalue = 0.002), “adipocytokine signaling 
pathway” (Pvalue = 0.003), “toxoplasmosis” (Pvalue = 0.004) and “rheumatoid arthritis” 
(Pvalue = 0.007) were particularly enriched in DEGs obtained by sihnRNP Q silencing, 
whereas “cell adhesion molecules (CAMs)” (Pvalue = 4.58E-05), “ECM-receptor 
interaction” (Pvalue = 0.001), “cytokine-cytokine receptor interaction” (Pvalue = 0.01), “T 
cell receptor signaling pathway” (Pvalue = 0.02) and “malaria” (Pvalue = 0.02) were 
particularly enriched in DEGs obtained by sihnRNP R silencing. 
In conclusion, this analysis suggested a specific specialization acquired from hnRNP Q and 
hnRNP R during evolution. In particular, GO terms linked to the organization of lipid 
layers and in the regulation of cell-cell and cell-extracellular matrix contacts seemed to be 
influenced by sinhnRNP Q treatment, while, GO terms associated with cell/tissue 
development and cell signalling was found to be regulated by depletion of hnRNP R. 
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Figure 39. GO enrichment analysis of hnRNP Q and hnRNP R DEGs. Biological process (BP), 
molecular function (MF) and cellular component (CC) GO categories are represented. Each category reported 
the first 15 sub-categories (P<0.05) of DEGs for cells treated with siRNA against both hnRNP Q and hnRNP 
R. 
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Figure 40. KEGG pathway analysis of hnRNP Q and hnRNP R.  (A) First 10 pathways identified in 
DEGs of SH-SY5Y cells treated with siRNA against hnRNP Q (P<0.05). (B) First 10 pathways identified in 
DEGs of SH-SY5Y cells treated with siRNA against hnRNP R (P<0.05). 
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4.5 An overview of the entire transcriptome status after 
silencing of TDP-43, DAZAP1, hnRNP Q and hnRNP R  
4.5.1 TDP-43, DAZAP1 and hnRNP Q share common regulated-
transcripts associated with ALS pathology 
Following the RNA-seq analysis of cells depleted for TDP-43, DAZAP1, hnRNP Q or 
hnRNP R we decided to combine all the DEGs (FC cut-off of 30% vs siLUC; P <0.05) of 
each hnRNP silencing in order to find commonly regulated transcripts (Figure 45). 
 
 
 
Figure 41. Venn diagramm of RNA-seq data. Comparison of the number of transcripts altered in TDP-43, 
hnRNP Q and hnRNP R depleted SH-SY5Y cell. Genes co-regulated by TDP-43, DAZAP1 and hnRNP Q 
but not hnRNP R are highlighted with red circle. 
 
As described previously, our results in SH-SY5Y cells and Flp-In HEK293 expressing 
TDP-43 12XQ/N demonstrated that DAZAP1 and hnRNP Q were particularly effective in 
modulating the activity of TDP-43 targets. In this way, we were interested in looking for 
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all the possible mRNA targets regulated by TDP-43, DAZAP1, hnRNP Q but not hnRNP 
R and we identified 214 genes reflecting these criteria (Figure 45, Table 22). This list of 
genes shows that more than 50% of the transcripts affected by TDP-43, DAZAP1, and 
hnRNP Q play an important role in neuronal maintenance/functions (such as NOVA2), 
immune system and inflammation (TNF, TNFRSF9, ICAM-1), and apoptosis (Figure 46). 
These observations lend further support to recent studies that hypothesize a role of immune 
system and apoptosis in the ALS pathogenesis. Furthermore, in this list of 214 co-regulated 
genes there are already several candidates that are extremely promising for the 
understanding the RNA misregulation occurring during neurodegenerative disorders and 
that will be discussed in the next chapter. 
 
Table 22. Co-regulated transcripts between TDP-43, DAZAP1 and hnRNP Q 
  
RNA-seq Fold Change 
ENSEMBL Gene Symbol TDP-43 DAZAP1 hnRNP Q 
ENSG00000181201 HIST3H2BA 0.1 3.6 0.1 
ENSG00000205625 RP11-15G8.1 0.2 0.6 0.7 
ENSG00000157703 SVOPL 0.3 0.3 0.2 
ENSG00000042832 TG 0.3 0.4 0.4 
ENSG00000100078 PLA2G3 0.4 0.3 0.3 
ENSG00000258472 RP11-192H23.4 0.4 0.2 0.2 
ENSG00000104967 NOVA2 0.4 0.7 0.7 
ENSG00000230138 RP11-117D22.2 0.4 0.3 0.2 
ENSG00000206838 SNORA5A 0.4 0.4 0.5 
ENSG00000162188 GNG3 0.4 0.4 0.6 
ENSG00000154997 SEPT14 0.4 2.3 2.2 
ENSG00000167244 IGF2 0.4 0.2 0.4 
ENSG00000130600 H19 0.4 0.2 0.6 
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ENSG00000132141 CCT6B 0.5 4.5 0.6 
ENSG00000130176 CNN1 0.5 0.6 2.2 
ENSG00000175785 PRIMA1 0.5 0.3 0.6 
ENSG00000165424 ZCCHC24 0.5 0.4 1.8 
ENSG00000265971 RP11-269G24.6 0.5 0.4 0.4 
ENSG00000179921 GPBAR1 0.5 0.2 1.8 
ENSG00000167889 MGAT5B 0.5 0.5 1.4 
ENSG00000142197 DOPEY2 0.5 0.5 0.5 
ENSG00000163536 SERPINI1 0.5 4.3 1.7 
ENSG00000115756 HPCAL1 0.5 0.5 1.6 
ENSG00000173517 PEAK1 0.5 2.3 0.6 
ENSG00000141753 IGFBP4 0.5 0.6 1.4 
ENSG00000092929 UNC13D 0.5 0.6 0.5 
ENSG00000123091 RNF11 0.6 0.4 0.7 
ENSG00000198570 RD3 0.6 0.2 0.5 
ENSG00000267980 AC007292.6 0.6 0.6 0.6 
ENSG00000271155 RP11-435O5.5 0.6 2.7 0.6 
ENSG00000179242 CDH4 0.6 0.5 1.7 
ENSG00000185900 POMK 0.6 0.5 0.4 
ENSG00000100092 SH3BP1 0.6 0.6 0.6 
ENSG00000135097 MSI1 0.6 0.5 0.5 
ENSG00000198929 NOS1AP 0.6 0.6 0.7 
ENSG00000177830 CHID1 0.6 1.5 1.3 
ENSG00000144677 CTDSPL 0.6 0.7 1.5 
ENSG00000183044 ABAT 0.6 2.1 0.4 
ENSG00000270015 RP11-540B6.6 0.6 1.3 1.4 
ENSG00000069431 ABCC9 0.6 0.3 0.6 
ENSG00000164125 FAM198B 0.6 0.4 1.5 
ENSG00000175093 SPSB4 0.6 0.6 0.6 
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ENSG00000084710 EFR3B 0.6 0.5 0.5 
ENSG00000167524 SGK494 0.6 0.5 0.4 
ENSG00000101115 SALL4 0.6 0.6 1.5 
ENSG00000088280 ASAP3 0.6 0.7 0.7 
ENSG00000171303 KCNK3 0.6 0.5 1.4 
ENSG00000159873 CCDC117 0.6 0.6 1.3 
ENSG00000175229 GAL3ST3 0.6 0.5 0.6 
ENSG00000101986 ABCD1 0.6 1.3 0.6 
ENSG00000003249 DBNDD1 0.6 0.7 0.6 
ENSG00000148700 ADD3 0.6 0.7 0.5 
ENSG00000197122 SRC 0.6 0.6 0.6 
ENSG00000174672 BRSK2 0.6 0.6 0.7 
ENSG00000176749 CDK5R1 0.6 0.4 0.6 
ENSG00000239887 C1orf226 0.6 0.5 0.7 
ENSG00000146094 DOK3 0.7 0.6 0.5 
ENSG00000125520 SLC2A4RG 0.7 0.3 0.6 
ENSG00000149295 DRD2 0.7 0.4 1.4 
ENSG00000198168 SVIP 0.7 0.5 0.6 
ENSG00000116981 NT5C1A 0.7 0.6 0.6 
ENSG00000122254 HS3ST2 0.7 0.4 0.7 
ENSG00000197586 ENTPD6 0.7 0.6 1.3 
ENSG00000173621 LRFN4 0.7 0.6 0.6 
ENSG00000165238 WNK2 0.7 0.7 0.7 
ENSG00000108433 GOSR2 0.7 1.4 1.4 
ENSG00000261762 RP11-650L12.2 0.7 0.3 0.6 
ENSG00000121039 RDH10 0.7 1.5 1.4 
ENSG00000073670 ADAM11 0.7 2.2 0.7 
ENSG00000128482 RNF112 0.7 0.5 0.6 
ENSG00000164742 ADCY1 0.7 0.6 0.6 
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ENSG00000172794 RAB37 0.7 0.7 1.4 
ENSG00000278619 MRM1 0.7 0.5 1.3 
ENSG00000149260 CAPN5 0.7 0.6 0.7 
ENSG00000259291 RP11-617F23.1 0.7 0.4 0.5 
ENSG00000141750 STAC2 0.7 0.3 0.7 
ENSG00000100034 PPM1F 0.7 0.7 1.3 
ENSG00000007402 CACNA2D2 0.7 0.7 0.6 
ENSG00000133997 MED6 0.7 1.6 1.3 
ENSG00000139200 PIANP 0.7 0.7 0.6 
ENSG00000015532 XYLT2 0.7 0.5 0.6 
ENSG00000171310 CHST11 0.7 0.5 0.5 
ENSG00000162959 MEMO1 0.7 0.6 0.5 
ENSG00000130772 MED18 1.3 1.5 1.6 
ENSG00000171295 ZNF440 1.3 1.4 1.5 
ENSG00000158373 HIST1H2BD 1.3 4.7 1.5 
ENSG00000185658 BRWD1 1.3 1.8 1.3 
ENSG00000171992 SYNPO 1.3 0.6 0.6 
ENSG00000155729 KCTD18 1.3 1.5 0.6 
ENSG00000136895 GARNL3 1.3 0.7 1.4 
ENSG00000177239 MAN1B1 1.3 1.6 1.4 
ENSG00000158470 B4GALT5 1.3 1.3 1.9 
ENSG00000112773 FAM46A 1.3 1.5 1.9 
ENSG00000169981 ZNF35 1.3 1.8 1.5 
ENSG00000139117 CPNE8 1.3 1.5 1.5 
ENSG00000152518 ZFP36L2 1.3 0.6 1.6 
ENSG00000181523 SGSH 1.3 1.3 1.7 
ENSG00000033100 CHPF2 1.3 1.9 1.5 
ENSG00000198046 ZNF667 1.4 1.6 1.4 
ENSG00000090263 MRPS33 1.4 1.3 1.4 
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ENSG00000188042 ARL4C 1.4 0.6 1.7 
ENSG00000126947 ARMCX1 1.4 0.6 1.3 
ENSG00000162396 PARS2 1.4 2.4 1.6 
ENSG00000136167 LCP1 1.4 3.7 2.7 
ENSG00000138760 SCARB2 1.4 1.5 0.6 
ENSG00000067113 PPAP2A 1.4 1.4 1.5 
ENSG00000106617 PRKAG2 1.4 1.5 0.7 
ENSG00000196437 ZNF569 1.4 1.6 0.7 
ENSG00000248383 PCDHAC1 1.4 2.1 2.2 
ENSG00000143469 SYT14 1.4 1.4 0.7 
ENSG00000273820 USP27X 1.4 1.6 1.4 
ENSG00000185947 ZNF267 1.4 1.6 1.6 
ENSG00000250091 DNAH10OS 1.4 1.3 0.3 
ENSG00000170035 UBE2E3 1.4 1.4 1.6 
ENSG00000146966 DENND2A 1.5 1.5 0.4 
ENSG00000272947 RP11-71H17.9 1.5 1.5 0.7 
ENSG00000116574 RHOU 1.5 0.5 0.7 
ENSG00000153214 TMEM87B 1.5 1.4 2.2 
ENSG00000003436 TFPI 1.5 1.5 1.9 
ENSG00000238105 GOLGA2P5 1.5 1.7 0.6 
ENSG00000138078 PREPL 1.5 1.5 1.4 
ENSG00000132824 SERINC3 1.5 1.4 1.4 
ENSG00000167740 CYB5D2 1.5 2.8 1.7 
ENSG00000186866 POFUT2 1.5 1.7 1.5 
ENSG00000031691 CENPQ 1.5 1.6 0.7 
ENSG00000088727 KIF9 1.5 2.1 1.6 
ENSG00000210107 MT-TQ 1.6 1.8 1.6 
ENSG00000106853 PTGR1 1.6 1.5 2.0 
ENSG00000153363 LINC00467 1.6 3.7 1.8 
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ENSG00000279192 PWAR5 1.6 1.9 1.6 
ENSG00000108733 PEX12 1.6 1.4 1.5 
ENSG00000171365 CLCN5 1.6 1.5 1.4 
ENSG00000157680 DGKI 1.6 2.0 1.8 
ENSG00000100906 NFKBIA 1.6 1.5 1.5 
ENSG00000135776 ABCB10 1.6 0.4 0.6 
ENSG00000105708 ZNF14 1.6 2.0 1.8 
ENSG00000107165 TYRP1 1.6 2.0 1.7 
ENSG00000256304 CCDC150P1 1.6 0.4 0.6 
ENSG00000171451 DSEL 1.6 0.5 0.5 
ENSG00000177272 KCNA3 1.6 2.3 2.9 
ENSG00000166192 SENP8 1.6 1.5 1.6 
ENSG00000128923 FAM63B 1.6 1.4 0.4 
ENSG00000164305 CASP3 1.6 1.3 1.7 
ENSG00000114923 SLC4A3 1.7 1.5 0.6 
ENSG00000134326 CMPK2 1.7 2.1 1.8 
ENSG00000118976 OTUD4P1 1.7 1.5 1.8 
ENSG00000280287 RP13-554M15.7 1.7 10.7 2.3 
ENSG00000253869 PIGFP1 1.7 1.7 1.6 
ENSG00000085449 WDFY1 1.7 1.6 1.5 
ENSG00000090612 ZNF268 1.7 2.1 1.4 
ENSG00000149243 KLHL35 1.7 0.3 1.6 
ENSG00000087074 PPP1R15A 1.7 2.7 1.9 
ENSG00000117586 TNFSF4 1.7 4.5 2.1 
ENSG00000162616 DNAJB4 1.7 2.6 1.5 
ENSG00000228876 AC010745.2 1.7 0.4 1.6 
ENSG00000163820 FYCO1 1.8 0.4 1.4 
ENSG00000128016 ZFP36 1.8 3.7 1.5 
ENSG00000166432 ZMAT1 1.8 6.6 0.4 
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ENSG00000127561 SYNGR3 1.8 2.3 0.6 
ENSG00000135318 NT5E 1.9 1.9 3.8 
ENSG00000223427 AC016716.1 1.9 0.5 1.6 
ENSG00000107201 DDX58 1.9 5.1 2.3 
ENSG00000168398 BDKRB2 1.9 2.0 2.8 
ENSG00000080709 KCNN2 1.9 4.0 2.6 
ENSG00000135926 TMBIM1 1.9 0.4 2.0 
ENSG00000168461 RAB31 2.0 2.5 1.5 
ENSG00000142102 ATHL1 2.0 0.6 0.6 
ENSG00000254473 RP11-522I20.3 2.0 8.8 2.9 
ENSG00000142303 ADAMTS10 2.0 4.1 0.5 
ENSG00000115665 SLC5A7 2.0 0.5 2.0 
ENSG00000156966 B3GNT7 2.1 0.3 2.1 
ENSG00000259381 RP11-192M23.1 2.2 2.0 2.0 
ENSG00000248323 LUCAT1 2.2 2.5 0.4 
ENSG00000259834 KCNA3 2.2 2.3 2.9 
ENSG00000166246 C16orf71 2.2 4.0 2.5 
ENSG00000135048 TMEM2 2.2 2.0 1.9 
ENSG00000050628 PTGER3 2.3 2.0 2.9 
ENSG00000248905 FMN1 2.3 1.6 1.7 
ENSG00000168026 TTC21A 2.3 7.3 1.8 
ENSG00000276603 RP11-425M5.7 2.3 9.0 2.1 
ENSG00000166401 SERPINB8 2.4 5.4 2.4 
ENSG00000168542 COL3A1 2.4 2.0 3.1 
ENSG00000267682 CTD-3220F14.2 2.5 3.2 3.0 
ENSG00000183696 UPP1 2.5 2.1 1.6 
ENSG00000130762 ARHGEF16 2.5 1.9 0.5 
ENSG00000148180 GSN 2.7 1.9 2.1 
ENSG00000175592 FOSL1 2.8 4.0 4.3 
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ENSG00000161638 ITGA5 2.8 3.8 2.6 
ENSG00000146592 CREB5 2.8 2.3 1.4 
ENSG00000247157 LINC01252 2.8 3.6 4.4 
ENSG00000136052 SLC41A2 2.8 2.9 0.5 
ENSG00000224165 DNAJC27-AS1 2.9 21.3 3.0 
ENSG00000137331 IER3 3.1 3.0 1.6 
ENSG00000125246 CLYBL 3.1 2.4 2.6 
ENSG00000063438 AHRR 3.1 2.9 3.8 
ENSG00000023839 ABCC2 3.3 5.3 2.9 
ENSG00000140511 HAPLN3 3.3 5.2 0.3 
ENSG00000114670 NEK11 3.3 8.7 2.9 
ENSG00000108846 ABCC3 3.5 3.1 2.3 
ENSG00000266921 RP11-15A1.7 3.7 13.4 3.9 
ENSG00000163131 CTSS 3.9 6.0 4.4 
ENSG00000172752 COL6A5 4.0 2.7 2.8 
ENSG00000159450 TCHH 4.2 6.6 5.9 
ENSG00000106366 SERPINE1 4.4 4.5 7.8 
ENSG00000240065 PSMB9 4.4 8.0 0.1 
ENSG00000106070 GRB10 5.4 2.0 2.2 
ENSG00000204248 COL11A2 5.8 12.2 3.0 
ENSG00000134070 IRAK2 6.5 4.7 3.3 
ENSG00000196664 TLR7 7.0 4.0 4.6 
ENSG00000187164 KIAA1598 7.6 7.6 2.3 
ENSG00000122861 PLAU 8.7 6.5 2.7 
ENSG00000232810 TNF 20.5 11.2 24.5 
ENSG00000049249 TNFRSF9 36.0 10.1 9.9 
ENSG00000090339 ICAM1 50.0 14.5 17.4 
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Figure 42. Pathways of genes co-regulated only by TDP-43, DAZAP1 and hnRNP Q. Classification of 
214 genes whose expression is co-regulated in TDP-43, DAZAP1, hnRNP Q, but not hnRNP R depleted SH-
SY5Y cells according to the GO categorization system. 
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5. DISCUSSION 
5.1 TDP-43 activity is modulated by the interaction with other hnRNP 
proteins 
Since TDP-43 was discovered as a major component of ubiquitinated inclusions in ALS 
and FTLD patients (Neumann et al., 2006) the interest in better characterizing the 
pathological role of this protein has considerably increased. In particular, in past years a lot 
of effort was put into better defining TDP-43 protein-protein interactions and in the 
identification of all the possible transcripts regulated by TDP-43 that could be altered in 
pathology. In this context, it has been well-characterized that TDP-43 can interact with 
other members of the hnRNP family and that this binding can affect the functions of both 
factors (Buratti and Baralle, 2012). Examples of TDP-43 interacting proteins are several 
members of hnRNP A/Bs family (D'Ambrogio et al., 2009; Romano et al., 2014), hnRNP 
H,  and FUS/TLS (Freibaum et al., 2010).  
In this thesis, I have investigated the relationship between TDP-43 and three hnRNP 
proteins (DAZAP1, hnRNP Q and hnRNP R) not yet completely characterized, although 
all these proteins were previously found to be associated with neuronal functions (Bannai 
et al., 2004; Glinka et al., 2010; Pastor and Pagani, 2011). We had also demonstrated, 
together with the Neurobiology group, that they represented powerful modifiers of TDP-
43/TBPH in Drosophila melanogaster. 
At the functional level, we first demonstrated that DAZAP1, hnRNP Q and hnRNP R can 
with different ability modify the splicing pattern or gene expression of well-known TDP-
43 targets, such as POLDIP3, TNIK, STAG2, MADD and BRD8. These genes are involved 
in several aspects of cell proliferation (POLDIP3, STAG2), apoptosis (MADD, BRD8) and 
neuronal functions (TNIK). In particular, alteration in the POLDIP3 (also known as SKAR) 
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pre-mRNA splicing profiles were previously reported to be associated with depletion of 
TDP-43 in vitro and in motor cortex, spinal cord and spinal motor neurons of patients 
affected by ALS (Shiga et al., 2012). This previous work observed that knockdown of 
TDP-43 regulated the production of an alternative splicing isoform, namely variant-2, 
through the skipping of exon 3 and therefore influenced POLDIP3 function in mediating 
cell proliferation and growth (Shiga et al., 2012). In our experiments, we demonstrated that 
the inclusion of POLDIP3 exon 3 was also significantly altered in the presence of 
DAZAP1 and hnRNP Q knockdown (Figure 23A), indicating that splicing regulation is not 
exclusive for TDP-43 but it can also depend on the participation of other factors. This 
hypothesis was also corroborated by the fact that the co-silencing of TDP-43 with 
DAZAP1 was able to recover the POLDIP3 splicing profile (Figure 24A), indicating that 
the engagement of DAZAP1 is able to modulate the TDP-43 activity. 
Other interesting observations supporting the role of DAZAP1, hnRNP Q and hnRNP R in 
regulating TDP-43 activity were obtained by studying the pre-mRNA splicing analysis of 
TNIK and STAG2 genes, as well as investigating changes in mRNA expression levels of 
TNIK.  
TNIK is a serine/threonine kinase belonging to the Ste20 family that was originally cloned 
from a human cDNA library and successively identified in mouse brain (Fu et al., 1999). It 
was also described as an important factor for synaptic functions and cytoskeleton 
organization (Traikov et al., 2014; Fu et al., 1999), as well as, as a potential risk factor for 
several mental disorders (Matigian et al., 2007; Glatt et al., 2005). The association between 
TDP-43 and TNIK arose from a transcriptomic study in 2015 where the analysis of TDP-
43 and FUS depletion led to the identification of several genes related to neuronal 
pathways and RNA metabolism, whose expression or pre-mRNA splicing profile was 
modified after siRNA treatment (Colombrita et al., 2015). In our study, we observed that 
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DAZAP1, hnRNP Q and even hnRNP R were able to alter TNIK’s splicing profile (Figure 
23B) and, in the case of DAZAP1 and hnRNP Q, also to recover it after TDP-43 depletion 
(Figure 24B). Furthermore, we showed a decrease of TNIK mRNA levels after treatment of 
cells with an siRNA against hnRNP Q (Figure 26C). 
Along the same lines, we looked at the STAG2 splicing profile. STAG2 is a component of 
the cohesin complex involved in separation of sister chromatids during cell division 
(Berkowitz, 2014). In 2015, our laboratory showed that STAG2 was involved in the 
accumulation of cells in G2/M phase due to upregulation of its exon 30b+ isoform after 
siTDP-43 treatment (De Conti et al., 2015). In this thesis I show that STAG2 exon 30b+ 
inclusion was also affected by DAZAP1 silencing (Figure 23C), and the depletion of both 
proteins was able to rescue the STAG2 profile (Figure 24C). 
To complete the list of known TDP-43 targets, we further tested our hnRNPs for mediating 
changes in MADD and BRD8 gene expression regulation. The MADD gene is expressed in 
low levels in all tissues and can act as a pro-apoptotic factor when its phosphorylation is 
reduced by the Tumour Suppressor Phosphatase and Tensin Homolog (PTEN) (Jayarama 
et al., 2014). Interestingly, the MADD gene was also found to be important for neuronal 
survival since alteration in its splicing isoforms were found in in neuronal cell lines 
exposed to high concentrations of oligomeric Aβ peptides (Mo et al., 2012). Tollervey et 
al. and subsequently De Conti et al. demonstrated that siTDP-43 treatment could affect 
both the splicing process of this gene, in particular by inducing exon 31 exclusion plus 
activation of a pseudoexon, but also its mRNA levels (De Conti et al., 2015; Tollervey et 
al., 2011). Here, we demonstrated that although none of the tested hnRNPs was able to 
modify the MADD splicing profile (Figure 26A), there was significant rescue of its mRNA 
expression after the contemporary silencing of TDP-43 with DAZAP1 using siRNA 
(Figure 26D). 
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Regarding BRD8, little information is available in the literature related to its cellular 
function. However, this protein is know to be a member of bromodomain (BRD)-
containing proteins required for genome maintenance, since its depletion was demonstrated 
to trigger p53-mediated apoptosis (Lashgari et al., 2018). Interestingly, although BRD8 
was identified as a TDP-43 target gene in HEK293 cells (De Conti et al., 2015), in the 
neuroblastoma cell line the silencing of TDP-43 was not able to induce an effect on BRD8 
expression levels, suggesting a cell-specific effect for this regulation (Figure 26B). 
Nevertheless, we could observe a slight and not significant overexpression in siDAZAP1 
treated cells (Figure 26B).  
Taken together these results suggested a strong correlation between TDP-43 function and 
hnRNPs, especially with regards to DAZAP1 and to hnRNP Q but not for hnRNP R. These 
data therefore represented the starting point of my further investigations. 
First of all, to complete the analysis of the effects of DAZAP1, hnRNP Q and hnRNP R on 
TDP-43, we assessed whether these could cause changes in TDP-43 protein levels after 
treatment with siRNAs against each individual hnRNP and vice-versa (Figure 22B-E). This 
was the first item that had to be tested because it has been shown that appropriate 
expression of TDP-43 is critical for carrying out its cellular functions. In fact, 
overexpression of TDP-43 was found to be toxic to neurons (Swarup et al., 2011; Li, Ray, 
Rao, Shi, Guo, Chen and Woodruff, 2010), and also its complete depletion to be lethal for 
mouse development (Sephton et al., 2010) and Drosophila survival (Feiguin et al., 2009). 
Similarly, the alteration of DAZAP1, hnRNP Q and hnRNP R expression could be linked 
to tumorigenesis (Lai et al., 2017; Prima and Hunger, 2007).  In my experiments, however, 
I saw that DAZAP1, hnRNP Q and hnRNP R were not able to change TDP-43 protein 
levels and the expression of each hnRNPs was not influenced after siRNA depletion of 
TDP-43.  
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We also looked at the TDP-43 subcellular localization in SH-SY5Y cells following 
sihnRNP treatment (Figure 27), since one of the most important features of TDP-43 is the 
ability to shuttle between nucleus and cytoplasm (Ayala et al., 2008). In fact, although 
most of the protein is physiologically present in nucleus, approximately 30% of TDP-43 is 
normally found to be localized in cytosol where it participates in regulating mRNA 
stability, export and localization of newly transcripts (Lagier-Tourenne et al., 2010). 
However, modification of TDP-43 homeostasis can lead to re-distribution within cells, as 
described in neurodegeneration processes in which TDP-43 undergoes cytoplasmic 
accumulation and consequent aggregation (Neumann et al., 2006). In our experiments, 
however, TDP-43 localization was not disrupted by depletion of DAZAP1, hnRNP Q and 
hnRNP R.  
Therefore, the results achieved so far indicated that the variations in splicing profile and 
gene expression levels of TDP-43 targets were not dependent on aberrant modifications of 
basic TDP-43 features, such as protein expression and subcellular localization. In support 
of these results, I also examined hnRNP effects using a more realistic scenario of TDP-43 
pathology and we analysed the capability of endogenous TDP-43 to aggregate in the 
presence of FLAG-TDP43-12XQ/N aggregates (Figure 28). In this LOF model, the 
endogenous TDP-43 can fully interact with these aggregates and undergo sequestration 
into nuclear and cytoplasmic insoluble aggregates (Budini et al., 2014). Basically, we 
concluded that in cells treated with siRNA against hnRNPs the aggregation propency of 
TDP-43 was not affected. Furthermore, we were able to confirm our previous results about 
the rescue of MADD and STAG2 splicing profile, following siDAZAP1 and sihnRNP Q 
treatment. 
Since DAZAP1 was the most consistent modifier of TDP-43 activity and no previous 
literature has undercovered a possible connection between these two proteins, our interest 
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then moved into the characterization of the relationship between TDP-43 and DAZAP1. 
After ascertaining that DAZAP1 was not directly binding to TDP-43 I saw that it could 
bind all its mRNA targets (Figure 29). Therefore, we decided to identify all the possible 
targets commonly regulated by knockdown of both proteins through RNA-seq analysis. 
We found that the depletion of TDP-43 and DAZAP1 prevalently determined an 
upregulation of genes with respect to the number of downregulated genes (Figure 30A) and 
the amount of DEGs grouped in the same categories of GO analysis (Figure 33A) were 
similar in both conditions, indicating therefore the possibility that both proteins could 
influence the same cellular pathways with an analogous mechanism. 
Moreover, these pathways mostly affected genes related to neuronal and inflammation 
pathways (Figure 30D and Figure 33B), confirming the importance of hnRNPs in the 
regulation of RNA metabolism in SH-SY5Y cells. In fact, taking a closer look at the 
regulated genes chosen for qPCR validation and belonging to the top 100 DEGs, we found 
nine interesting genes associated to brain functions and inflammatory response: ACHE, 
STX3, ELAVL3, NOVA2, CELF5, TNF, TNFRSF9, YPEL4 and ICAM1 (Figure 30B-C). 
Notably, these genes were found to be upregulated (ACHE, STX3, CELF5, TNF, 
TNFRSF9, ICAM1, YPEL4) and downregulated (ELAVL3, NOVA2) in the same direction 
in both siTDP-43 and siDAZAP1 treated cells, supporting again the idea of a common 
mechanism of action of these two hnRNPs (Figure 30B).  
In this respect, it is therefore worthwhile to better describe the role of these factors in the 
nervous system: 
ELAVL3 (also known as HuC) is a member of the Elav-like family and one of the 
mammalian homologous of Drosophila Elav (Ogawa et al., 2018). The ELAV-like family 
is composed of four members: three specifically expressed in neurons known as neuronal 
ELAVL (nELAVL: ELAVL2, ELAVL3 and ELAVL4) and one ubiquitously expressed 
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(ELAVL1). nELAVL proteins are RNA-binding proteins involved in RNA metabolism, 
promoting neuronal differentiation. They are also implicated in neurodegenerative 
diseases, including Alzheimer’s and Parkinson’s disease (Ogawa et al., 2018). ELAVL3 
has been demonstrated to regulate proteins implicated in amino acid biosynthesis, and it 
plays a role in mRNA stability and in alternative splicing of genes important for synaptic 
cytoskeletal dynamics (Ince-Dunn et al., 2012). In particular, ELAVL3 affects the 
alternative splicing of neuronal pre-mRNAs acting with the same dependence on binding 
position observed for other RBPs such as TDP-43 (Tollervey et al., 2011), PTB (Llorian et 
al., 2010) and NOVA (Ule et al., 2006).  Moreover, ELAVL3 was found to control 
glutamate levels, a major neurotransmitter in brain (Ince-Dunn et al., 2012).  
NOVA2 is a member of the neuronal RBP collectively known as the NOVA family. The 
major components of this family are NOVA1 and NOVA2. Compared to NOVA1, which 
is prevalently expressed in hindbrain and ventral spinal cord, NOVA2 was found in 
neocortex. The NOVA family was also described to be involved in Paraneoplastic 
Neurodegeneration (PND). Regarding NOVA2, it has been found to modulate ~ 7% of 
brain-specific splicing events in neocortex (Ule et al., 2005) and successively it has been 
demonstrated that it is important in the alternative splicing of genes involved in axon 
guidance (Leggere et al., 2016; Saito et al., 2016).  
Acetylcholinesterase (AChE) is a hydrolase encoded by ACHE gene that is required for the 
regulation of cholinergic signalling (Soreq and Seidman, 2001). In the brain, two isoforms 
are expressed: a soluble and predominant variant called AChE-S (synaptic AChE) and an 
inducible variant called AChE-R (read-through) (Soreq and Seidman, 2001). While AChE-
S can exist in both soluble and membrane-bound forms, AChE-R was found only in a 
soluble form (Perrier et al., 2002). However, the expression of both those variants occurs in 
cholinergic neurons (Johnston et al., 1979), astrocytes (Sáez-Valero et al., 2003) and 
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cholinoceptive neurons (Aubert et al., 1994). Several studies have reported an aberrant 
production of AChE during the pathogenesis of AD (Navaratnam et al., 1991; Fishman et 
al., 1986; Whitehouse et al., 1982). In particular, it has been demonstrated that AChE could 
promote the formation of amyloid-β (Aβ) fibrils binding Aβ protein (Alvarez et al., 1997) 
and determining neurotoxicity (Muñoz and Inestrosa, 1999). Indeed, increased levels of 
AChE were reported to speed up Aβ plaque formation in brains of transgenic mice 
suffering from neurodegeneration (Rees et al., 2003). Moreover, N-glycosylated AChE 
was found to be overexpressed in the cerebrospinal fluid of patients with AD (Sáez-Valero 
et al., 1997). Recently, it has been demonstrated that increased levels of N-glycosylated 
AChE can disrupt the interaction between O-glycosylated β-neurexins and neuroligin-1 
determining loss of glutamatergic synapses and accumulation of post-synaptic proteins 
(Xiang et al., 2014). 
Sintaxin 3 (STX3) is a member of SNARE (Soluble N-ethylmaleimide Sensitive Factor 
Attachment Protein Receptor) machinery that in turn is important for the vesicle trafficking 
in polarized epithelial cells (Jahn and Scheller, 2006). In particular, STX3 is located to 
apical plasma membranes (Soo Hoo et al., 2016) where it is involved in fusion post-Golgi 
vesicles with the membrane (Sharma et al., 2006). In 2006, Darios and colleagues 
demonstrated that the omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) could 
change the STX3 structure triggering its binding to the syntaxin partner SNAP25 
(Synaptosomal-associated Protein of 25 kDa) and therefore strongly stimulating the neurite 
outgrowth (Darios and Davletov, 2006). In a previous work, our group established an 
indirect connection between TDP-43 depletion and STX3. In particular, the 
downregulation of miRNA Let-b induced by loss of TDP-43 could alter the expression of 
let-7b targets, including STX3 (Buratti et al., 2010). 
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CELF5 belongs to the Bruno-like (Brunol) proteins and it is one of the mammalian 
homologues of Drosophila Bruno (Good et al., 2000). Successively, the Bruno-like family 
were collectively referred as CUGBP, Elav-like family (CELF) because of the first two 
members identified in humans: CUG binding protein (CUG-BP, now called CELF1) and 
Elav-type RNA Binding Protein 3 (ETR-3, now called CELF2) (Ladd et al., 2001). 
Overall, this family is composed of six proteins, namely CELF1, CELF2, CELF3, CELF4, 
CELF5 and CELF6 that are widely expressed in brain even if CELF1 and CELF2 are 
found in many tissues (Gallo and Spickett, 2010). To date there is little information 
regarding the function of CELF proteins. However, they seem to regulate the alternative 
splicing of transcripts expressed in brain and CELF2, CELF3 and CELF5 could also play a 
role in neuronal development (Ladd, 2013). Regarding CELF5, it was found expressed all 
over in the brain, albeit low-expression was detected in medulla oblongata and spinal cord 
(Ladd, 2013). CELF5 was also linked to Myotonic Dystrophy of Type 1 (DM1), since it 
was observed to modulate the alternative splicing of Tau exon 6 (Leroy et al., 2006).  
YPEL4 belongs to the Yippe-like (YPEL) family and contains a Yippe-like domain that is 
putatively identified as a zing-finger-like, metal-binding domain (Roxström-Lindquist and 
Faye, 2001). This protein family takes its name from the Drosophila counterpart namely 
Yippe, which shares the 76% of similarity with the human cDNA clone (Roxström-
Lindquist and Faye, 2001). In human there are five YPEL proteins: YPEL1, YPEL2, 
YPEL3, YPEL4 and YPEL5 whose functions still remain to be elucidated (Hosono et al., 
2004). However, it is known that YPEL4 is expressed in all human tissues and its functions 
seem to be connected with ETS Domain-containing Protein Elk-1 (Elk-1) /MAPK 
signalling pathways (Liang et al., 2010) and cell division (Hosono et al., 2004). Moreover, 
it was identified as a putative gene involved in Schizophrenia (Schizophrenia Working 
Group of the Psychiatric Genomics Consortium, 2014). 
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Finally, we also included in our qPCR validation TNF, ICAM1 and TNFRSF9 genes. 
TNF-a is encoded by the TNF gene and it is a pro-inflammatory cytokine implicated in the 
regulation of the inflammatory response in body and brain (Neniskyte et al., 2014). In 
healthy brains, it is expressed at low levels but during injuries or in the presence of 
ischemia and neurodegenerative disorders the levels of TNF-a increased promoting 
neuronal inflammation (Neniskyte et al., 2014; Santello and Volterra, 2012).  
TNF-a is also important for release of the neurotransmitter norepinephrine (NE) in the 
central nervous system (Ignatowski et al., 1997), as well as it contributes to the synapse 
plasticity (Stellwagen and Malenka, 2006).  
TNFRSF9 (also known as CD137) is a member of the Tumor Necrosis Factor Receptor 
(TNFR) Superfamily and is found in wide range of tissues, including brain (Reali et al., 
2003). In particular, in central nervous system (CNS) is expressed on plasma membrane 
and cytoplasm of neurons and astrocytes and its upregulation was described to be mediated 
by Fibroblastic Growth Factor 2 (FGF2) (Reali et al., 2003) and associated with melanoma 
brain metastasis (Mittelbronn et al., 2014). The reserve signalling between CD137 and its 
ligand CD137L was reported to inhibit cell survival in mouse neural stem cells (Yun et al., 
2013).  
ICAM-1 is an adhesion molecules encoded by ICAM1 gene and produced by endothelial 
cells. It is important for mediating the transfer of neutrophil into the brain during brain 
injuries (Hess et al., 1994). Interestingly, it was described to be upregulated in age-
dependent neurodegeneration (Miguel-Hidalgo et al., 2007) and localized in amyloid 
plaques of Alzheimer’s patients (Verbeek et al., 1994). 
TNF, ICAM1 and TNFRSF9 genes are very interesting because they are involved 
inflammation pathways. Indeed, the activation of the immune system is commonly 
accepted as one of the central mechanisms underlying neurodegeneration, and capable to 
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modulate it in a beneficial or detrimental manner. Different events can trigger 
neurodegenerative pathways, including the deposition of misfolded proteins in CNS, the 
release of toxic components associated with neurons or synapses destruction and the 
dysregulation of immune system (Glass et al., 2010; Block and Hong, 2005; Wyss-Coray 
and Mucke, 2002). For example, in ALS pathology, infiltration of leucocytes (mostly T 
cells) and deposition of IgG were found in motor neurons subjected to injuries (Holmøy, 
2008). T cells inflitration could results in neuronal damage or neuronal protective action. 
Indeed it has been found that they could lead to cells death through release of cytokine and 
TNF-α (Neumann et al., 2002), or promote neurogenesis by secretion of Brain Derived 
Neurotrophic Factor (BDNF) supporting motor neuron survival in mice (Serpe et al., 
2005). Moreover, increasing levels of several cytokines were also observed in the 
cerebrospinal fluid of ALS patients with advanced disease, including Transforming 
Growth Factor Beta (TGF-β) (McGeer and McGeer, 2002).  
Overall, my results have demonstrated the potential impact of not well-characterized 
hnRNPs, in particular DAZAP1 in brain functions and I have linked this activity to genes 
affected by TDP-43 misregulation. Moreover, my experiments have strengthened the 
importance of inflammation during neurodegeneration, since many of the DEGs identified 
following siTDP-43 and siDAZAP1 are related to inflamatory response. 
 
5.2 hnRNP Q and hnRNP R have evolved to perform different functions 
within cells 
The second part of my PhD thesis was focused on the establishment of a functional 
diversity between to closely related hnRNPs, namely hnRNP Q and hnRNP R in 
mammalian cells. As described in the paragraph above, these two proteins were able to 
modulate in a different manner the splicing profile and mRNA expression of TDP-43 
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controlled genes. The peculiarity of hnRNP Q and hnRNP R is the extreme similarity in 
their protein sequences, reflecting the fact that in lower organisms, such as Drosophila, 
they are present as one single protein (McDermott et al., 2012). Here, we demonstrated that 
in SH-SY5Y cells, hnRNP Q and hnRNP R are expressed in different splicing isoforms 
and also that they show different cell distribution (Figure 35-36). Regarding this issue, I 
found that the majority of hnRNP Q protein is located in the cytoplasm (Figure 35) and this 
was confirmed by the expression of the Q1 counterpart in the cytosol fractions (Figure 
36A). On the other hand, I identified hnRNP R as mainly expressed in the nucleus (Figure 
35), as also confirmed in the nuclear cytoplasm analysis of SH-SY5Y cells (Figure 36B). 
Moreover, the cellular localization of both proteins was not altered by the downregulation 
of each other or after cell differentiation into more neuronal-like cells (Figure 37-38). 
These findings indicate that in mammals hnRNP Q and hnRNP R have differentiated in 
two distinctive proteins in order to carry out specific functions within cells. In fact, 
following an RNA-seq analysis of the whole transcriptome status of cells after siRNA 
depletion of hnRNP Q and hnRNP R, we were able to observe several common but also 
many unique features associated with the depletion of both these proteins (Figure 43). 
Regarding hnRNP Q depleted cells, the most enriched in GO terms were related to 
membrane architecture, while for hnRNP R depleted cells, the most significant GO terms 
were connected to tissue and system development, as well as cellular signalling. Taken 
together these data indicate the functionally diversification of this two proteins during 
evolution. Interestingly, although the amount of DEGs derived from hnRNP Q silencing 
was similar between up- and downregulated genes (Figure 39A), in cells silenced with 
siRNA against hnRNP R we observed a prevalently overexpression of target genes (Figure 
40A). 
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Nonetheless, in both the conditions we identified several genes related to neural and 
inflammatory pathways (Figure 39-40). In particular, our study on hnRNP Q depletion in 
SH-SY5Y cells suggests a potential role of this factor in the regulation of three immune-
related categories of KEGG pathway analysis namely "Rheumatoid arthritis", 
"Toxoplasmosis" and "Toll-like receptor signalling pathway" that were enriched after its 
depletion (Figure 44A). Taking a closer look at these three pathways we found that the 
infection of the parasite Toxoplasma gondii can affect different neuronal cells, including 
astrocytes and neurons, and trigger a chronic inflammation due to the contemporary action 
of host immunity and the evasion of the immune response by the parasite (Carruthers and 
Suzuki, 2007). Interestingly, an epidemiological study indicated that pharmacological 
therapy with TNF blocking agents used for the treatment of rheumatoid arthritis could be 
protective against AD (Chou et al., 2016). Finally, the activation of Toll-like receptor 
(TLR) signalling has been suggested to contribute to neuronal injury in several 
neurodegenerative disorders, including ALS (Casula et al., 2011), AD (Reed-Geaghan et 
al., 2009) and multiple sclerosis (Marta et al., 2008; Prinz et al., 2006). 
The same KEGG pathway analysis was repeated for hnRNP R DEGs and the results 
obtained showed not only its engagement in the regulation of inflammatory response but 
also the participation in brain functions (Figure 44B). Indeed, three main pathways have 
been identified by this analysis: "Cell adhesion molecules (CAMs)", "Neuroactive ligand-
receptor interaction" and ECM-receptor interaction". Intriguingly, in mature neurons, 
neural CAMs participates to the control of synaptic formation, structure, plasticity, and 
release of neurotransmitters (Leshchyns’Ka and Sytnyk, 2016). Furthermore, the 
expression and function of these molecules was found to be changed in neurodegenerative 
disorders, such as AD (Leshchyns’Ka and Sytnyk, 2016). Other factors involved in the 
organization of brain architecture are the extracellular matrix (ECM) molecules (Barros et 
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al., 2011). In fact, ECM molecules are important for preserving the neural stem cell 
behavior, for providing a scaffold for neuronal migration and for supporting axonal growth 
and myelination (Barros et al., 2011). Aberrant protein levels of ECM molecules were also 
described in Parkinson’s disease and ALS (He et al., 2013; Lim et al., 1996). 
For both hnRNP Q (Figure 39B-C) and hnRNP R (Figure 40B-C), the qPCR validation of 
DEGs was carried out through the selection of genes that are ranked in the top 100 of most 
enriched genes and that correlated with the immune response and brain functions.  
Taking a closer look at genes regulated by hnRNP Q depletion, we analysed overexpressed 
genes, such as PENK, NRG3, KLF4, KLHL4, TNF, ICAM1 and TNFRSF9, as well as 
downregulated genes, such as RAB26 and ARHGAP36. In particular, proenkephalin A 
(encoded by PENK gene) is the opioid peptide precursor of enkephalin peptides. The 
proteolytic cleavage of this precursor is able to generate neuropeptides, including peptide 
F, peptide E, Met-enkephalin, Leu-enkephanlin, BAM20 and BAM22, that seem to be 
involved in nociception (Lembo et al., 2002; Höllt et al., 1982). Proenkephalin A is 
expressed in the nervous system and in other tissues such as heart, kidney, intestine and 
skeletal muscle (Denning et al., 2008) and it can be also released from different immune 
cells (Plotnikoff et al., 1997). Moreover, it has been found that the expression of 
proenkephalin A could be altered in patients suffering from dementia or acute 
neuroinflammatory disorders (Ernst et al., 2010).  
Neuregulin 3 (encoded by NRG3 gene) is the neural-enriched member of the Epidermal 
Growth Factor (EGF) family proteins and it is structurally related to neuregulin 1 (Zhang et 
al., 1997). In humans, the interaction between neuregulin 3 and the tyrosine kinase Erb4 
was associated with synaptogenesis (Müller et al., 2018) and oligodendrocyte survival 
(Carteron, 2006). In rat, this interaction was also described to promote the development of 
adult forebrain through the migration and differentiation of precursor progenitors (Anton et 
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al., 2004). Interestingly, several polymorphisms in the NRG3 genes were described to be a 
risk factor for neuropsychiatric disorders (Chen et al., 2009). 
Klf4 (encoded by KLF4 gene) is a transcription factor containing a zing-finger motif that is 
involved in several cellular functions, including proliferation and differentiation. In 
particular, together with Oct4, c-Myc and Sox2 is one of the induced pluripotent stem (iPS) 
genes able to induce cell pluripotency (Takahashi and Yamanaka, 2006), as well as being 
important for maintaining self-renewal of embryonic stem cells (ESCs) (Hall et al., 2009). 
Moreover, Klf4 was reported to be a transcription repressor of axon growth of central 
nervous system neurons (Moore et al., 2009) and the regulation of its production was 
demonstrated to be critical for the proper formation of mouse cerebral cortex (Qin and 
Zhang, 2012).  
Rab26 (encoded by RAB26 gene) is a small GTPase belonging to the Rab family. This 
large Rab family is implicated in the control of vesicle trafficking from their formation to 
membrane fusion. Although the function of Rab26 is still not fully elucidated, it was 
reported to localize with presynaptic membrane vesicles in fly neuromuscular junctions 
and recruit two components of pre-autophagosomal machinary, namely Atg16L1 and 
Rab33B (Binotti et al., 2015). This observation is particularly intriguing because it 
suggests a role of hnRNP Q in the recycling of synapse vesicles via autophagy system, thus 
providing a further link with TDP-43, since the fly orthologous of TDP-43 was 
demonstrated to be important for the formation of NMJs. Indeed, the generation of TBPH-
null allele flies (Feiguin et al., 2009; Godena et al., 2011; Langellotti et al., 2016; Romano 
et al., 2018) and hTDP43A315T transgenic mouse (Magrané et al., 2013) dramatically 
induced morphological modifications at synaptic terminals and a strong reduction of 
synaptic vesicles in the NMJs, respectively.  
Furthermore, neuronal expression was also described for both KLHL4 and ARHGAP36 
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even if possible neuronal implications, including relationship with neurological disorders, 
are still unknown (Rack et al., 2014; Braybrook et al., 2001).  
On the other hand, looking at DEGs obtained from silencing of hnRNP R we validated six 
overexpressed genes, including CARTPT, FOSB, JAG1, DUOXA1, HMOX1 and ICAM5 
and four downregulated genes, such as KCNAB1, SDCBP2, EFEMP1 and APC5. Notably, 
the CARTPT gene is responsible for the production of CART mRNA whose expression was 
found to be increased in the rat brain after stimulation with psychomotor agents (Douglass 
et al., 1995). The resulting CART neuropeptides was successively described to localize 
with gamma-aminobutyric acid (GABA) (Smith et al., 1999) and substance P (Hubert and 
Kuhar, 2005), indicating that these species could act as a neurotransmitter.  
The FOSB gene encodes both FosB and its alternative splicing variant DFosB. Both 
proteins belong to the Fos family of transcription factors and their production can be 
promoted especially in the nucleus accumbens and dorsal striatum following 
administration of many drugs (Nestler et al., 2001). Expression of Fos proteins was also 
detected in dentate gyrus of hippocampus and cerebral cortex (Ohnishi et al., 2011). The 
activated form of Fos proteins is achieved by the heterodymerization with Jun proteins 
resulting in the generation of the Active Activator Protein-1 (AP-1) complex that 
recognizes AP-1 sites in various promoters (Chinenov and Kerppola, 2001). Fosb 
expression was also discovered to be linked to neurological disorders, since Fosb-null mice 
highlighted the adult-onset of spontaneous epilepsy (Yutsudo et al., 2013) and exhibited 
depression-like behaviors (Ohnishi et al., 2011), as well as to neuroinflammation through 
the regulation of the receptors of the anaphylatoxin C5a: C5AR1 and/or C5AR2 (Nomaru 
et al., 2014).  
The DUOXA1 gene encodes the maturation factor of DUOX1 (Dual Oxidase 1) that is a 
member of the NADPH oxidase family (Bedard and Krause, 2007). It has been reported 
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that NADPH oxidase provides the major source of reactive oxygen species (ROS) essential 
for inducing neuronal differentiation, neuronal signalling and neurite formation 
(Munnamalai and Suter, 2009; Tejada-Simon et al., 2005; Knapp and Klann, 2002). In 
mouse embryonal carcinoma p19 cells, it has been also demonstrated that their neuronal-
like differentiation resulted from the interaction between p53 and DUOXA1 
(Ostrakhovitch and Semenikhin, 2011). Moreover, an excessive production of ROS by 
NADH oxidase can trigger neuroinflammation during CNS pathology, as described for 
Alzheimer’s and Parkinson’s disease (Kim et al., 2015). 
Jagged1 (encoded by the JAG1 gene) is one of five ligands that participate to the Notch 
signalling pathway (Grochowski et al., 2016). In mammals, it is widely expressed during 
development and it is also present in postnatal brain (Irvin et al., 2004; Stump et al., 2002; 
Jones et al., 2000). In mouse, Jagged1/Notch signalling was found to control 
oligodendrocyte differentiation and myelination (Wang et al., 1998). Moreover, Jagged1 is 
essential for the maintenance of neuronal stem cell niche in adult brain (Nyfeler et al., 
2005), as well as being important for synaptic signalling (Alberi et al., 2011). 
Jagged1/Notch signalling is also involved in spatial memory. Indeed, in hippocampus of 
patients suffering from Alzheimer’s disease their expression was found to be altered 
(Marathe et al., 2017).  
Heme oxigenase 1, also known as HO-1 (encoded by the HMOX1 gene) is the first of three 
members belonging to the HO family. The production of HO-1 is regulated by stress 
stimuli, such as UVA irradiation, sodium arsenite and hydrogen peroxide (Keyse and 
Tyrrell, 1989). Neuronal protection against glutamate-induced oxidative cell death was 
observed after overexpression of HO-1 (Chen et al., 2001). Notably, upregulation of the 
HMOX1 gene was also found in neurons and astrocytes derived from hippocampus, 
cerebral cortex, and subcortical white matter of Alzheimer’s patients, supporting the role of 
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chronic oxidative stress in the establishment of neuropathological disorders (Schipper et 
al., 1995). 
KCNAB1 (also known as Kbv1 gene) encodes the subunit b of the shaker-related voltage-
gated potassium channel Kv1 (Leicher et al., 1996). Three different splicing isoforms are 
present for this gene: Kbv1.1, Kbv1.2 and Kbv1.3 (Rettig et al., 1994). Kbv1.2 and Kbv1.3 
are preferentially transcribed in heart, while Kbv1.1 is expressed in brain, especially in 
hippocampus and striatum (Rettig et al., 1994). This particular potassium channel is able to 
inactivate the subunit a, that is the second subunit that constitutes the Kv1 channel. 
Potassium channels are extremely important for transducing signals in nervous system 
(Kuang, 2015) and Kbv1.1 knockout mice showed normal synaptic plasticity but 
impairment of learning skills (Giese et al., 1998).  Furthermore, a specific mutation in 
KCNAB1 gene was also found to be the causative agent of epilepsy and developmental 
disabilities in a Chinese children (Zhang et al., 2015). 
Syntenin-2 (encoded by SDCBP2) is a novel PDZ (Postsynaptic density protein, Discs-
large, Zona occludens) protein able to bind phosphatidylinositol 4,5-bisphosphate (PIP2) 
(Geeraerts et al., 2013). This protein is encoded by two alternative splicing isoforms, 
namely 2a and 2b, and it shares ∼70% with the most famous syntenin-1 (Koroll et al., 
2001), that is a scaffold protein involved in the regulation of the neural membrane 
architecture (Hirbec et al., 2005). The available literature has not fully elucidated the 
cellular function of syntenin-2 in depth. However, syntenin-2 isoform 2a was found to 
interact with the neural cell-adhesion molecules, namely neurexin-1, suggesting a potential 
role in brain dynamics (Koroll et al., 2001). 
Fibulin-3 (encoded by EFEMP1) is a calcium-binding ECM protein belonging to the 
Fibulin protein family (Timpl et al., 2003) consisting of Fibulin-1, Fibulin-2, Fibulin-3, 
Fibulin-4 and Fibulin-5. These proteins contain three domains, where the central domain 
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III contains nine epidermal growth factor (EGF)-like motifs able to bind calcium (Timpl et 
al., 2003). For most fibulin proteins, the interaction with calcium is essential for binding 
other ECM proteins and cellular receptors, allowing them to carry out their cellular 
function in joining supramolecular structures such as basement-membrane networks, 
elastic fibres, several types of microfibrils and proteoglycan aggregates (Timpl et al., 
2003). The function of fibulin-3 is still unknown. However, fibulin-3 expression was 
strongly detected only in the primary visual cortex (V1C) region of prenatal brain (Ayana 
et al., 2018) while it was found weakly expressed in adult normal brain but upregulated in 
gliomas where it promotes cell tumor growth and invasion through the regulation of Notch 
signalling (Hu et al., 2009, 2012). Moreover, a single mutation in EFEMP1 was described 
to be associated with age-related macular degeneration (Stone et al., 1999). 
Finally, we noticed that the silencing of hnRNP Q could lead to the overexpression of three 
genes related to inflammatory pathways that we previously illustrated to be upregulated in 
response to siRNA depletion of both TDP-43 and DAZAP1:  ICAM1, TNF and TNFRSF9. 
This finding corroborated our previous results, regarding the ability of DAZAP1 and 
hnRNP Q to modulate TDP-43 activity in SH-SY5Y cells.  
By contrast, the silencing of hnRNP R led to the overexpression of other two immune-
related proteins (ICAM5 and ACP5) without inducing a significant alteration of the same 
inflammatory genes controlled by TDP-43, DAZAP1 and hnRNP Q. 
Overall, this second part of the work allowed a better characterization of the functional 
diversification of hnRNP Q and hnRNP R, highlighting their importance in controlling 
genes associated with immune system and neuronal development, differentiation and cell 
signalling. Most importantly, I was able to relate the majority of them to their aberrant 
regulation during neurodegenerative diseases. 
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5.3 TDP-43, DAZAP1 and hnRNP Q potentially regulate same 
transcripts important for ALS pathogenesis 
Over the last decades, perturbations of RBP homeostasis have increasingly acquired 
significance in the pathogenesis of ALS. Especially TDP-43 was the first hnRNP proteins 
associated with ALS, since in 2006 it was discovered as a component of ubiquitinated 
cytoplasmic inclusions in brain of patients (Neumann et al., 2006). Subsequent studies 
have also identified ALS-causative mutations in the TDP-43 encoding gene, and in other 
members of hnRNP family, including FUS, hnRNP A1, hnRNP A2/B1, TIA-1 and matrin-
3 (Purice and Taylor, 2018). 
Therefore, the identification of all possible targets regulated by TDP-43 and other hnRNP 
proteins acting on the same biological pathway could lead to the understanding of the 
molecular mechanisms behind the onset and progression of neurodegeneration. Thanks to 
sequencing technologies it has been possible to characterize gene expression changes or 
splicing variations associated with RBP misregulation (Buratti et al., 2013).  
In this study DAZAP1 and hnRNP Q were found to be the most promising tested hnRNPs 
able to modulate TDP-43 activity. Interestingly, the combination of RNA-seq results 
obtained after depletion of TDP-43, DAZAP1 and hnRNP Q have highlighted the presence 
of brain /ALS-related genes commonly affected by these proteins (Figure 45), contributing 
to expand the list of genes that can potentially affect neurodegeneration. 
Table 23 presents some promising genes and summarizes the knowledge already available 
in literature regarding their relationship with brain function and/or ALS pathology. 
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Table 23. Genes commonly regulated by depletion of TDP-43, DAZAP1 and hnRNP Q in SH-SY5Y cells 
which showed an involvement in brain disorders and/or ALS pathology. 
Gene Symbol/(Description) Brain disorders /ALS pathology References 
IGF2 (Insuline-like Growth Factor 
2) 
 
IGF-2 could protect against ALS degeneration 
of human motor neurons derived from iPSCs 
through phosphorylation of Akt and glycogen 
synthase kinase-3b and upregulation of b-
catenin. 
 
(Allodi et al., 2016) 
SYT14 (Synaptotagmin 14) 
 
SYT14 mutations are causative of autosome-
recessive spinocerebellar ataxia-11 (SCAR 
11). 
 
t(1;3)(q32.1;q25.1) leads to disruption of 
SYT14 and it is associated with 
developmental abnormalities. 
 
(Doi et al., 2011) 
 
 
 
(Quintero-Rivera et 
al., 2007) 
ABAT (4-Aminobutyrate 
Aminotransferase) 
 
Strong expression in neuronal tissue; 
responsible for catabolism of GABA 
(neurotransmitter) into succinic semialdehyde. 
ABAT plays an essential role in the 
conversion of dNDPs to dNTPs in the 
mitochondrial nucleoside salvage pathway and 
causes a neurometabolic disorder that includes 
encephalomyopathic MDS. 
 
Identification of ABAT as putative gene in 
autism following genotype-based association 
analysis. 
 
ABAT was found to be associated with 
neurofibrillar tangles (NFTs) following 
genome-wide analysis of 5-
hydroxymethylcytosine regions in AD brain. 
 
 
 
 
 
(Besse et al., 2015) 
 
 
 
 
 
 
 
 
(Barnby et al., 
2005) 
 
 
(Zhao et al., 2017) 
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ABCC9 (ATP Binding Cassette 
Subfamily C Member 9) 
 
ABCC9/SUR2 gene encoded an ATP- 
sensitive potassium channel that is strongly 
implicated in human aged-related neurological 
disorders, including hippocampal sclerosis of 
aging (HS-Aging). 
 
 
 
(Nelson et al., 
2015) 
ADCY1 (Adenylate Cyclase 1) 
 
ADCY1 gene encoded an adenylyl cyclase 
specifically expressed in brain; it was found to 
be upregulated in frontal cortex of ALS 
patients. Notably, in our results it was found 
downregulated in all tested hnRNPs. 
 
 
(Andrés-Benito et 
al., 2017) 
ADD3 (Adducin 3) 
 
ADD3 gene encoded γ-adducin subunit of 
membrane-skeletal protein, namely Adducin. 
Mutation of ADD3 was found to inhibit the 
binding of γ-subunit to α-subunit and 
determinate cerebral palsy.  
 
ADD2-knockout mice showed synaptic 
plasticity, motor coordination and behavioral 
deficits accompanied by changes in the 
expression and phosphorylation levels of the 
α- (ADD1) and γ-adducin (ADD3) subunits. 
 
Adducin is highly phosphorylated in spinal 
cord tissue derived from ALS patients 
comparing to individuals without neurological 
disease. 
 
Upregulated upon TDP-43 depletion in adult 
mouse brain. 
 
(Kruer et al., 2013) 
 
 
 
 
 
(Porro et al., 2010) 
 
 
 
 
 
(Hu et al., 2003) 
 
 
 
 
(Polymenidou, 
Lagier-Tourenne, et 
al., 2011) 
CAPN5 (Calpain 5) 
 
CAPN5 has been shown to be the second most 
abundantly expressed calpain in the 
mammalian central nervous system. 
 
(Singh et al., 2014) 
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CASP3 (Caspase 3) 
 
CASP3 is an important mediator of neuronal 
programmed cell death. It is also associated 
with chronic neurodegenerative diseases. 
 
 
In transgenic mice expressing mutant SOD1, 
inhibition of caspase-3 was found to have a 
protective role in ALS pathology. 
 
 
(Troy et al., 2011; 
Ribe et al., 2008; 
Ekshyyan, O. and 
Aw, 2004) 
 
(Li et al., 2000) 
CDK5R1 (Cyclin Dependent Kinase 
5 Regulatory Subunit 1) 
 
CDK5R1 gene encoded p35, the main 
activator of Cyclin-dependent kinase 5 
(CDK5). It has been associated with AD onset 
and progression. 
 
It was found to be upregulated in frontal 
cortex of ALS patients. Notably, in our results 
it was found to be downregulated in all tested 
hnRNPs. 
 
 
(Spreafico et al., 
2018) 
 
 
 
(Andrés-Benito et 
al., 2017) 
CTSS (Cathepsin S) 
 
Significant increased expression of Cathepsin 
S (encoded by CTSS gene) was found in the 
anterior lumbar spinal cord in ALS. 
 
 
(Berjaoui et al., 
2015) 
TLR7 (Toll Like Receptor 7) 
 
Significant increased expression of TLR7 was 
found in the anterior lumbar spinal cord in 
ALS. 
 
 
(Berjaoui et al., 
2015) 
DDX58 (DExD/H-Box Helicase 58) 
 
RNA helicase upregulated in ALS mouse 
model: TDP-43 (A315T) mice. In particular, 
TDP-43 bound to its mRNA. 
 
 
 
 
 
 
(MacNair et al., 
2016) 
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HS3ST2 (Heparan Sulfate-
Glucosamine 3-Sulfotransferase 2) 
 
HS3ST2 is an heparan sulfate biosynthetic 
enzyme showed greatest decreases in 
expression in FTLD-U human samples. 
 
 
(Chen-Plotkin et al., 
2008) 
RAB31 (RAB31, Member RAS 
Oncogene Family) 
 
GTP-binding protein upregulated upon TDP-
43 depletion in adult mouse brain. 
 
 
(Polymenidou, 
Lagier-Tourenne, et 
al., 2011) 
PPP1R15A (Protein Phosphatase 1 
Regulatory Subunit 15A) 
 
PPP1R15A is also known as GADD34. 
Mutant SOD1 mice that are haploinsufficient 
for GADD34 have a remarkably ameliorated 
disease. 
 
 
(Wang et al., 2014) 
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6. CONCLUSION AND FUTURE DIRECTIONS 
In conclusion, my work has provided novel insights on the involvement of the hnRNP 
family in controlling neuronal and inflammatory pathways, suggesting that differential 
expression of these proteins could play an essential role in modulating the onset and 
progression of neurodegenerative disorders, especially those related to TDP-43 pathology. 
The future direction of this work could examine the synaptic plasticity/death-signalling 
pathways after overexpression/depletion of neuronal genes identified by RNA-seq analysis 
of TDP-43, DAZAP1, hnRNP Q using a cellular model of TDP-43 aggregation and/or 
using iPSC cells derived from patients carrying TDP-43 mutations. This data will be useful 
to identify the most promising common neuronal targets identified by RNA-seq analysis of 
TDP-43, DAZAP1, hnRNP Q that can affect neurodegeneration. This task will also be 
made easier by performing RNA-seq analysis for other hnRNP proteins that our group has 
demonstrated can “worsen” TDP-43 gain-of-function toxicity in the Drosophila eye, 
namely CG30122 (hnRNP U), Bl/CG13425 (hnRNP K) and Sqd/CG16901 (hnRNP D). 
This last aim is currently underway and I am also actively involved in taking forward this 
part of the work. 
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